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1 SUMMARY 
The active contribution of oligodendrocytes and astrocytes to sustain brain physiology was 
completely underestimated, but severe consequences of their dysfunction in various 
diseases and glia-specific mutants emphasized their importance in maintaining neuronal 
integrity and function. By the intimate interconnection between neurons, oligodendrocytes 
and astrocytes a network is established allowing bidirectional interaction. Improved 
techniques to analyze brain energy metabolism revealed that a high amount of glucose is not 
oxidatively metabolized. Thus, lactate, the end-product of aerobic glycolysis, is accepted to 
play an important role in fueling the brain. In this context, oligodendrocytes and astrocytes 
were assumed to produce lactate that is shuttled to neuronal compartments to benefit 
mitochondrial respiration and local energy requirements. To obtain supportive evidence for 
this hypothesis, conditional mouse mutants were generated by targeting COX10, essential to 
assemble COX (cytochrome c oxidase), the terminal complex of the mitochondrial respiratory 
chain. Consequently, Cox10-deficient cells can only survive by aerobic glycolysis or die. By 
using well-established Cre-driver mouse lines, selective recombination was achieved in 
oligodendrocytes and mature Bergmann glia, a cerebellar subpopulation of astrocytes, 
respectively. In both, disrupted oxidative phosphorylation did not affect the survival of Cox10-
ablated cells. In the CNS, neurodegeneration, secondary inflammation or abnormal 
regeneration were not detected in both conditional mutants. Furthermore, the absence of 
oligodendroglial myelin defects and the normal appearance of synapses engulfed by 
Bergmann glia, respectively, reflect the ease of adaptation to aerobic glycolysis of these 
cells. Importantly, elevated lactate concentrations were detected in the living brain of 
oligodendroglial mutant and control mice by in vivo magnetic resonance spectroscopy. This 
was only reached when mice were exposed to isoflurane anaesthesia which blocks the 
pyruvate dehydrogenase complex. Furthermore, lactate accumulations immediately dropped 
by the end of anaesthesia to undetectable levels suggesting a model in which aerobic 
glycolysis products from oligodendrocytes are rapidly metabolized within white matter tracts 
in the healthy brain. To investigate a possible underlying mechanism, PKM2 expression was 
analyzed. This is an isozyme of the pyruvate kinase, specifically upregulated in cancers and 
highly proliferating cells. The shift of PKM1 to PKM2 is debated to promote aerobic glycolysis 
in cancer cells and thus tumor growth and proliferation. In adult wildtype mouse brains PKM2 
was expressed in cells with oligodendrocyte-like morphology and protein analysis displayed 
high PKM2 expression abundance in white matter tracts. A possible regulatory mechanism 
controlling PKM2 activity and thus the velocity of glycolysis was unraveled by the detection of 
phosphorylated PKM2 in different adult brain regions. Taken together, these findings 
implicate specific metabolic properties of oligodendrocytes and astrocytes enabling a 
metabolic coupling to neurons that serves a physiological function. 
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2 INTRODUCTION 
2.1 CELLS IN THE CENTRAL NERVOUS SYSTEM 
Specialization of both neurons and glial cells and their persistent interactions are key 
features of evolution that allowed vertebrate species to develop fast and permitted rapid and 
coordinated responses to environmental changes. As brains became larger and more 
complex during vertebrate evolution, the proportion of glia increased and outnumbered the 
neurons (Sherwood et al., 2006). Despite the role of glia during development, their active 
participation in the physiology of the brain and the consequences of their dysfunction on the 
pathology of the nervous system has only been emphasized in recent years.  
The mammalian central nervous system (CNS) comprises neurons and glial cells, which can 
be further divided into microglia and macroglia including oligodendrocytes and astrocytes. 
Neurons are very specialized cells appearing as heterogenous subpopulations throughout 
the CNS, but all of them have in common that they are responsible for processing and 
transmission of information. Electric impulses are conducted along axons to their synapses 
or other connections to cells, where the action potential is normally converted to a chemical 
signal. Like neuronal cells, oligodendrocytes and astrocytes derive from neuroepithelial cells 
and cover a variety of subclasses that are structurally and functionally highly diverse. 
Microglia, the macrophages of the CNS, which originate from hematopoietic stem cells, are 
the primary immune cells of the CNS. They respond to pathogens and injuries by becoming 
“activated” – a process in which they rapidly change morphology, proliferate and migrate to 
the site of infection/ injury where they phagocytose pathogens and remove damaged cells 
(Davalos et al., 2005; Dibaj et al., 2010). In the following I will focus only on astrocytes and 
oligodendrocytes, since both types of glial cells are hypothesized to be involved in the 
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Fig. 1  Glial cells in the CNS 
Scheme illustrates the tight interconnection between neurons and glial cells in the CNS. Myelinating 
oligodendrocytes enwrap up to 40 different axonal segments with myelin enabling fast propagation of 
action potentials, but also lead to the isolation of axons from the extracellular space. Astrocytes are in 
direct contact with blood capillaries and they are interconnected among each others and to 
oligodendrocytes via gap junctions. Additionally, astrocytic processes are coupled to nodes of Ranvier 
and surround many synapses. Microglia, the macrophages of the CNS, are involved in the immune 
defense. Picture adapted from Baumann and Pham-Dinh, 2001. 
 
2.1.1 OLIGODENDROCYTES– NOT JUST PASSIVE INSULATORS MEDIATING 
MYELINATION 
The best understood function of oligodendrocytes in the CNS and Schwann cells in the 
peripheral nervous system (PNS) is the myelination of axons, which is considered as the last 
true invention of vertebrate evolution in the architecture of the nervous system, allowing rapid 
impulse propagation and space economy. In contrast, in the invertebrate nervous system fast 
conduction of electric impulses is accompanied by increased axonal calibers. The myelin 
sheath constitutes the most abundant membrane in the vertebrate nervous system and is a 
spiral structure of lipid-rich plasma membrane extentions of myelinating glia, each of which 
contacts and repeatedly envelopes a stretch of axon with subsequent condensation 
(compact myelin). These insulating segments are called internodes which are separated by 
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gaps, also known as nodes of Ranvier. These are places where the axolemma is exposed to 
the extracellular environment, playing a major role in speeding up nerve impulse propagation 
and reduction of axonal energy consumption by enabling saltatory conduction velocity of 
action potential (Bunge, 1968; Peters, 1966; Nave, 2010), a prerequisite for the development 
of complex nervous systems operating quickly and efficiently (Zalc et al., 2008). Besides 
myelination, there is growing evidence that myelinating glia are not only passive insulators, 
but also have a crucial role in metabolic support of associated axons, which is important for 
the maintenance of axonal integrity and survival (Nave, 2010; Amaral et al., 2013; Morrison 
et al., 2013). Initial indications have emerged from mouse mutants carrying mutations in 
oligodendrocyte-specific genes and analysis of post-mortem brain tissue of patients with 
neurological diseases showing neurodegeneration.  
The first indication that oligodendrocytes influence and support axonal function was 
uncovered by the study of mouse mutants lacking the proteolipid protein (Plp1), a tetraspan 
membrane protein in CNS myelin. In these mutants, oligodendrocytes assemble stable 
myelin and display only minor ultrastructural abnormalities. However, aged Plp1-null mutants 
suffer from insufficient axonal transport, followed by axonal swellings and Wallerian 
degeneration (Griffiths et al., 1998; Edgar et al., 2004). Additionally, MAG-deficient mice 
(myelin-associated glycoprotein, a non-compact myelin protein) are fully myelinated but 
exhibit a decrease in axon calibers and neurofilament spacing, which probably cause axonal 
loss (Yin et al., 1998). Similar neurodegenerative phenotypes could be observed in mouse 
mutants deficient of CNP1 (2',3'-cyclic nucleotide 3’-phosphodiesterase), which is localized in 
the non-compact myelin. Like PLP1, CNP1 is not essential for proper myelination, but is 
required for axonal integrity (Lappe-Siefke et al., 2003; Edgar et al., 2009). Cnp1-null mutant 
mice are more severely affected than Plp1-null mice, with an earlier onset of axonal swellings 
and neurodegeneration prior to defects of axonal transport, already detectable at P10 in the 
spinal cord (Fig. 2a, b). This axonopathy is progressive over age and results in premature 
death of Cnp1-null mutants at the age of 9 to 10 months. In striking contrast, shiverer mice 
lacking MBP (myelin basic protein, a compact myelin protein) display no axonal 
degeneration, although they are severely dysmyelinated (Rosenbluth, 1980). However, these 
findings strongly imply that axonal survival can be sustained despite the near loss of myelin, 
but not in the presence of ´unfunctional myelin´. Thus, myelin is not only a passive, electric 
insulator, but also benefits axonal survival and function by support mechanisms (Nave, 
2010). 
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Fig. 2  Cnp1-null mutants develop a severe axonopathy and exhibit normal myelin 
(a.) Electron micrographs and high power magnification of white matter tracts in spinal cord cross-
sections of Cnp1-null mutant mice at 2.5 months display normally assembled myelin (lower panel) 
which is comparable to age-matched controls (upper panel). (b.) Depicted are spinal cord cross-
sections of Cnp1-null mutants. Already at the age of P10 axonal spheroids as sign of axonal pathology 
are visible (left). This is progressive with age and characterized by the accumulation of membranous 
organelles and multivesicular bodies at 7 months (right). Pictures were taken from Edgar et al., 2009; 
Lappe-Siefke et al., 2003. 
 
Many clinical phenotypes of neurological diseases in humans are caused by the loss of 
myelin. The best examined example is multiple sclerosis (MS), which has been historically 
assumed to be a myelin-specific autoimmune disease without affecting axons. However, this 
consideration has changed in the mid-1990s. Histological investigations of post-mortem 
brains from MS patients exhibited an early involvement of axons, characterized by transected 
axons and Wallerian degeneration already obvious with the onset of disease, which results in 
progressive axon loss and brain atrophy (Dziedzic et al., 2010; Peterson et al., 2001; Trapp 
et al., 1998). So far, the interplay between inflammation, demyelination, and 
neurodegenerative alterations that correlate best with clinical disability of patients are still not 
fully elucidated. It rather emphasizes the need to explore axon-glia interactions essential for 
neuronal survival and function. 
To better understand the interdependence of oligodendrocytes and neurons it is important to 
have a detailed look at the ultrastructure of the myelin sheath that covers almost the entire 
surface of the axon serving for electrical insulation but also isolates the axon from the excess 
to nutrients from the extracellular space. In contrast, non-compacted regions of the myelin, 
which consist of the lateral endings of each myelin layer (known as “paranodal loops”) and 
the inner tongue remain in close contact with the underlying axon forming cytoplasmic 
channels (Fig.3). Recently, Snaidero and colleagues (2014) could even show by electron 
microscopy of freshly highpressure frozen optic nerves that within the developing myelin 
sheath numerous cytoplasmic channels are located that changed the view of CNS myelin 
ultrastructure (Snaidero et al., 2014). Thus, a physical connection between myelin, especially  
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Fig. 3 Schematic view at the CNS myelin ultrastructure.  
Myelinating oligodendrocytes form several processes that ensheath individual axonal segments with 
myelin (internodes). The illustration of an unwrapped myelin sheath reveals small areas of 
uncompacted myelin, which are the paranodal loops (lateral loops), inner and outer tongues (inner and 
outer loop) generating an interface between the oligodendroglial cytoplasm and the axonal surface. 
Figure taken from Aggarwal et al., 2011. 
 
the non-compacted regions and its associated axon is generated. Additionally, astrocytes 
which are in direct connection to the blood-brain-barrier and therewith to nutrients of blood 
vessels are also contributors to the axo-glial interplay. They are partners of neurons by 
contacting them at the nodes of Ranvier and as well as of oligodendrocytes via gap junctions 
(Black and Waxman, 1988; Nagy et al., 2003). 
Proper repetitive axonal firing causes massive sodium influx and requires subsequent 
repolarization that is mediated by energy-consuming Na+-K+-ATPases, which were shown to 
be distributed along the internodal axolemma (Young et al., 2008), where most of axonal 
mitochondria reside, which was validated by 3D-EM analysis of the optic nerve (Edgar et al., 
2008; Ohno et al., 2011). Since mitochondria are the major source of ATP by oxidizing 
glycolysis end products, the internodal accumulation of stationary mitochondria may help to 
facilitate active, energy-dependent axonal transport and simply reflects high metabolic 
demands at these sites. More distal compartments like synaptic terminals and active growth 
  INTRODUCTION 
 
   7
cones (Kang et al., 2008; Morris and Hollenbeck, 1993) require also much energy and are 
dependent on proper trafficking of glycolytic enzymes and mitochondria for the local 
maintenance of sufficient energy production. However, the anterograde travelling rates of 
cargoes, mitochondria and cytosolic proteins are comparably slow. Pulse-chase 
radiolabelling studies revealed that membrane-spanning or anchoring domains packaged 
into cargoes are conveyed via fast axonal transport at overall rates of 50–400 mm/ day 
(Perrot and Julien, 2009), whereas cytosolic proteins are shuttled much more slowly at rates 
of 1–10 mm/ day, (Brady and Lasek, 1981; Oblinger et al., 1988; Yuan et al., 1999). 
Considering the length, an axon can reach (motoneurons up to 100 cm in humans) and 
especially the sluggish transfer of cytosolic proteins, including glycolytic enzymes, the 
metabolic supply of the axon presents a logistical problem. This might be overcome by an 
oligodendroglial trophic support to neurons, e.g. by shuttling of glycolytic end products 
(lactate, pyruvate) to mitochondria in the axonal compartment, where their metabolization via 
oxidative phosphorylation benefits neuronal energy requirements (Nave, 2010; Amaral et al., 
2013; Morrison et al., 2013). This hypothesis could also explain the length-dependent axon 
loss in many neurological diseases and mouse mutants with primary non-compacted myelin 
deficits. 
Interestingly, a study of activity markers of glycolysis and oxidative phosphorylation in white 
matter tracts and cortex by Morland and colleagues revealed that glucose oxidation is low in 
normal white matter when compared to grey matter (Morland et al., 2007). Furthermore, the 
authors calculated that half of the glucose taken up by white structures might be processed 
glycolytically suggesting that white matter is a possible source of the glycolytic end products 
pyruvate and lactate for other cellular compartments. 
Based on these data a new research direction has emerged recently assessing 
oligodendrocytes´ function not only as passive insulators, but has attracted attention to their 
possible metabolic importance supporting neuronal ATP demands. Two recent papers have 
shed new light on axonal support mechanisms. 
Evidence for this hypothesis is provided by the group of Jeffrey D. Rothstein, who 
investigated the monocarboxylate transporter MCT1 which was shown to be the most 
abundant MCT in the CNS (Rinholm et al., 2011). MCT1 transports, along with the neuron-
specific MCT2 and astrocyte-specific MCT4, monocarboxylic acids including lactate, 
pyruvate and ketone bodies. Hence, they might provide routes for glycolytic end products. By 
generating a MCT1 BAC transgenic mouse model they showed in vivo that MCT1 expression 
is almost exclusively found in oligodendrocytes and its downregulation led to axonal defects 
in vitro and in vivo (Lee et al., 2012). Treatment of spinal cord organotypic cultures with 
shRNA specific for MCT1 or its pharmacological inhibiton resulted in motor neuron loss 
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whereas oligodendroglial death could not be observed. Interestingly, neuron death could be 
prevented by adding exogenous lactate to the medium, supporting the hypothesis that failed 
lactate release from oligodendroglia and therewith its uptake into neurons is the cause for 
neurodegeneration. Mct1-null mutants are embryonically lethal. But more importantly, 
heterozygous Mct1-null mice, with 50% reduction in MCT1 expression or following lentiviral-
mediated gene silencing in oligodendrocytes caused a late-onset axonopathy and 
neurodegeneration in brain and spinal cord (Lee et al., 2012). Notably, axon pathology in 
these mice is similar to Cnp1- and Plp1-null mice. Taken together, the results suggest that 
MCT1-regulated lactate export from oligodendroglia is a crucial component of the local 
energy supply to axons, and the disruption of this transport leads to axon dysfunction and 
ultimately to neuron degeneration. Thus, lactate release from oligodendrocytes is indeed 
essential for long-term axonal integrity. 
In parallel, the group of Klaus-Armin Nave independently investigated the role of 
oligodendrocytes regarding a hypothetical metabolic coupling to axonal compartments 
(Fünfschilling et al., 2012). Parts of this PhD thesis contributed to this analysis and will be 
described in more detail in the results chapter. In short, conditional mouse mutants were 
generated, in which specifically mature oligodendrocytes fail to assemble stable 
cytochrome c oxidase, the complex IV of the mitochondrial respiratory chain. Thus, mutant 
oligodendrocytes are forced to live by glycolysis alone. Interestingly, oligodendrocytes 
lacking the ability to generate energy by oxidative phosphorylation survived. Moreover, no 
sign of brain pathology could be observed (Fünfschilling et al., 2012). This stands in striking 
contrast to mouse mutants, in which the same genetic modification driven selectively in a 
subset of projection neurons, suffering from severe neurodegeneration that caused 
premature death of mutants at around 4 months of age (Fukui et al., 2007) strongly indicating 
the dependence of neurons on mitochondrial energy production. However, proton NMR 
spectroscopic analysis of mouse brains, in which oligodendrocytes specifically lost their 
capacity for oxidative phosphorylation revealed significantly elevated lactate concentrations 
when compared to controls. In this context mice were anaesthetized with isoflurane, which is 
an inhibitor of mitochondrial metabolism, enabling detection of lactate accumulations by 
NMR. Importantly, at the end of anaesthesia the observed increase of lactate recurred to 
normal, undetectable levels, implying its rapid use by other cellular compartments 
(Fünfschilling et al., 2012).  
These studies proposed a link between glycolytic metabolism in oligodendrocytes and axonal 
integrity and function. With regard to the broad spectrum of neurodegenerative diseases that 
are associated with myelin defects denotes the necessity to better understand the axo-glia 
interplay in order to develop new therapeutic approaches. 
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2.1.2 ASTROCYTES– MORE THAN JUST PASSIVE SCAFFOLDING CELLS 
Historically, astrocytes were often considered as passive scaffolding cells of the mammalian 
CNS. However, work over the past 2 decades suggests that astrocytes play a more active 
role and are involved in a wide variety of complex and essential functions in the healthy 
brain. Astrocytes are specialized glial cells that are distributed throughout the CNS. 
According to their cellular morphology and location, astrocytes can be divided into two main 
classes, the protoplasmic and fibrous astrocytes. The latter are located in white matter tracts 
and are characterized by long, sparsely branched processes contacting nodes of Ranvier. 
Protoplasmic astrocytes, which are found in grey matter regions, have many branching 
processes, which envelop synapses (Cajal, 1909). As heterogenous as they are there are 
even more astrocytic subpopulations including Bergmann glia in the cerebellum, Müller glia 
in the retina, pituicytes in the neurohypophysis, cribrosocytes at the optic nerve head, and 
others. 
Astrocytic endfeet project directly to blood vessels, therewith participating in the formation 
and maintenance of the blood-brain barrier and providing access to nutrients from the 
cerebral blood stream (Kacem et al., 1998), whose flow velocity can be adapted by 
astrocytes in response to changes in neuronal activity (Attwell et al., 2010; Gordon et al., 
2007). Moreover, astrocytes are interconnected among each other in a coordinated 
syncytium and are coupled to oligodendrocytes via gap junctions (Giaume et al., 1991; Nagy 
et al., 2003). In this manner a highly organized network between neurons, astrocytes, 
oligodendrocytes and capillaries is generated that allows bidirectional communication and 
may provide routes for metabolites. 
The relationship between astrocytes and neurons, assured by the intimate physical 
connection of astrocytic processes to synapses, starts already during neurogenesis when 
astrocytes guide neuronal migration, survival and process extension. Later they are involved 
in formation, maintenance and remodelling of synapses mainly through release of trophic 
factors such as brain-derived neurotrophic factor (Powell et al., 1999; Ullian et al., 2001a). 
There is growing evidence that in adulthood astrocytes are active partners of synapses. They 
express a plethory of transporters important for the clearance of neurotransmitters from the 
synaptic cleft (Genoud et al., 2006). Moreover, they were reported to be responsible for the 
recycling of synaptically released glutamate and GABA through the glutamate/GABA-
glutamine cycle (Bak et al., 2006; Rothstein et al., 1996). A variety of receptors are 
expressed on astrocytes, which response to neuronal activity with an increase of intracellular 
calcium concentrations (Dani et al., 1992; Nimmerjahn et al., 2009). A specific consequence 
of astrocytic internal calcium elevations is the secretion of so-called gliotransmitters, 
including glutamate, adenosine triphosphate, GABA and d-serine (Parpura et al., 1994; 
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Zhuang et al., 2010; Panatier et al., 2006), which adapts synaptic transmission and plasticity 
(Gourine et al., 2010; Chen et al., 2012). This often results in several, often opposite types of 
effects, including stimulation or inhibition of synaptic transmission and participation in long-
term potentiation or depression (Panatier et al., 2011; Yang et al., 2003; Shigetomi et al., 
2013). The underlying mechanism how astrocytes release transmitters still remains a subject 
of debate (e.g. reviewed by Hamilton and Attwell, 2010; Araque et al., 2014). However, these 
findings have led to the concept of “tripartite synapse”, which represents a functional view of 
synaptic physiology that considers astrocytes as active contributors controlling neuronal 
information transfer. 
Concomitantly, another model has flourished implying that astrocytes also support brain 
activity by supplying neurons with energy metabolites. This concept was originally proposed 
by Magistretti and Pellerin in 1994 claiming “Glutamate uptake into astrocytes stimulates 
aerobic glycolysis” (Pellerin and Magistretti, 1994a). This publication could be considered as 
the cornerstone for the beginning of a new research field and the development of the 
“Astrocyte-to-Neuron-Lactate-Shuttle” (ANLS) hypothesis. Here, they described a tight 
metabolic connection between cortical synapses and their surrounding glial cell, in which the 
activity-dependent glutamate release in the synaptic cleft at glutamatergic synapses in the 
cortex is followed by the clearance of glutamate via glutamate transporters on astrocytes. 
The entry of sodium that is cotransported with glutamate activates astrocytic Na+/K+ ATPase, 
whose activity results in an enhancement of the glycolytic flux, hence the glucose uptake 
from the capillaries is stimulated. Lactate, the major end product of aerobic glycolysis, is 
released by astrocytes and taken up by neurons where it can be further metabolized in the 
tricarboxylic acid (TCA) cycle, thereby contributing to the energy budget of neurons (Pellerin 
and Magistretti, 1994). The rapid exchange of metabolites, such as lactate across the plasma 
membrane of cells requires expression of appropriate transporters. Monocarboxylate 
transporters (MCT) catalyze the proton-linked transport of glycolysis products pyruvate or 
lactate (Pierre and Pellerin, 2005). Three isoforms (MCT1, 2, and 4) are expressed in the 
CNS, whose distribution is heterogenous (Halestrap and Wilson, 2012). MCT1 and MCT4 
were shown to be expressed by astrocytes, whereas MCT2 is preferentially expressed by 
neurons (Pellerin et al., 1998; Pierre et al., 2000, 2002), which is one prerequisite for lactate 
shuttling from astrocytes to neurons. Importantly, the disruption of actrocyte- or neuron-
specific MCTs affects long-term memory in vivo, suggesting a trophically, supportive role of 
astrocytes for neuronal function (Suzuki et al., 2011). 
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Fig. 4 Schematic representation of the ANLS hypothesis 
Glutamate (Glu) release at the active synapse stimulates neuronal glutamatergic receptors (GluR). A 
large proportion of the glutamate is taken up by astrocytes via excitatory amino acid transporters 
(EAATs, more specifically GLT-1 and GLAST) together with sodium ions (Na+). Na+ is extruded by the 
Na+/K+ ATPase, consuming ATP which triggers nonoxidative glucose utilization in astrocytes and 
glucose uptake from blood vessels through the glucose transporter GLUT1. Pyruvate is converted to 
lactate by the lactate dehydrogenase 5 (LDH5) and shuttled to neurons via monocarboxylate 
transporters (MCT1 and MCT4 in astrocytes, MCT2 in neurons). In neurons, this lactate is metabolized 
to pyruvate (Pyr) by LDH1 and used as a metabolite to support the neuronal energy budget. 
Concomitantly, astrocytes participate in the recycling of synaptic glutamate by its conversion to 
glutamine (gln) by the glutamine synthetase (GS) and its subsequent transport to neurons, where it is 
converted back to glutamate by glutaminase (GLS). This figure is taken from Bélanger et al., 2011. 
 
The concept of the ANLS based on several studies revealing striking metabolic differences 
between astrocytes and neurons. That neurons consume most of the energy during brain 
activation was already discovered in 1977 by positron emission tomography (PET) imaging 
of labelled F-fluoro-2-deoxyglucose (Sokoloff et al., 1977). Several PET studies in awake 
adult humans by Fox and Raichle, led to a fundamental rethinking of brain metabolism. They 
detected that the activity-dependent increases in blood flow and glucose uptake were only 
partly matched by parallel raises in oxygen utilization (Fox et al., 1988; Fox and Raichle, 
1986). These investigations strongly indicate that neuronal activity stimulates aerobic 
glycolysis. Nonetheless, due to resolution limitations the cellular contribution remained 
elusive. However, studies on transcriptomic level of individually isolated cells revealed a 
different metabolic profile of neuronal and astrocytic cells indicating a prevalence of glycolytic 
pathways in astrocytes (Lovatt et al., 2007; Cahoy et al., 2008). In accordance with this, 
investigations of Itoh and Bouzier-Sore confirmed a higher glycolytic capacity in astrocytes 
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when compared to neurons in which oxidative metabolism predominates. Further, they 
figured out that astroglia metabolize glucose mainly to lactate which is released into the 
extracellular space and preferentially taken up and oxidized by neurons over pyruvate/ 
lactate produced intracellularly by glycolysis (Itoh et al., 2003; Bouzier-Sore et al., 2006). 
This lactate utilization was directly assessed in human brains by MRS imaging of 13C-labeled 
lactate and was detected to be neuron specific (Boumezbeur et al., 2010). More important, 
lactate is able to maintain neuronal activity in vivo and even a preference of neurons to 
lactate over glucose in the presence of both metabolites is observed (Wyss et al., 2011). 
However, the cellular origin and its possible contribution to the energy metabolism of the 
CNS are still issues of controversial debate. By now, direct in vivo evidence for the ANLS 
hypothesis is elusive and emphasizes the importance to further investigate the metabolic 
interactions between astrocytes and neurons. 
 
2.2 THE WARBURG EFFECT– PKM2 MIGHT SERVE AS A MODULATOR OF 
GLYCOLYSIS 
That mammalian cells metabolize glucose via glycolysis, citrate cycle and oxidative 
phosphorylation is an established dogma of cell biology and only few exceptions were made 
for cellular conditions in which only limited oxygen levels are available like in skeletal muscle 
cells during exercise. This was originally overcome by Otto Warburg who discovered that 
cancer cells rely on glycolysis for energy production, despite the presence of sufficient 
oxygen (Warburg, 1926). This phenomenon has been termed the Warburg effect or aerobic 
glycolysis. However, tumor growth is not always connected to a high rate of glucose 
conversion to lactate. It has been shown that several tumor cell lines are able to proliferate in 
media with low glucose supply without producing lactate via glycolysis (Mazurek et al., 1998; 
Mazurek, Michel, et al., 1997; Reitzer et al., 1979). Furthermore, aerobic glycolysis is not 
only an unique feature of cancer cells. In normal proliferating cells such as lung, fat, 
embryonic or adult stem cells a dependency on the glycolytic pathway was determined 
(McKeehan, 1982).  This provides a dual advantage for dividing cells, including cancer cells, 
ensuring the supply with energy and glycolytic intermediates (phosphometabolites) that are 
required as precursors for the synthesis of nucleic acids, amino acids, lipids and additionally 
the regeneration of NADPH, which is needed for fatty acid synthesis (Mazurek et al., 1997; 
Dringen et al., 2007). 
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Fig. 5 Gross overview about glucose metabolism 
After entering the cell, glucose is glycolytically converted in several steps into pyruvate that produces 2 
molecules ATP. Normally, pyruvate is shuttled into the mitochondrium, where it is further metabolized 
via the Krebs cycle. By that reduction equivalents (NADH) are produced, whose electrons are 
transported along three pumps (complex I, II and III) of the respiratory chain, which are bound in the 
inner mitochondrial membrane. Finally, the electrons are transferred to oxygen. The electron 
conveyance leads to a proton flow from the matrix to the intermembrane space of the mitochondrium 
and generates a proton gradient, powering the ATPase to catalyze a huge amount of energy. By this 
process termed oxidative phosphorylation 34 molecules ATP per glucose molecule are produced. 
However, in some exceptions, energy metabolism is restricted to glycolysis. In that case pyruvate is 
converted to lactate, an absolutely necessary step regenerating NAD+ that ensures continuous 
glycolysis. Debranching synthetic pathways were not considered in the depicted scheme. Picture 
adapted from Biochemistry, Volume 6. 
 
Investigations of mechanisms controlling the Warburg effect of tumor metabolism put 
attention to the pyruvate kinase (PK), that catalyzes the conversion of phosphoenolpyruvate 
(PEP) to pyruvate, which is the last but rate-limiting step of glycolysis. Depending on 
metabolic requirements different isozymes of PK are expressed in various cells and tissues. 
In total four isozymic forms, consisting of type L, R, M1 and M2 are known to be present in 
the mammalian organism. PKL is found in tissues with high rates of gluconeogenesis such 
as liver and kidney (Domingo et al., 1992). Erythrocytes, in which mitochondria are absent, 
express type R (Rodriguez-Horche et al., 1987). PK isozymes type L and R are encoded by 
the same gene, but are under the control of different promoters. PKM1 expression is 
ubiquitous, but to a higher extent in tissues, in which rapid supply of large ATP amounts is 
important such as in muscle and brain.  
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Fig. 6 Summary of PKM1 and PKM2 characteristics 
PKM1 and PKM2 are alternative splicing transcripts originating from the same gene, but differing 
slightly in their exon composition. The majority of differentiated cells expresses PKM1 that has a high 
affinity to its substrate PEP and its activity can not be modulated. In contrast, the activity of PKM2 can 
be regulated by several posttranslational modifications such as phosphorylation that leads to the 
dissociation of active PKM2 tetramers, by what the glycolytic rate is slowed down. The accumulation of 
fructose-1,6-bisphosphate causes the tetramerization and activation of PKM2. The activity state of 
PKM2 is associated to its cellular localization. Whereas the dimeric, inactive form is found in the 
nucleus, the tetrameric PKM2 is distributed in the cytoplasm. PKM2 is strongly expressed in 
embryonic phases and is replaced in most cells by PKM1 during development. In still high 
proliferating, differentiated cells the cytoplasmic form of PKM2 is still present. In cancer cells PKM2 is 
strongly expressed and found to be translocated to the nucleus. Picture adapted from Mazurek, 2011. 
 
PKM2 is expressed during embryonic development and in rapidly dividing cells, including 
lung cells, adult stem cells and especially tumor cells (Reinacher and Eigenbrodt, 1981; 
Eigenbrodt et al., 1985; Staal et al., 1991; Hacker et al., 1998). PK isozymes type M1 and M2 
are differently spliced products of the same mRNA transcript (exon 10 is excluded in PKM1 
and exon 9 is excised in PKM2) and differ in 22 of 531 amino acids (Noguchi et al., 1986; 
Tanaka et al., 1967). 
In the following only on PKM1 and PKM2 will be focussed due to their (possible) importance 
in brain metabolism.  
PK has been largely conserved throughout evolution and usually appears as a homotetramer 
composed of four identical subunits. However, PKM1 and PKM2 display various regulatory 
properties. PKM1 is constitutively active, efficiently converting PEP and ADP to pyruvate and 
ATP (Ikeda and Noguchi, 1998). In comparison, the modulation of PKM2 activity is controlled 
by a tightly woven regulatory network that decides the fate of glucose to promote either 
synthetic pathways or energy production. PKM2 can exist in an active tetrameric state, which 
is the common PKM2 appearance of normal proliferating cells (Mazurek and Eigenbrodt, 
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2003; Kumar et al., 2007). However, in response to different stimuli such as metabolic 
intermediates or oncogenes PKM2 tetramers dissociate into dimers, which are inactive and 
consequently slow down glycolysis and thus ATP generation. This allows accumulation of 
glycolytic intermediates used in anabolic pathways to build up amino acids, nucleotides and 
lipids. Importantly, the Pentose-Phosphate-Pathway (PPP), a debranching pathway of 
glycolysis, is indirectly coupled to fatty acid synthesis due to its delivery of NADPH by PPP 
that is crucial for the synthesis of fatty acids and cholesterol, two major lipids of myelin 
(Mazurek, Boschek, et al., 1997; Dombrauckas et al., 2005; Christofk et al., 2008; Gui et al., 
2013). In addition, PPP-derived NADPH is needed for the function of glutathione that is 
important for the defense against oxidative stress (Hirrlinger et al., 2002). 
Knockout studies with different cancer cell lines indicate a regulatory mechanism underlying 
the alternative splicing of the PKM gene controlled by c-Myc that mediates the expression of 
heterogeneous nuclear ribonucleoproteins hnRNPA1 and hnRNPA2. These hnRNPs bind 
repressively to the PKM sequence flanking exon 9, which results in exon 10 inclusion (David 
et al., 2010). Further, it was reported that the activation of epidermal growth factor receptor 
(EGFR) signalling promotes upregulation of PKM2 expression (Yang et al., 2011). 
On protein level a key metabolite regulating the PKM2 tetramer/ dimer ratio is fructose-1,6-
bisphosphate (FBP), an upstream intermediate of PEP. Binding of FBP leads to PKM2 
tetramerization, whereas its release causes subunit dissociation into inactive dimers 
(Ashizawa et al., 1991). Furthermore, the interaction with different oncoproteins such as the 
E7 oncoprotein of human papilloma virus type 16 is described to induce dimer formation 
(Zwerschke et al., 1999). Apart from that, several posttranscriptional modifications, including 
phosphorylation, acetylation, oxidation and sumoylation are suggested to be involved in 
PKM2 dimer formation (Anastasiou et al., 2011; Hitosugi et al., 2009; Lv et al., 2011; Spoden 
et al., 2009). However, by a phosphoproteomic analysis of Hitosugi and colleagues (2009) it 
was demonstrated that specific phosphorylation of PKM2 at tyrosine residue 105 (Y105) 
masks the binding site of FBP and thus inhibits the association of PKM2 tetramers. Further, 
they figured out that in many human cancers PKM2 is phosphorylated at Y105 and observed 
a decreased growth rate when the tyrosine residue 105 was substituted by phenylalanine, 
but only under hypoxic conditions (Hitosugi et al., 2009). Therefore, this study proposes that 
phosphorylation and dephosphorylation kinetics at Y105 of PKM2 influence the velocity of 
glycolysis which regulates the cell proliferation index in tumors.  
However, other residues of PKM2 were detected to be phosphorylated. An in vitro kinase 
assay containing PKM2 and active extracellular signal-regulated kinase 2 (ERK2) showed 
that ERK2 phosphorylates PKM2 specifically at serine residue 37, whereas mutated 
serine 37 remains unphosphorylated (Yang, Zheng, et al., 2012). Further, the authors 
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showed that upon EGF-induced ERK activation PKM2 translocates into the nucleus, whereas 
PKM1 is observed to remain in the cytoplasm (Yang, Xia, et al., 2012; Yang et al., 2011; Lv 
et al., 2013). Gel filtration chromatography indicated that nuclear PKM2 is completely 
dimeric, while the cytoplasmic PKM2 exists in both dimeric and tetrameric state and it could 
be determined that the malignancy grade of human cancer cell lines corresponds to a higher 
level of nuclear PKM2 (Gao et al., 2012). Further, there is emerging evidence that the 
nuclear PKM2 does not act as a pyruvate kinase anymore, but functions as a transcription 
factor. By now several independent studies displayed participation of PKM2 in activation of 
mek5, transcription 3 (STAT3), ß-catenin transcription leading to upregulation of LDHA, 
GLUT1 and PKM2 itself and thus promoting tumor growth and cell proliferation (Lv et al., 
2013; Yang et al., 2011; Yang, Xia, et al., 2012). 
Thus, PKM2 can be considered as a key enzyme responsible for keeping the balance of 
macromolecule formation (dimer) and energy production (tetramer) according to cell 
demands- at least in cancer cells. However, underlying regulatory mechanisms seem to be 
very complex and are still subject of controversial debate.  
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3 AIMS OF THE STUDY 
Recently, several studies suggested that oligodendrocytes and astrocytes have a trophic 
function for the survival and integrity of neurons. Specifically, they are hypothesized to 
produce lactate to support neuronal energy requirements by shuttling lactate. To address this 
question, conditional mouse mutants were generated by targeting the Cox10 gene, in which 
exon 6 is flanked by LoxP sites. Cox10 is ultimately necessary to assemble COX, the 
terminal complex of the mitochondrial respiratory chain. Hence, in Cox10 mutant mice, COX 
is cell-type specifically disrupted. Consequently, lactate needs to be generated to maintain 
the NAD+/ NADH equilibrium ensuring continuous glycolysis. Hence, Cox10-deficient cells 
live by aerobic glycolysis or simply die.  
Part I: To study the energy metabolism of mature oligodendrocytes and their dependency on 
oxidative phosphorylation, floxed Cox10 mice were crossbred with the CNP1-Cre and the 
tamoxifen-sensitive PLP1-CreERT2 driver mouse lines mediating recombination specifically 
in myelinating glia. How the loss of mitochondrial respiration affects the structural and 
functional integrity of the PNS (Schwann cells) and the CNS (oligodendrocytes) are 
analyzed. In addition, magnetic resonance spectroscopy is performed in the living brain to 
investigate the cellular origin and contribution of lactate in energy metabolism and to get a 
better insight into the trophic function of oligodendrocytes.  
Part II: To address the open question whether adult astrocytes in vivo are capable of 
providing lactate to neighboring synapses to support the local energy budget, floxed Cox10 
mice were as well used. By crossbreeding them with mice expressing the tamoxifen-sensitive 
Cre-recombinase from the GLAST (Slc1a3)-promoter, astrocyte specific deletion of Cox10 
was achieved. Since GLAST is expressed by the majority of Bergmann glial cells, a specific 
astrocyte subpopulation in the cerebellar cortex, the analyses mainly focussed on the 
cerebellum. How the disruption of mitochondrial function affects the integrity of the 
cerebellum is studied to draw conclusion to the origin and fate of lactate 
Part III: The established presumably link between an aerobic glycolytic metabolism of 
oligodendrocytes and the maintenance of axonal integrity requires the understanding of 
underlying mechanisms. The pyruvate kinase isozyme PKM2 is highly discussed to be 
important for adapting cancer metabolism since the switch from PKM1 to PKM2 is involved in 
tumor growth and proliferation. To study whether PKM2 has a role in the modulation of 
aerobic glycolysis in glial cells, its expression is studied in vitro and in vivo. Moreover, 
expression levels of PKM1, PKM2 and PKM2 that is phosphorylated at tyrosine residue 105 
in different brain regions at important developmental stages and in adulthood are evaluated. 
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4 PART I:  
GLYCOLYTIC OLIGODENDROCYTES MAINTAIN MYELIN AND LONG-
TERM AXONAL INTEGRITY 
4.1 RESULTS 
4.1.1 GENERATION OF CONDITIONAL COX10 MUTANT MICE 
To investigate whether oligodendrocytes in the living brain are dependent on oxidative 
phosphorylation we crossbred Cox10fl/fl mice, in which exon 6 of the Cox10 gene is flanked 
by LoxP sites, with Cre driver mouse lines mediating recombination specifically in 
myelinating glia (oligodendrocytes and Schwann cells). Cox10 encodes for a hemefarnesyl 
transferase that participates in the biosynthesis of heme α from the cytochrome c oxidase 
(COX), the terminal complex of the respiratory chain. Thus, by disruption of the Cox10 locus 
functional COX can not be assembled, as successfully shown in other mouse models (Diaz 
et al., 2008, 2005a; Fukui et al., 2007). Hence, Cox10-deficient cells should fail to fully 
metabolize glucose by oxidative phosphorylation and therefore produce most energy 
glycolytically. Consequently, lactate needs to be generated to maintain the NAD+/ NADH 
equilibrium for continuous glycolysis.  
To target myelinating glia CNP1-Cre mice were used (Lappe-Siefke et al., 2003), whose 
promoter activity starts in oligodendrocytes (CNS) at early postnatal states and in the 
Schwann cell lineage (PNS) already during embryonic development (Gravel et al., 1998; 
Scherer et al., 1994). This Cre driver mouse line was crossbred with Cox10fl/fl mice (Diaz et 
al., 2005). Conditional Cnp1Cre/+ * Cox10fl/fl mice were phenotypically indistinguishable from 
controls at birth, but fewer mutant pups were born than expected (11% compared with 25% 
that were calculated according to Mendelian ratios, n=466). The prenatal death of some mice 
is best explained by CNP1 expression in a subset of neural precursor cells. Moreover, these 
mutants developed signs of muscle atrophy already at P21 that was progressive over age. 
By two months, mutants exhibited reduced weight, tremors, and hindlimb weakness. This 
neuropathological phenotype further worsened and led to complete hindlimb paralysis, 
severe muscle atrophy and forelimb paresis by the age of 9 months, at which time-point 
mutant animals had to be euthanized. Control mice were heterozygously and mutants 
homozygously floxed for the Cox10 gene and both carryied Cre on one allele. In the following 
chapter data are from these control and mutant mice, unless otherwise stated.   
Additionally, crossbreedings of Cox10fl/fl mice with tamoxifen-sensitive PLP1-CreERT2 mice 
(Leone et al., 2003) enabling recombination in a timely controlled fashion were performed. To 
truly recombine only mature myelinating glial cells after nearly finished myelination mice 
Part I Glycolytic Oligodendrocytes Maintain Myelin and Long-Term Axonal Integrity RESULTS 
 
   19
received tamoxifen injections for 2 weeks, beginning at 1 month of age. Control mice were 
also homozygously floxed for Cox10, but they either lacked PLP1-CreERT2 expression and 
were injected with tamoxifen or expressed CreERT2 and got the vehicle only. 
Plp1-CreERT2 * Cox10fl/fl mutants were obtained in normal Mendelian ratios, appeared 
normal, well groomed and were long-lived. 
The recombination level of Cox10 genomic DNA at 2 months was analyzed by qPCR and the 
subsequent long-term ablation of COX protein was examined by WB analysis at 14 months 
(Fig.I - 1a.).  
For all investigated tissues a partial loss of exon 6 could be confirmed and thus an 
infunctional Cox10 gene. Whole brain homogenates of both conditional mutants displayed a 
recombination rate of approximately 15% compared to control mice. In comparison mutant 
sciatic nerve and optic nerve samples revealed much higher recombination efficiencies 
(sciatic nerve around 67%, optic nerve around 45%), which correspond to the expected 
percentage of Schwann cells in sciatic nerves and oligodendrocytes in optic nerves (Burne et 
al., 1996; Herculano-Houzel and Lent, 2005; Nakao et al., 1997) and suggests that all 
Schwann cells and oligodendrocytes are targeted by recombination (Fig.I - 1b.,c.). 
Indeed, the exon 6 excision of Cox10 caused COX deficiency. Immunolabelling against 
subunit1 of COX resulting in a brown staining determined the lack of COX from many 
Schwann cells in mutant sciatic nerve cross-sections that was obvious already at P21. 
Axonal mitochondria of mutants and controls exhibited equally intense COX expression 
(Fig.I – 1d.). WB analysis of 14 months optic nerves of Plp1-CreERT2 * Cox10fl/fl mutant mice 
validated a strong long-term reduction of subunit 1 of COX in comparison to age-matched 
controls. The quantification revealed a diminishment of around 45% compared to control 
optic nerves, which is in accordance with the estimated fraction of oligodendrocytes in this 
brain region (Fig.I - 1e.,f.).   
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Fig. I - 1 Genetic targeting of Cox10 leads to the loss of COX in myelinating glia 
(a.) Time-scale indicating the conditional deletion of Cox10 in Schwann cells and oligodendrocytes by 
using CNP1-Cre (denoted in red) and PLP1-CreERT2 (denoted in grey) driver mouse lines. Since the 
mitochondrial half-life is about 3 weeks, Cox10 disruption is not followed by a rapid COX loss. Cox10 
deletion mediated by PLP1-CreERT2 was induced by tamoxifen administration at 1 month. To 
evaluate the deletion of Cox10, qPCRs on genomic DNA were performed at 2 months and the 
resulting COX loss was determined by WB analysis at 14 months using Plp1-CreERT2 * Cox10fl/fl 
mutants. (b.) Conditional recombination of the floxed Cox10 gene, deleting exon 6 flanked by LoxP 
sites. Arrows indicate the location of primers used for genotyping (blue/red) and qPCR (red/red), the 
latter amplifying only the floxed allele. (c.) Quantification of the floxed Cox10 gene disruption in 
different tissues of both conditional mutants at 2 months. Highest percentage of Cox10 disruption was 
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found in sciatic nerve (67 ± 4%), followed by optic nerve (49.9 ± 4% and 39.4 ± 4.0%) and total brain 
(15.9 ± 8.8% and 12.9 ± 7.1%). Mean percentages are ± s.d.; n= 3–5. (d.) Left: scheme of a Schwann 
cell and their corresponding axon to represent precise COX localization. Right panel: Already at P21 
immunostainings with Cox4.1 of mutant sciatic nerves displayed the absence of COX (in brown) in 
Schwann cells, whereas COX is present in axonal compartments. In comparison, control sciatic 
nerves showed COX-positive signals in Schwann cells and axons. Schwann cell nuclei were visualized 
by haemalaun in blue. Scale bar, 10 µm (e.) Left: Obvious reduction of COX subunit1 in optic nerves 
of Plp1-CreERT2 * Cox10fl/fl mutants at 14 months compared to age-matched controls revealed by 
western blot analysis. Right: Quantification determined a decrease of COX4-1 expression by 45 ± 
10.6% in mutant optic nerves. Depicted are means ± s.e.m.; n= 3–5. opt.n., optic nerve; sc.n., sciatic 
nerve; N, nucleus; con, control; mut, mutant; mon, months In collaboration with Dr. Ursula 
Fünfschilling (recombination efficiency and immunohistochemistry). 
 
4.1.2 THE PNS OF COX10 MUTANTS DISPLAYS SIGNS OF A SEVERE NEUROPATHY 
To assess the functional integrity of peripheral nerves, conduction velocities in mutant and 
control sciatic nerves were determined at P21. Nerves were electrically stimulated proximally 
at the sciatic notch and distally at the ankle. The compound muscle action potentials were 
recorded in the foot. Control animals showed a motor conduction velocity of about 15 m/s. In 
contrast, motor conduction velocities in all analyzed mutants could not be determined, 
because they displayed functional blocks upon proximal stimulation (Fig.I - 2a.). Distal 
stimulation elicited a compound muscle action potential also in the mutant animals, but the 
amplitude was significantly reduced by a factor of two compared to controls. This implies that 
mutant animals suffer from peripheral neuropathy with features of both axonal and glial 
defects already at the age of P21. The drastic electrophysiological defect could be due to 
loss of axons or, more likely, to a significant change in the myelination status of the nerve. 
TdT-mediated dUTP nick end labelling (TUNEL) staining of semithin sciatic nerve sections at 
6 months detected no evidence for Schwann cell death as possible cause of hypomyelination 
(Fig.I - 2b.). In fact, the number of endoneurial nuclei was increased by 25% in the mutants 
(Fig.I - 2c.), which is a common feature in dysmyelinated nerves (Sancho et al., 2001). By 
P21 the cross-sectional area of mutant sciatic nerves was significantly reduced compared to 
controls (Fig.I - 2d.) and the number of total myelinated axons was already decreased by 
40% in mutants that further progressed by 9 months indicating axon loss (Fig.I - 2e.). 
Electron microscopic analyses revealed that C-fibers were not correctly sorted by Remak 
bundles by failing to envelop single axons in mutant sciatic nerves already at P21 compared 
to age-matched controls (Fig.I - 2f.). Further, many medium-sized axons remained 
completely unmyelinated although they corresponded to caliber size of above 1 µm and 
appeared next to sufficiently myelinated axons (Fig.I - 2g.). This implies that Schwann cells 
that still need to myelinate are dependent on ATP delivery by oxidative phosphorylation to 
fulfill their function. 
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Fig. I - 2 Cox10 mutant mice exhibit a severe peripheral neuropathy  
(a.) Recordings of the amplitudes of sciatic nerve compound muscle action potentials of control and 
mutant mice at P21, which was strongly reduced after distal and almost not detectable after proximal 
stimulation in mutant sciatic nerves. (b.) TUNEL staining of sciatic nerves revealed no Schwann cell 
death at P21, but a strong reduction of the mutant cross-sectional area. Cell nuclei were 
counterstained with haemalaun (in blue). (c.) The Schwann cell nuclei number was significantly 
increased in mutant sciatic nerves (control, 361 ± 39.6; mutant 453 ± 42.1), (d.) and the cross-
sectional area was significantly diminished at P21 (control, 0.808 ± 0.12 mm2; mutant, 0.578 ± 0.088 
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mm2). (e.) The absolute number of myelinated axons of sciatic nerves was reduced at P21 and further 
progressive by 9 months (control, 4376 ± 843, mutant, 2610 ± 383 at P21 and control, 5416 ± 582; 
mutant, 1744 ± 54 at 9 months). (f.-j.) Electron microscopic analyses. (f.,g.) In control Remak bundles, 
C-fibre axons were correctly engulfed by Schwann cell processes but not in mutants. (h.) Many 
unmyelinated medium-caliber axons were observed that appeared next to normally myelinated axons. 
Schwann cell nuclei were unaffected. (i.,j.) At higher magnification, myelin had developed 
morphologically normal, but mutant mitochondria were clearly enlarged and more abundant. Scale 
bars are 500 nm, besides from h., 2 µm. Numbers are mean ± s.d.. con, control; mut, mutant; A, 
unmyelinated medium-sized axon; N, normal myelinated axon; S, Schwann cell nuclei; mon, months. 
In collaboration with Dr. Ursula Fünfschilling (analyzed the data), Dr. Bastian Brinkmann 
(electrophysiology) and Dr. Wiebke Möbius (electron microscopy). 
 
Indeed, already at P21 mutant sciatic nerve mitochondria appeared aberrantly large and 
abundant which is a hallmark of mitochondrial diseases pointing to mitochondrial defects 
going along with Cox10 inactivation. 
 
4.1.3 THE CNS OF COX10 MUTANT MICE APPEARS NORMAL 
To assess whether respiration-deficient oligodendrocytes were capable to myelinate, 
Gallyas´ silver impregnation on sagittal brain sections was performed at P21. Mutant brains 
seemed unaffected and white matter tracts such as corpus callosum, anterior commissure or 
cerebellar white matter were normally myelinated compared to controls (Fig.I - 3a.). Most 
likely, residual, but sufficient mitochondrial respiration of mutant oligodendroglial 
mitochondria ensures proper myelination. The discrepancy between PNS and CNS might be 
explained by different temporal activity patterns of the CNP1 promoter. In the PNS, CNP1 
drives recombination in still proliferating Schwann cells during embryonic phases, which 
causes a fast dilution of mutant mitochondria to their progeny and hampers efficient 
myelination. In contrast, in the CNS, the CNP1-Cre-mediated Cox10 elimination takes place 
in already postmitotic oligodendrocytes that does not disturb myelination. Since Cox10 
depletion is not followed by a direct COX loss due to the calculated mitochondrial half-life of 
3 weeks, the Cox10 inactivation in postmitotic oligodendrocytes rather leads to a functional 
ageing of mitochondria that preserves correct myelination. 
Thus, we investigated mutant mice at 9 months, at which age they had to be euthanized 
because of severe features of peripheral neuropathy. Surprisingly, no white matter pathology 
could be detected by Gallyas´ silver impregnation of coronal brain sections. The mutants 
were normally myelinated compared to controls and exhibited no sign of morphological 
alterations (Fig.I - 3b.). Even at ultrastructural level, the mutant myelin appeared normal, no 
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evidence for demyelination or other abnormal features such as split or redundant myelin 
could be observed (Fig.I - 3c.). This suggests that mature, postmyelinating oligodendrocytes 




Fig. I - 3 The CNS appears normal and white matter tracts are preserved in Cox10 
mutant mice 
Gallyas´ silver impregnation revealed (a.) no gross morphological or myelinic differences between 
mutant and control of sagittal brain sections at P21, (b.) and white matter tracts were still well 
preserved in mutant coronal brain sections at 9 months when compared to controls. Scale bars, 1 mm. 
(c.) The mutant myelin ultrastructure appeared normal and displayed no sign of hypo- or 
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Alteration of cell size or cytoplasmic composition are known changes evoked by energy 
deprivation (Leist et al., 1997) or lactate accumulation. At ultrastructural level, no overt 
morphological variations of the nucleus or cytoplasm of respiration-deficient oligodendrocytes 
were visible and mitochondria seemed not to be affected in size or abundance (Fig.I - 4a.). 
WB analysis of VDAC (Voltage-dependent anion channel), a major protein of the outer 
mitochondrial membrane, revealed no protein expression difference between 14 months old 
optic nerves of PLP1-CreERT2 * Cox10flox/flox mutants and controls, suggesting a normal 
amount of mutant mitochondria (Fig.I - 4b.,c.).  
 
 
Fig. I - 4 Mitochondria of differentiated oligodendroglia were grossly unaffected in 
Cox10 mutant mice 
(a.) Ultrastructural analysis of mutant mitochondria in optic nerve cross-sections indicated normal 
morphology and abundance (mitochondria are marked by asterisks), (b., c.) the latter was as well 
confirmed by western blot examination of Plp1-CreERT2 * Cox10fl/fl optic nerves at 14 months which 
showed equally intense signal for VDAC, a major mitochondrial protein, compared to controls. 
Numbers are mean ± s.e.m. (d.) Stainings against SDH detected abnormal enlargements of 
mitochondria of CC1-positive mature olgodendrocytes. Scale bar, 500 nm for a. and 10 µm for d. In 
collaboration with Dr. Don Mahad (immunohistochemistry). 
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However, immunostainings against succinate dehydrogenase (SDH), the complex II of the 
respiratory chain, clearly displayed an abnormal expansion of mitochondria of mature CC1-
positive oligodendrocytes in mutant corpus callosum at 9 months, indicating functional 
deficits of mitochondrial respiration (Fig.I – 4d.).  
Although SDH immunolabelling showed an abnormal expansion of mitochondria in 
differentiated oligodendrocytes, the loss of COX function remains to be elusive. To truly 
prove whether the lack of any CNS pathology might be caused by still functional 
mitochondria, sequential COX/ SDH histochemistry on sagittal brain cryosections was 
performed at age of P21 and 9 months. This is a widely used approach to study 
mitochondrial function (Mahad et al., 2009), in which COX activity leads to a brown 
precipitate that completely saturates mitochondria and prevents incorporation of a blue 
precipitate converted by SDH in a subsequent step. At P21 saturation with a brown 
precipitate that covers the entire area of the mutant corpus callosum was obvious and 
comparable to controls (Fig.I - 5a.). The absence of blue, COX-deficient mitochondria in the 
mutants emphasized functional mitochondria at that age, which is in line with the normal 
myelin appearance in white matter tracts in the CNS of Cox10 mutants. Mitochondrial COX 
activity in the corpus callosum of 9 months old mutants yielded a brown saturation of cellular 
compartments and cells, such as axons and astrocytes. By successive SDH histochemistry 
COX-inactive cells could be detected by the accumulation of blue precipitate and were 
identified as oligodendrocytes by labelling with Olig2, a specific transcription factor of the 
oligodendroglial lineage. In age-matched controls evidence for blue, COX-inactive cells was 
neither present in the corpus callosum nor in any other brain region (Fig.I - 5b.). Thus, a 
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Fig. I - 5 Sequential COX/ SDH histochemistry proves the loss of COX activity in 
differntiated oligodendrocytes 
(a.) At P21 all cells of mutant corpus callosum were homogenously saturated by a brown precipitate 
which verified COX activity and were comparable to age-matched controls. (b.) At 9 months the 
mutant corpus callosum showed the incorporation of a blue precipitate (left) in Olig2-positive cells (in 
red, middle) which validated the disruption of COX activity in differentiated oligodendrocytes. Other 
cellular compartments of the mutant corpus callosum were COX-active proven by brown saturation. 
The control corpus callosum showed persistend incorporation by the brown precipitate. Scale bars, 20 
µm. mon, months. In collaboration with Dr. Don Mahad (serial SDH/ COX histochemistry). 
 
Theoretically, white matter integrity could be preserved when newly synthesized 
oligodendrocytes would serve for steady myelination. These cells might survive and 
myelinate for several weeks after Cox10 recombination. To get a first impression whether the 
oligodendrocyte ratio is changed in the mutants, immunostainings against Olig2, a marker for 
the whole oligodendrocyte lineage, were performed on spinal cord cross-sections at P21 and 
9 months. Using an ImageJ Plugin the number of Olig2-positive oligodendrocytes was 
calculated and demonstrated no difference between mutants and controls at both ages 
(Fig.I - 6a.,b.). By this a constant dying of unfunctional respiration-deficient oligodendrocytes 
and their replacement by newly generated ones, that are indeed Cox10 recombined, but still 
have functional mitochondria for a short time could not be excluded. Therefore the analysis 
was extended by a detailed determination of the oligodendrocyte proliferation index in the 
brain which was achieved by a daily treatment with BrdU (5-bromo-2'-deoxyuridine) for 4 
weeks which was induced at 4 months of age. BrdU is a synthetic nucleoside and an analog 
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to thymidine that incorporates into newly synthesized DNA during cell replication. Histological 
investigations revealed that the proliferation rate of BrdU-positive cells in the fimbria of 
Cox10 mutants and controls was nearly the same. Identification of BrdU-incorporated 
oligodendrocytes by co-immunolabelling with Olig2 revealed only sporadic double-positive 
cells (Fig.I - 6c.,d.). To directly evaluate cell death TUNEL staining was performed and 
exhibited no apoptotic cells in all white matter tracts of the mutant brain at 9 month 
(Fig.I - 6e., left and middle). This strongly indicates that mature oligodendrocytes do not 
depend on ATP delivery from oxidative phosphorylation for their survival. For comparison, 
when using CKIIα-Cre mice to delete Cox10 in cortical neurons beginning at age P5–10 
(CKIIαCre/+ * Cox10fl/fl), we observed a massive apoptosis of projection neurons in the 
forebrain at 4 months (Fig.I – 6e., right). This confirms that neuronal survival strictly requires 
oxidative phosphorylation which is in contrast to the viability and function of mutant 
oligodendrocytes. 
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Fig. I - 6 Survival of oligodendrocytes in conditional Cox10 mutant mice 
(a.) By immunostaining against Olig2 of spinal cord cross-sections, the number of oligodendrocytes 
was determined at P21 and 9 months. Sections were counterstained with haemalaun (blue) (b.) The 
quantification of Olig2-positive oligodendrocytes in mutants was comparable to age-matched controls 
(at P21 controls, 11.3 ± 0.4; mutants 12.3 ± 1.4 and at 9 months controls, 9.8 ± 1.3 and mutants, 
8.6 ± 1.0 Olig2-positive oligodendrocytes). (c.) Followed by daily administration of BrdU (denoted in 
green, arrows), a changed proliferation rate of mitotic Olig2-positive oligodendrocytes (depicted in red, 
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arrows) in the fimbria could not be observed in mutant mice. (d.) Significant differences were neither in 
BrdU-positive oligodendrocytes (7.8 ± 1.1 in controls and 6.4 ± 0.9) nor in the total number of BrdU-
incorporated cells (11.6 ± 1.2 in controls and 9.8 ± 1.2) detected. (e.) TUNEL labelling revealed no 
apoptosis in the corpus callosum of 9 months mutants which was a feature of the positive control 
(Cox10fl/fl * CKIIα-Cre, 4 months). All sections were counterstained with hemalaun (blue). Scale bars 
are 250 µm and 100 µm for a., 20 µm for b., 100 µm for c. Numbers are ± s.e.m. n.s., not significant. 
 
 
Severe pathological features such as cell death as a consequence of potentially energy-
deprived Cox10-deficient oligodendrocytes were not detected. However, neuroinflammation 
is a very sensitive sign of degenerative processes in the brain. To assess whether mutants at 
9 months, the end-point of analysis, were affected, several inflammatory markers were tested 
on coronal brain sections. Astrogliosis was not observed in mutant corpus callosum when 
compared with controls, which was detected by immunostaining for GFAP (Fig.I - 7a.). No 
increase of activated microglia visualized by Mac3 immunosignals (Fig.I - 7b.) or invading 
CD3-positive T-lymphocytes (Fig.I - 7c.) were detected in the corpus callosum of conditional 
mutants compared to controls and were only sporadically found in both genotypes. Due to 
tight interconnection between oligodendrocytes and neurons the presence of APP-positive 
endosomes was examined. Accumulation of APP in axonal spheroids is a sign of disturbed 
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Fig. I - 7 No sign of inflammation or neurodegeneration in the brain of Cox10 mutants 
(a.) Immunostaining for GFAP (astrogliosis) of coronal brain sections revealed no difference between 
controls and mutant corpus callosum at the age of 9 months. (b.) Immunosignals for Mac3 (activated 
microglia) and (c.) for CD3 (invading T cells) exhibited a normal range in the corpus callosum and 
were comparable to controls (arrows pointing to single immunocells). (d.) APP positive plaques 
(axonal pathology) could not be detected in both controls and mutants (9 months). All sections were 
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These findings described a normal CNS phenotype in mice harboring respiration-deficient 
oligodendrocytes were astonishing and led to the conclusion, that differentiated mutant 
oligodendrocytes survived by ATP supply from increased aerobic glycolysis. Thus, elevated 
lactate levels were predicted. Localized proton magnetic resonance spectroscopy (MRS) was 
performed to detect levels of different metabolites, among them lactate, in the living brain. 
Indeed, Cox10 mutants showed a significantly increased lactate resonance compared with 
controls in both cortex and white matter at 6–7 months of age (Fig.I - 8a, red asterisks). 
Additionally, the detection of certain other metabolites further confirmed the absence of 
neurodegeneration and oligodendrocyte survival. This was supported by unchanged spectra 
of N-acetylaspartate (a marker of viable neurons and axons), choline-containing compounds 
(indicators of membrane turnover) and myo-inositol (an osmolyte and glial membrane 
constituent). However, it has to be emphasized that accumulated brain lactate was 
detectable only under isoflurane anaesthesia. This narcotic drug is known to inhibit the 
pyruvate dehydrogenase complex by blocking the entry of pyruvate into mitochondria, which 
shifts the glucose metabolism from oxidative phosphorylation towards lactate production and 
enables the enrichment of lactate. Under physiological conditions, lactate levels never reach 
MRS detectability in vivo, unless challenged by isoflurane anaesthesia. Thus, also in controls 
observable lactate concentrations in both analyzed regions could be displayed (Fig.I - 8a.). 
The analysis of mutant cortices and corpora callosa revealed approximately doubled lactate 
concentrations each in contrast to the control regions at both ages, suggesting that Cox10-
ablated oligodendrocytes survive by enhanced aerobic glycolysis (Fig.I - 8b.). More 
important, control white matter displayed higher lactate levels than cortical regions, which 
implies that wildtype oligodendrocytes are best equipped to be lactate-producing cells since 
the corpus callosum is highly enriched with oligodendrocytes in comparison to cortices 
(Fig.I – 8b.). At the end of anaesthesia those lactate increases immediately fell very 
drastically within minutes and finally dropped to undetectable levels when mice woke up 
(Fig.I - 8c.). Hence, lactate that had accumulated under isoflurane anaesthesia was rapidly 
used by other cellular compartments when the narcosis was shut off.  
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Fig. I - 8 Isoflurane-induced elevated lactate levels were rapidly used by cellular 
compartments after anaesthesia 
(a.) Localized proton magnetic resonance spectroscopy of the cortex (left) and corpus callosum (right) 
from mutant and control mice at 6–7 months displayed spectra of different metabolites. In narcotized 
Cox10 mutants lactate was highly accumulated in both regions. Red asterisks denote lactate. (b.) 
Lactate level quantification of the cortex (left) and white matter (right) exhibited an increase in mutant 
mice compared to controls under isoflurane anaesthesia. In control mice higher lactate concentrations 
were obtained in white matter than in cortices. (c.) At the end of isoflurane anaesthesia lactate levels 
dropped to undetectable levels within 30 min. Data are mean ± s.e.m.; n= 6–7 per genotype. Asterisks 
denote significance level  (* p < 0.05). Lac, lactate; Cr, total creatine; Ins, myo-inositol; Glu; glutamate; 
Gln, glutamine; Cho, Choline; NAA, N-acetyl-aspartate; p.p.m., parts per million; mon, months. In 
collaboration with Prof. Jens Frahm and Prof. Susann Boretius. 
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4.2 DISCUSSION 
For decades oligodendrocytes have been considered to be only passive cells that insulate 
their corresponding axons by enwrapping them with myelin. Thus a tight connection between 
oligodendrocytes and the axonal compartment is generated that physically isolates the axon 
from the extracellular space. This enables fast conduction velocity of action potentials, but 
also separates axonal compartments from access to nutrients. Investigations in recent years 
provided growing evidence that oligodendrocytes might as well metabolically support the 
integrity of neurons (Edgar et al., 2004; Griffiths et al., 1998; Lappe-Siefke et al., 2003). One 
highly discussed support mechanism is that oligodendrocytes might shuttle glycolytic end-
products, namely pyruvate or lactate, to axons to promote neuronal energy requirements 
(Nave, 2010; Amaral et al., 2013; Morrison et al., 2013). 
To shed light on this hypothetical metabolic coupling between oligodendrocytes and axons, 
we focused on the possible role of oligodendrocytes to serve as a source of energy-rich 
glycolytic metabolites. Therefore we asked whether oligodendrocytes in the living brain are 
dependent on oxidative phosphorylation and generated mouse models, in which 
oligodendrocytes that could not survive by aerobic glycolysis alone would simply die. This 
was achieved using Cox10 mice  (Diaz et al., 2005), in which exon 6 was flanked by loxP 
sites. The Cox10 gene is evolutionarily highly conserved and exon 6 was identified to share 
sequence homology to the region that codes for part of the active site of the bacterial 
enzyme (Saiki et al., 1993). By crossbreeding them with well-established Cre driver mouse 
lines, the CNP1-Cre and the tamoxifen-sensitive PLP1-CreERT2 mice (Lappe-Siefke et al., 
2003; Leone et al., 2003) recombination was specifically mediated in myelinating glia 
(oligodendrocytes and Schwann cells). Cox10 is essential for the assembly of the 
cytochrome c oxidase (COX), which is the terminal proton-pumping complex of the 
mitochondrial respiratory chain. Thus, by disruption of Cox10 functional COX can not be 
assembled. This has been successfully shown in other mouse models targeting hepatocytes, 
muscle cells or neurons (Diaz et al., 2008, 2005; Fukui et al., 2007). Consequently, COX10-
deficient cells should fail to fully metabolize glucose by oxidative phosphorylation and 
produce most energy by aerobic glycolysis. Hence, lactate needs to be generated to 
maintain the NAD+/ NADH equilibrium for continuous glycolysis. Indeed, elevated lactate 
levels have been observed by MRI analysis in many patients suffering from mitochondrial 
disorders due to defects in one of the complexes of the respiratory chain (Lebre et al., 2011). 
Cox10 disruption in different tissues was reliably revealed in both mouse mutants by 
analyzing the exon 6 excision of the Cox10 locus using qPCRs at the age of 2 months. The 
percentage of detectable Cox10 elimination (in average; brain, 15%; optic nerve, 45% and 
sciatic nerve, 67%) was in accordance with estimated ratios of oligodendrocytes and 
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Schwann cells in the corresponding tissue (Ling and Leblond, 1973; Burne et al., 1996; 
Nakao et al., 1997; Sandell and Peters, 2002; Walhovd et al., 2014) and led to the 
conclusion that all oligodendrocytes and Schwann cells were targeted by Cre recombination. 
Already at P21 an obvious reduction of COX protein in sciatic nerve cross-sections, 
specifically from Schwann cells, was found and confirmed the loss of COX following Cox10 
ablation. COX deficiency was validated to be long-term as shown by WB analysis of 14 
months optic nerves. Importantly, by sequential COX/ SDH histochemistry of brain sections 
the inactivity of COX and thus the disruption of oxidative phosphorylation could be clearly 
depicted specifically in postmyelinating oligodendrocytes. 
By using the CNP1-Cre driver mouse line for targeting Cox10, mice appeared normally 
developed after birth. However, fewer mutants were obtained than expected indicating 
prenatal death of some mice that can be due to the known expression of CNP1-Cre in a 
subset of neuronal precursor cells (Lappe-Siefke et al., 2003). Phenotypical signs of a 
peripheral neuropathy were already detectable at P21 that worsened with increasing age and 
resulted in a premature death at around 9–10 months of age. Schwann cell mitochondria 
were found to be enlarged and increased in number, which is a common feature of 
mitochondrial dysfunction (Diaz et al., 2008; 2005). By ultrahistological analyses, we 
observed pathological features in the PNS already at P21, including dysmyelination of 
medium-sized axons and defects of Remak bundle sorting that was accompanied by axonal 
loss at older age. This indicated that myelination is an energy-consuming process relying on 
proper mitochondrial respiration and thus its immense ATP generation. Interestingly, no 
Schwann cell death could be detected implying that Schwann cells survive despite the lack of 
ATP generation by oxidative phosphorylation. In line with this another mouse model, in which 
the Schwann cell-specific deletion of the mitochondrial transcription factor A gene (Tfam), 
required for mitochondrial DNA transcription and replication (Larsson et al., 1998), caused a 
similar peripheral neuropathy (Viader et al., 2011). In that case the Cre-recombinase was 
expressed under the control of P0 promoter inducing recombination in Schwann cells starting 
at E13.5–E14.5 (Feltri et al., 1999). These mice were characterized by Remak bundle 
disruption and axonal degeneration, and also exhibited Schwann cell survival. In contrast, 
these mutants displayed no obvious dysmyelination (Viader et al., 2011), although 
mitochondria are known to be essential for the synthesis of cholesterol and fatty acids as 
building blocks of myelin (Aeberhard and Menkes, 1968; Matthieu et al., 1973; Saher et al., 
2005). Indeed, mitochondrial diseases display a broad spectrum of clinical phenotypes in 
patients, but are often reported to affect the integrity of myelin in the brain and peripheral 
nerves that can result in the development of leukodystrophies (Cheon et al., 2002; Kumakura 
et al., 2009; Nishino et al., 1999). An example is the Leigh syndrome, a human 
neurodegenerative disease caused by various genetic defects in the respiratory chain, 
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including COX disorders (DiMauro et al., 1987; Cavanagh and Harding, 1994; Yiş et al., 
2009). In patients it has been shown that Cox10 is one of 3 genes responsible for COX 
defects (Valnot et al., 2000) and several missense mutations in the Cox10 gene have been 
found in patients suffering from leukodystrophy or the Leigh syndrome (Antonicka et al., 
2003; Valnot et al., 2000). The ablation of Tfam affects all mitochondrial-encoded proteins, 
thus every complex of the respiratory chain (Larsson et al., 1998). However, Tfam-deficiency 
leads to the disruption of the catalytic core of COX since this part is encoded by 
mitochondrial DNA (Capaldi, 1990). The best explanation for the initially normally developed 
myelin in conditional Tfam mouse mutants (Viader et al., 2011) is that mitochondrial function 
is not completely disrupted during the myelination process. The P0 promoter is indeed 
already active in premyelinating Schwann cells, but only to a very low extent (Feltri et al., 
1999; Lee et al., 1997). Investigations of the temporal expression profile of different Schwann 
cell proteins, including CNP1 and P0 have clearly shown that P0 expression increases during 
postnatal states and peaks around P21 (Stahl et al., 1990). In comparison, CNP1 is the 
earliest marker of the Schwann cell lineage and represents high expression levels already 
during embryonic development (Chandross et al., 1999; Stahl et al., 1990). Thus, it is 
conceivable that many premyelinating Schwann cells escaped Cre-recombination due to 
insufficient early P0 promoter activity resulting from low expression levels at embryonic 
states. Regarding the averaged half-life of mitochondrial proteins of around 24–26 days 
(Beattie et al., 1967; Menzies and Gold, 1971), elimination of mitochondrial DNA is not 
accompanied by an immediate loss of mitochondrial function. Hence, myelination which 
occurs within the first weeks of age in mice should be preserved in conditional Tfam mutants 
(Foran and Peterson, 1992; Skoff et al., 1980; Sturrock, 1980). Further analyses by Viader 
and colleagues uncovered that Tfam-deficient Schwann cells were not energy depleted at 
2 months although all complexes of the mitochondrial respiration are affected by the loss of 
Tfam. The authors found an activation of stress response and a shift in the lipid metabolism 
away from synthesis towards oxidation in respiration-disrupted Schwann cells as likely 
drivers of the demyelinating phenotype observed in these mice (Viader et al., 2013). 
Conditional Cox10 mutants, in whose Cox10 recombination is already induced by early 
CNP1 promoter activity led to a fast dispersion of infunctional mitochondria by mitotic 
expansion of mutant Schwann cell precursors. The progressive dysmyelinating pathology in 
the PNS of Cox10 mutants is an indicator for Schwann cell dependency on functional 
mitochondria to maintain proper myelination. 
The absence of affected myelin in the CNS of conditional Cox10 mutants is as well explained 
by differences in the spatio-temporal expression pattern of CNP1, whose promoter activity 
starts remarkably later in development, when oligodendrocytes were already postmitotic. Due 
to a comparatively slow loss of mitochondrial COX, myelination defects should be prevented 
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by residual mitochondrial function of still myelinating Cox10-deficient oligodendrocytes. Since 
myelination itself requires cholesterol and fatty acid synthesis which takes place in 
mitochondria, it is conceivable that myelinating oligodendrocytes rely on proper mitochondrial 
function (Cuzner and Davison, 1968; Matthieu et al., 1973; Orth and Bellosta, 2012; Saher et 
al., 2005; Aeberhard and Menkes, 1968). This is as well suggested by the sensitivity of 
oligodendrocytes to the COX inhibitor sodium azide (Rinholm et al., 2011). These cells 
correspond to pre-myelinating oligodendrocytes in vivo, and it seems that metabolic 
properties of oligodendrocyte lineage cells change during maturation.  
However, it remains remarkable that pathological alterations could not be observed in the 
adult CNS, even not in aged mice at 9 months when they had to be euthanized due to severe 
PNS neuropathy. At ultrastructural level, myelin appeared normal and oligodendrocytes were 
not obviously affected in conditional Cox10 mutants. By EM analyses neither the density nor 
the morphology of mitochondria in oligodendrocytes seemed to be unchanged. However, 
mitochondria of 9 months old mutants displayed a clear abnormal expansion visualized by 
immunostainings against succinate dehydrogenase, also known as complex II of the 
respiratory chain, and indicated mitochondrial dysfunction. Nonetheless, inflammatory 
processes as a subtle response to the possible lack of ATP supply in oligodendrocytes were 
not a feature of the Cox10 mutant CNS. These results strongly indicate that mature 
oligodendrocytes can easily adapt to aerobic glycolysis ensuring their survival and function. 
Since high dynamics of oligodendrogenesis is a known compensating mechanism in many 
neurological diseases like MS (El Waly et al., 2014), a continuous replacement circle of 
mutant oligodendrocytes by newly synthesized cells that maintain normal oligodendrocyte 
function for several weeks after Cox10 recombination could be a consequence of energy-
deprived oligodendrocytes. Basically, there is no strong evidence for oligodendrocyte 
turnover during healthy young adulthood. Moreover, a recent study analyzing the integration 
of 14C derived from nuclear bomb-tests in 1940 in post-mortem human brains revealed that 
the oligodendrocytic population is very stable throughout life (Yeung et al., 2014). However 
the possibility of replacement was proven by several experiments. The number of Olig2-
positive oligodendrocyte lineage cells of conditional Cox10 mutants at different ages was 
determined which was each comparable to age-matched controls. Direct tracing of 
proliferating cells by EdU incorporation revealed no alterations in the mutants in comparison 
to controls. Moreover, evidence for oligodendrocyte death or a general increased cell death 
could not be observed by TUNEL assessment, demonstrating survival of Cox10-deficient 
oligodendrocytes. These results verified that mature oligodendrocytes, once myelination is 
complete, are independent from energy supply by oxidative phosphorylation and able to 
maintain the integrity of myelin and their associated axons. That differentiated 
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oligodendrocytes survive by aerobic glycolysis similar to cancer cells was unexpected. 
Whether myelinating oligodendrocytes display the same metabolic properties remains to be 
elusive. 
These findings are in agreement with a previous study providing evidence that in various 
white matter tracts of rodent adult brains the glycolytic activity significantly exceeded 
oxidative activity relative to those in grey matter (Morland et al., 2007). Similar, by MRI 
analysis of anaesthetized Cox10 control mice elevated lactate levels were found in the 
corpus callosum when compared to cortical regions. Lactate is a surrogate marker for 
aerobic glycolysis and its stronger accumulation in the control corpus callosum as an 
oligodendrocyte-dense brain structure reflects a higher glycolytic rate in white matter tracts 
compared to the cortex. In Isoflurane-narcotized Cox10 mutant brains significant higher 
lactate levels were observed in both CNS regions when compared to control mice, which 
might originate from mutant oligodendrocytes surviving by enhanced aerobic glycolysis. Of 
note, under physiological conditions lactate is normally not detectable by MRI resolution, 
unless challenged by isoflurane anaesthesia, which inhibits the pyruvate dehydrogenase 
complex and blocks the entry of pyruvate into mitochondria. Lactate production assures 
continuous glycolysis by concomitant NADH regeneration. The detection of lactate in 
anaesthesized control and mutant brains strongly implies that lactate is not disposed by the 
blood flow since isoflurane is described to slightly increase the cerebral blood flow velocity 
(Duong, 2007; Li, Patel, et al., 2013). Directly after switching off isoflurane narcosis lactate 
concentrations fell within minutes to undetectable levels. Thus, the rapid decline of observed 
lactate indicates that lactate, which is the necessary by-product of aerobic glycolysis, is not 
drained by the blood stream. It is more likely that the accumulated lactate is locally taken up 
by other cellular compartments. Therefore, we suggested a model, in which oligodendrocytes 
are metabolically coupled to axons by shuttling glycolysis products to support axonal energy 
demands.  
Traditionally, glucose has been considered as the obligate energy substrate fueling the brain. 
More recent studies showing that neuronal activity can be maintained only in the presence of 
lactate in ex vivo optic nerve preparations (Wyss et al., 2011). Further, cytosolic proteins, to 
which glycolytic enzymes belong, are shuttled via slow axonal transport from neuronal cell 
bodies to more distal compartments (Brady and Lasek, 1981; Oblinger et al., 1988; Yuan et 
al., 1999). Considering the lengths some axons can reach, especially those of motoneurons, 
the sufficient metabolic equipment for glycolysis in distal parts of axons, like synapses, is a 
logistical problem. Thus, this might be overcome by the intimate physical connection of 
oligodendrocytes to axonal compartments enabling metabolic interaction in the axo-glia 
interface. The possibility of shuttling lactate between brain cell types in the living brain is 
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determined by the expression of monocarboxylate transporters (MCT) transferring 
monocarboxylates, including lactate and pyruvate. It has been shown that MCTs are not only 
expressed during suckling in the rodent CNS, when lactate is an important source feeding 
the brain, but also in the adult brain (Vannucci and Simpson, 2003). In fact, their 
concentration remains fairly constant throughout life indicating a necessity for the transport of 
glycolytic intermediates in the adult brain (Vannucci and Simpson, 2003). By immunogold 
labelling of MCT1 the precise oligondroglial expression domain could be assigned to ab- and 
adaxonal myelin regions and the inner tongue (Rinholm et al., 2011; Saab et al., in prep.), 
whereas MCT2 is restricted to myelinated neurons. Thus, a network of transporters is 
generated, which is a prerequisite for providing routes shuttling lactate between 
oligodendrocytes and their associated axons. 
Moreover, MCT1 BAC transgenic mouse indicated that MCT1 is almost exclusively 
expressed by oligodendrocytes (Lee et al., 2012). The inhibition of MCT1 by specific shRNAs 
or pharmacological treatment of spinal cord organotypic cultures resulted in motor neuron 
loss, without affecting oligodendroglial survival. Importantly, neuronal death could be 
prevented by adding exogenous lactate. In vivo disruption of MCT1 genetically or by lentiviral 
knockdown specifically in oligodendrocytes caused a neuropathy in brain and spinal cord. 
This axonal pathology was characterized by swellings of myelinated axons without disrupting 
oligodendrocytic integrity (Lee et al., 2012). These results support the conclusion that the 
lactate transfer of oligodendrocytes is crucial for axonal integrity. The transport direction of 
MCTs is determined by intra- and extracellular concentration gradients of lactate and 
hydrogen (Merezhinskaya and Fishbein, 2009). Hypothetically, the neurodegenerative 
phenotype induced by MCT1 downregulation could also be caused by reduced lactate import 
into oligodendroglia. This possibility is unlikely because the lactate application into the media 
of organic cultures prevented the observed pathology. Further, no sign of oligodendroglial 
apoptosis could be found in vitro and in vivo. Thus, this analysis contributes to the emerging 
concept that oligodendrocytes support axonal survival and function independent from 
myelination (Nave, 2010; Amaral et al., 2013; Morrison et al., 2013) and provides insight that 
the underlying mechanism might rely on lactate supply from oligodendroglia to their 
corresponding axon (Lee et al., 2012). 
These findings serve in vivo evidence that denotes a link between glycolytic metabolism of 
oligodendrocytes and axonal integrity and suggests a metabolic coupling in the axo-glia 
compartment essential to support the ATP budget of energy-deprived axons by shuttling 
energy-rich intermediates from oligodendrocytes to neurons (Lee et al., 2012, Fünfschilling et 
al., 2012). Thus, it will be important to unravel the complexity of metabolic capabilities of 
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oligodendrocytes to understand the contribution of insufficient metabolic support of 




Fig. I - 9 Hypothetical model of the metabolic coupling in the axon-glia compartment 
Oligodendrocytes import glucose via Glucose transporter 1 (GLUT1) and possibly from astrocytes 
through gap junctions (CX, connexins) for glycolysis. Pyruvate enters the mitochondria (yellow) and is 
used in the oxidative phosphorylation for immense ATP production (TCA, tricarboxylic acid cycle). 
With the onset of myelination glucose also contributes to the synthesis of fatty acids (FAS) and myelin 
lipids from acetyl-CoA. In post-myelinating oligodendrocytes aerobic glycolysis is sufficient to cover 
oligodendroglial energy needs. Glycolysis products (lactate) are used by myelinated axons when 
energy-deprived. Lactate can be directly shuttled to axons via monocarboxylate transporters (MCT1 
and MCT2) that are expressed in the internodal myelin and axonal compartments. Picture is taken 
from Fünfschilling et al., 2012. 
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4.3 DETAILED SUMMARY 
Oligodendrocytes ensheath their corresponding axons with myelin, a multi-lamellar, lipid-rich 
membrane enabling fast velocity of action potentials, but also isolates almost the entire 
axonal surface from nutrients in the extracellular space. Mice carrying myelin defects often 
develop neurodegenerative phenotypes in the presence of normal appearing myelin which 
argued for a crucial role of oligodendrocytes in maintaining axonal integrity. Myelin is not an 
impermeable layer. The connection between axons and oligodendrocytes is ensured by 
myelinic cytosolic channels and integrated glucose and monocarboxylate transporters which 
might serve as routes for energy-rich metabolites through the myelin sheath to support 
neuronal energy demands. To obtain supportive evidence for the trophic function of 
oligodendrocytes, conditional mutants were generated by crossbreeding mice floxed for the 
Cox10 gene with mice expressing the Cre-recombinase from the CNP1 promoter which is 
cell type-specifically active in myelinating glia. Since Cox10 is essential for the assembly of 
cytochrome c oxidase (COX), the terminal proton-pumping complex of the respiratory chain, 
its ablation leads to the gradual loss of mitochondrial function. In the PNS, Cox10 mutant 
mice exhibited a severe neuropathy characterized by dysmyelination, abnormal Remak 
bundles and paralysis. Interestingly, in the adult CNS, no signs of myelin deficits, 
neurodegeneration, secondary inflammation or abnormal regeneration were observed in 
conditional Cox10 mutant mice. The pathology in the PNS is most likely caused by the early 
activity of the CNP1 promoter when Schwann cells are still proliferating, whereas in the CNS 
CNP1 drives Cre-recombination in largely postmitotic oligodendrocytes, which presumably 
preserves myelinogenesis by residual mitochondrial function. However, it remained 
remarkable that the inactivation of oxidative phosphorylation did not affect the survival of 
mature oligodendrocytes indicating their independency of ATP supply by mitochondrial 
function. Importantly, by magnetic resonance spectroscopy enhanced lactate concentrations 
in the living brain were revealed only when isoflurane anaesthesia was applied. This narcotic 
agent is an inhibitor of the pyruvate dehydrogenase complex. The lactate accumulation in 
control and mutant mice upon isoflurane exposure and the rapid drop of lactate increases to 
undetectable levels by the end of anaesthesia implied that aerobic glycolysis products from 
oligodendrocytes are normally metabolized by other cellular compartments under 
physiological conditions. Since lactate can sustain neuronal spiking activity of myelinated 
axons, these findings suggest a model in which a link between an oligodendroglial glycolytic 
metabolism and the shuttling of energy-rich metabolites that derived from oligodendrocytes 
can be correlated with neuronal integrity 
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5 PART II: 
SURVIVAL OF RESPIRATION-DEFICIENT ASTROCYTES BY AEROBIC 
GLYCOLYSIS IN VIVO 
5.1 RESULTS 
5.1.1 SURVIVAL OF ASTROCYTES AND DEATH OF NEURONS UPON INHIBITION OF 
THE MITOCHONDRIAL COMPLEX I BY ROTENONE IN VITRO 
To compare the ability of cultured rat astrocytes and neurons to survive glycolytically in the 
presence of oxygen, purified cells were treated with rotenone (concentrations ranging from 
10 nM to 40 nM), which is a plant-derived inhibitor of the mitochondrial respiratory chain 
complex I. The exposure of astrocytes to rotenone for 24 hours caused no obvious alteration 
of astrocyte morphology (Fig.II - 1a.) and no signs of cell death, as quantified by Trypan Blue 
exclusion (Fig.II - 1b.). In contrast, neurons responded very sensitive to the loss of complex I. 
Already the application of 10 nM rotenone led to a striking loss of Tuj1-expressing processes 
and apoptosis as revealed by pycnotic cell nuclei. At higher rotenone concentrations (20 and 
40 nM) complete neuronal loss was observed within 24 hours (Fig.II - 1c.). 
 
 
Fig. II - 1 Cultured astrocytes resist Rotenone treatment that is toxic for neurons 
(a.) Rotenone treated astrocytes (concentrations as indicated) were indistinguishable regarding 
density and morphology from untreated astrocytes shown by GFAP immunolabelling (green). (b.) 
Rotenone did not affect astrocyte survival as quantified by Trypan Blue exclusion. The number of 
viable cells was obtained as followed: 1.47 ± 0.17 * 104 (untreated), 1.18 ± 0.24 * 104 (10 nM 
Rotenone), 1.92 ± 0.46 * 104 (20 nM Rotenone) and 1.91 ± 0.24 * 104 (40 nM Rotenone). (c.) 
Rotenone treatment was absolutely toxic to neurons shown by reduction in Tuj-1 expression (red) and 
pycnotic neuronal nuclei (NeuN in green, DAPI in blue). Scale bars, 50 μm. Numbers are ± s.e.m. 
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Since rotenone also causes mitochondria to generate reactive oxygen species (ROS) (Li, 
Fang, et al., 2013), it could mask respiratory chain energy defects and be more toxic for 
neurons than for astrocytes, which are even protective to neurons in mixed cultures in the 
presence of rotenone (Chang et al., 2013). Therefore we turned to a long-term in vivo 
analysis and to mitochondrial complex IV, whose functional loss is only associated with the 
delayed generation of ROS (Diaz et al., 2012). 
 
5.1.2 GENERATION OF AN INDUCIBLE AND ASTROCYTE-SPECIFIC COX10  MUTANT 
MICE 
In order to analyze whether adult astrocytes in the living brain are dependent on oxidative 
phosphorylation we crossbred Cox10fl/fl mice with tamoxifen-sensitive GLAST-CreERT2 mice 
selectively targeting astrocytes in a temporally controlled fashion. By disruption of the Cox10 
gene functional COX can not be assembled. This was shown in other mouse models, in 
which mutant cells either die or survive by aerobic glycolysis (Fukui et al., 2007b; 
Fünfschilling et al., 2012b). Astrocytes that fulfill their own ATP needs in the absence of 
respiration must generate lactate in order to maintain the NAD+/ NADH equilibrium for 
continuous glycolysis.  
Mice received daily tamoxifen injections for 5 consecutive days, beginning at postnatal 
day 30 (P30). Age-matched control mice were homozygous for the floxed Cox10 gene, but 
either lacked GLAST-CreERT2 when injected with tamoxifen or expressed GLAST-CreERT2 
but received the vehicle only. Considering the calculated half-life time of mitochondrial 
proteins of 3 weeks in the brain (Beattie et al., 1967b; Menzies and Gold, 1971b) histological 
and electron microscopic analyses were performed at the age of 3 months when a significant 
loss of mitochondrial COX function is expected. Additionally, long-term effects in Cox10 
mutant mice were investigated at about one year of age (Fig.II - 2a.). All mutant mice were 
obtained at the expected Mendelian ratio, indistinguishable from control littermates regarding 
phenotypical appearance, cage behaviour, and life-span. 
Recombination of the floxed Cox10 locus was confirmed by PCR analysis of genomic DNA 
purified from the cerebellum and the cerebrum (Fig.II - 2b.,c.). For both regions the loss of 
Cox10 exon 6 could be detected, implying the absence of functional Cox10. In brain genomic 
DNA from control mice no corresponding PCR product was detectable at 3 months 
(Fig.II - 2c.) 
Recombination efficiencies were determined by crossbreeding Cox10fl/fl * Glast-CreERT2 to 
reporter mice R26R-EYFP that express the yellow fluorescent protein YFP upon Cre-
mediated excision of a loxP-flanked transcriptional "stop" sequence (Srinivas et al., 2001a)  
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Fig. II - 2 Inducible deletion of Cox10 and specific reporter gene recombination 
(a.) Mice were tamoxifen injected for 5 consecutive days beginning at P30 to circumvent 
developmental defects. Since the estimated mitochondrial half-life is around 3 weeks, first analysis 
was performed at 3 months. (b.) Conditional mutagenesis of the floxed Cox10 gene, deleting exon 6, 
results in PCR product of 465 bp. Arrows indicate the position of primers for the amplification of the 
recombined allele. (c.) Detection of recombined Cox10 allele from cerebral (cereb) and cerebellar 
genomic DNA (cer) from mutant animals (3 months), but not from age-matched controls. (d.) To 
confirm recombination efficiency, Cox10 mutants were crossbred with a reporter mouse line 
expressing EYFP upon successful recombination. (e.) Virtually all Bergmann glia in the cerebellar 
Purkinje cell layer (labeled with S100β, red) were targeted for recombination as demonstrated by 
intense Cre-sensitive expression of the reporter signal EYFP (green, enhanced with anti-GFP 
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labelling), whereas considerably fewer astrocytes in the underlying granule cell layer and white matter 
were recombined (denoted by green arrowheads). (f.) The recombination of cortical astrocytes was 
quite mosaic. Green arrowheads pointing to recombined astrocytes (labelled with S100ß, red). (g.) 
Quantification revealed an astrocyte recombination ratio of 93.0 ± 2.4% in the pcl; 25.9 ± 4.6% in the 
granule cell layer and 26.4 ± 6.1% in the white matter and 56.2 ± 1.1% in the somatosensory cortex. 
Data are mean ± s.e.m. All scale bars are 50 μm. cer, cerebellum; ml, pcl, Purkinje cell layer; gcl, 
granule cell layer; wm, white matter. 
 
(Fig.II - 2d.). Identification of astrocytes was achieved by colabelling YFP+ cells with S100ß, 
a calcium binding protein and widely used astrocytic marker. As expected, inducible Glast-
CreERT2 expression was mosaic throughout the brain (Mori et al., 2006). In the cerebellum, 
the highest degree of recombined astrocytes (93 ± 2.4%) was found in the Purkinje cell layer. 
These cells were characterized as Bergmann glia (BG) by their localization, shape and 
S100ß-expression. In contrast, in the underlying cerebellar granule cell layer and white 
matter tracts only about 25% of all S100ß-positive astrocytes were targeted by Cre 
recombination (Fig.II - 2e.,g.). In the somatosensory cortex only 55% of S100ß-marked 
astrocytes were recombined (Fig.II - 2f.). Due to high recombination efficiency of BG further 
analyses mainly focussed onto this subgroup of astrocytes. 
To show long-term functional loss of mitochondrial respiration in mutant glial cells, sequential 
COX and succinate dehydrogenase (SDH, also known as mitochondrial complex II) 
histochemistry was performed on brain sections at the age of 14 months. This is a widely 
used approach to study mitochondrial dysfunction (Mahad et al., 2009; Campbell et al., 2011; 
Fünfschilling et al., 2012), in which COX activity results in a brown precipitate that completely 
saturates mitochondria and prevents incorporation of a blue precipitate converted by active 
SDH in a subsequent step. In cerebellar sections of controls the tissue was saturated with 
the brown precipitate, evidence that all cells harbored functional and active COX (Fig.II - 3, 
left). In mutant cerebella the absence of COX activity from Cox10-deficient BG cells was 
validated by the emergence of a blue precipitate (arrows), which was almost absent from 
other cell types. Few bluish spots in the mutant granule cell layer were observable, that most 
likely belong to recombined astrocytes in this region (Fig.II - 3, middle). The scheme 
illustrates the precise localization of mutant, respiration-deficient (blue) BG and astrocytes in 
the granule cell layer of the cerebellum (Fig.II - 3, right). 
 
Part II   Survival of Respiration-Deficient Astrocytes by Aerobic Glycolysis RESULTS 
 
   46
 
Fig. II - 3 Serial COX and SDH histochemistry proves the loss of COX activity in 
Bergmann Glia 
In controls (left) mitochondrial COX activity yielded a brown precipitate in all cells of the cerebellum at 
14 months. In age-matched mutants (middle) cells with BG characteristics were visibly stained by 
active SDH revealing COX inactivity (blue precipitate, white arrows). Bluish spots in the granule cell 
layer indicating recombined astrocytes in this region. Scheme illustrating the precise localization of 
mutant BG in the Purkinje cell layer (in blue, arrows), where as well Purkinje cells (brown, COX active) 
are resided. ml, molecular layer; pcl, Purkinje cell layer; gcl, granule cell layer. In collaboration with Dr. 
Don Mahad and Graham Campbell (serial COX/ SDH histochemistry). 
 
5.1.3 THE CEREBELLUM OF CONDITIONAL COX10 MUTANT MICE APPEARS NORMAL 
To assess whether the conditional lack of COX activity from astrocytes affects the gross 
organization of cerebella hemalaun stainings of cerebellar sections at 3 and 14 months were 
performed. At both ages the cerebellar cytoarchitecture and size (and any other brain region) 
were unchanged in mutant mice (Fig.II - 4a.). Co-immunolabelling with S100ß and GFAP 
displayed unchanged BG morphology and their many processes had properly developed. No 
overt differences of BG cell density could be observed in conditional Cox10 mutants, 
implying that respiration-deficient BG cells were not affected (Fig.II - 4b.). At ultrastructural 
level BG identified by glycogen inclusions appeared normal and their mitochondria were 
unaltered in size and number (Fig.II - 4c.), which suggests that BG cells do not rely on 
oxidative phosphorylation for survival, very similar to myelinating oligodendrocytes in the 
CNS white matter (Fünfschilling et al., 2012).  
 
.  
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Fig. II - 4  The cerebellum and Bergmann glia cells appear normal in Cox10 mutant 
mice 
(a.) The cerebellum appeared normally in mutant mice revealed by haemalaun staining (14 months). 
(b.) BG co-stained with antibodies against S100ß (red) and GFAP (green) were morphologically not 
affected. (c.) Electron microscopy of healthy Bergmann glia nuclei identified by surrounding glycogen 
inclusion showed an unchanged glycogen content and mutant mitochondria were unaltered in size and 
number comparable to controls (10 months). Scale bars are 500 µm for a., 100 µm for b., 500 nm for 
c. G, glycogen; N, nucleus; M, mitochondria 
 
Inflammatory processes can be subtle responses to metabolic deprivation of astrocytes 
(Xanthos and Sandkühler, 2014). However, no evidence for astrogliosis by GFAP 
immunostaining of brains from 14 months old Cox10 mutant mice could be found 
(Fig.II - 5.a.). Furthermore, staining with Mac3, a marker for microgliosis, demonstrated no 
alterations compared to controls (Fig.II - 5b.). Only a few invading T-cells, positive for CD3 
could be observed in brain sections, but comparable to controls (Fig.II - 5c.). Considering 
tight interactions between neurons and astrocytes, it is conceivable that altered function of 
astrocytes can cause CNS pathologies. Therefore, APP immunostainings were performed to 
check for APP-positive endosomes in axonal spheroids, which is evidence for a disturbed 
axonal transport. The presence of APP plaques in Cox10fl/fl * CKIIα-Cre mice driving  
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Fig. II - 5 No sign of inflammation or neurodegenerative processes in Cox10 mutants  
(a.) Immunostaining for GFAP (astrogliosis) in sagittal cerebellar sections revealed no significant 
difference between controls and mutant mice at the age of 14 months. The GFAP-positive cerebellar 
area of sections accounted for 0.79 ± 0.4% in controls and 0.70 ± 0.1% in mutants. (b.) Staining for 
Mac3 (activated microglia) displayed no significant alteration between mutants (7.17 ± 1.5) and 
controls (6.5 ± 1.5) per section. (c.) Immunolabelling for CD3 displayed no increase of invading T-cells 
in the 14-month-old mutants (9.0 ± 1.2) compared to age-matched controls (5.8 ± 3.1) per section. 
Arrowheads point to single immunocells. (d.) APP positive plaques (axonal pathology) could not be 
detected in controls and mutants (14 months), whereas APP positive plaques were accumulated in the 
forebrain of CKIIα-Cre*Cox10fl/fl mice at 4 months. All sections were counterstained with hemalaun 
(blue) to display nuclei. Scale bars, 100 μm. Numbers are ± s.e.m. n.s., not significant. 
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recombination in cortical projection neurons starting from P5–P10 was a key feature of the 
neurodegenerative pathology in these mice. In comparison, even aged conditional 
Cox10fl/fl * GLASTcreERT2 mutant mice (14 months) did not exhibit any sign of APP 
accumulation (Fig.II - 5d.). 
 
5.1.4 NO EVIDENCE FOR ABNORMAL REGENERATION OR CELL DEATH  
CNS integrity could theoretically be preserved when Cox10 mutant astrocytes are rapidly 
replaced by newly generated astrocytes that have escaped Cre recombination. Therefore, 
the proliferation index of astrocytes after a 2-week treatment with EdU (5-ethynyl-2'-
deoxyuridine) beginning 50 days after tamoxifen-induced deletion of Cox10 was explored. 
Histological analysis detected a normal proliferation rate in mutants compared to controls 
(Fig.II - 6a.,b.). Moreover, co-immunolabelling with S100ß bared only sporadic dividing 
astrocytes in mutants and controls. To directly investigate apoptosis in the cerebellum 
TUNEL staining was performed. Neither in the brains of mutant mice nor in age-matched 
controls evidence for increased apoptotic cell death at 3 months and 14 months of age could 
be found (Fig.II - 6c.). In contrast, Cox10-deficient cortical projection neurons, using Cox10fl/fl 
* CKIIα-Cre mice showed massive apoptosis in the forebrain confirming strict dependency of 
neurons on oxidative phosphorylation (Fig.II - 6d.). 
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Fig. II - 6 Survival of Bergmann glial cells of Cox10 mutant mice 
(a.) Proliferation index was determined by EdU (red) administration. Mitotic S100ß+ cells (green) in the 
cerebellum of mutant mice and controls were almost absent. Asterisks denote dividing non-astrocytic 
cells. (b.) Similarly, there was no significant difference in the total number of EdU positive cells 
(47.7 ± 8.3 in controls and 41.75 ± 3.1 in mutants). Scale bar, 20 μm. Numbers are ± s.e.m. (c.) By 
TUNEL labelling of the cerebellum at 3 and 14 months, control and mutant mice revealed no apoptotic 
cells, (d.) which were easily detectable in a positive control (forebrain of Cox10fl/fl * CKIIα-Cre at 4 
months). Scale bar, 100 µm. cer.sec., cerebellar section; n.s., not significant. 
 
5.1.5 NORMAL BERGMANN GLIA MORPHOLOGY AND SYNAPSE DENSITY 
Astrocytes contribute to the formation and maintenance of synapses and are thought to be 
involved in the regulation of synaptic transmission and plasticity (Chen et al., 2012; Gourine 
et al., 2010; Ullian et al., 2001a) The close proximity of astrocytic processes to synapses 
allows a bidirectional communication between both cellular compartments. To assess 
whether respiration-deficient BG cause morphological changes of the tripartite synapse 
compartments consisting of parallel fiber (PF) projecting to Purkinje cell spine (PC) and their 
ensheathing BG process ultrastructural analysis were performed. Quantification of PF-PC  
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Fig. II - 7 Normal synapse density and BG process coverage in Cox10 mutant mice 
(a.) EM images of the upper third of the ML from control and mutant mice at 9–10 months of age. BG 
processes are false-colored pink and synapses are indicated with asterisks. Scale bar, 1 μm. (b.) PF-
PC synapse density was quantified in randomly acquired EM images. At both timepoints no significant 
differences could be observed between control and mutant mice. At 3 months, controls revealed a 
synaptic density of 14.7 ± 0.9; mutants 17.8 ± 0.2 and at 9–10 months, 16.8 ± 0.6 in controls and 
18.2 ± 1.9 PF-PC synapses in mutants each per 100 µm2. (c.) Mutant PF-PC synapses  were normally 
covered by BG processes (pink) when compared to controls at both timepoints analyzed (at 3 months, 
controls 100 ± 8.4%, mutants 74.7 ± 24.3% and at 9–10 months, controls 100 ± 7.8%, mutants 89.8 ± 
11.9%). (d.) The mitochondrial density in mutant BG processes was normal compared to controls at 
9–10 months and displayed per 100 µm2 36.4 ± 2.1 in controls and 33.7 ± 0.9 mitochondria in mutants. 
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synapses in the upper part of the molecular layer displayed normal synaptic densities in 
conditional Cox10 mutant mice in comparison to controls (Fig.II - 7a.,b.). Further, BG 
processes surrounding PF-PC synapses were investigated. Swollen BG processes can be 
an indicator for accumulated lactate and thus acidosis, and process retraction is reported to 
be associated with synapse dysfunction (Saab et al., 2012). The calculation of BG process 
area of mutant relative to control mice revealed no differences at 3 and 10 months of age 
(Fig.II - 7a.,c.). Moreover, the mitochondrial density in BG processes was normal in mutants 
compared to age-matched controls (Fig.II - 7d.). This is in agreement with the finding that 
glycolytic astrocytes maintained normal brain functions in vivo.
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5.2 DISCUSSION 
The cellular origin and fate of lactate and its contribution to brain energy metabolism are 
important, and still open issues and led to diverse hypotheses mainly based on conflicting in 
vitro data (Pellerin and Magistretti, 1994; Bouzier-Sore et al., 2013; Dienel, 2012; DiNuzzo et 
al., 2010; Hertz et al., 2014; Magistretti and Allaman, 2015; Patel et al., 2014). More than 30 
years ago as the discovery of the misbalance between cerebral oxygen utilization, blood flow 
and glucose consumption during brain activation was unraveled using improved 
neuroimaging techniques (Fox et al., 1988; Fox and Raichle, 1986) a new research direction 
was introduced, which finally originated in diverse concepts by today. There are two main 
models facing each other. Studies by Dienel and Cruz implied that lactate, wherever 
generated, is detrimental for the CNS and is rapidly disposed of by the blood stream (Dienel 
and Cruz, 2003). That lactate is a by-product of active synapses, which is dispersed via gap 
junction coupled astrocytes into capillaries, was specified by Gandhi and collegues (Gandhi 
et al., 2009). Controversely, the observation has been made that glutamate, the main 
neurotransmitter in the CNS, can be taken up by astrocytes which stimulates glucose uptake. 
This triggers the production of lactate by aerobic glycolysis, which is in turn shuttled to 
glutamatergic synapses to cover neuronal energy requirements (Bouzier-Sore et al., 2006; 
Pellerin and Magistretti, 1994; Pellerin et al., 1998). However, direct in vivo approaches to 
determine the role of endogenously generated lactate are difficult to implement technically.  
To address the open question whether astrocytes in vivo are capable of providing lactate to 
neighboring cells to support neuronal energy demands, a new mouse model was generated. 
Therefore, the mitochondrial complex IV (COX) was indirectly inactivated by targeting the 
Cox10 allele (Diaz et al., 2005) in adult astrocytes by using the tamoxifen-inducible 
GLASTcreERT2 mouse line (Mori et al., 2006). Successful recombination by Cre activity was 
displayed by intense reporter EYFP expression of almost all Bergmann glial cells in the 
cerebellum (Srinivas et al., 2001), and called for further analyses of this brain region. Cox10-
mutant astrocytes are forced to live glycolytically, whereby lactate as a necessary by-product 
needs to be generated to retain the NAD+/ NADH equilibrium ensuring continuous glycolysis. 
Elevated lactate levels as a consequence of Cox10 ablation have been reported in 
conditional mouse mutants harboring Cox10-deficient oligodendrocytes and in patients with 
Cox10 germline mutations (Valnot et al., 2000; Antonicka et al., 2003; Fünfschilling et al., 
2012). 
Conditional Cox10flox/flox * GLASTcreERT2 mutants were obtained at expected Mendelian 
ratios. They appeared normal and were phenotypically indistinguishable from controls up to 
an old age of 14 months. Long-term effects of Cox10 disruption was proven by sequential 
COX/ SDH histochemistry at the age of 14 months which revealed the absence of COX 
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activity from BG cells. Notably, histological analysis exhibited a normal cerebellar structure at 
3 months (when COX ablation in BG is expected) as well as at 14 months. Morphology or 
density of BG cells themselves were not altered, which is in good agreement with the survival 
of cultured rotenone-treated astrocytes. Astrocytes are normally not postmitotic in the healthy 
brain, but it is conceivable that mutant astrocytes could be replaced by newly generated 
astrocytes, which have escaped Cre-recombination. However, evidence for apoptosis or 
elevated astrogenesis could not be detected in mutant mice. Thus it is more likely that 
astrocytes survive as glycolytic cells and are still able to fulfill their functions. Additionally, 
glycogen, which is the astrocyte-specific storage form of glucose and largest energy reserve 
the in the adult brain (Brown et al., 2004; Magistretti et al., 2008), was normally distributed in 
conditional mutants. It has been shown that astrocytic glycogen mobilization is essential to 
sustain neuronal firing in optic nerve preparations (Brown et al., 2005; Tekkök et al., 2005) 
and in vitro studies suggested that glycogenolysis results in lactate release (Brown, 2004; 
Dringen et al., 1993). Moreover, pharmacological blocking of glycogen breakdown interferes 
with hippocampal long-term memory formation, which also suppresses the increase of 
lactate that is normally associated with memory formation (Suzuki et al., 2011). 
Importantly, no sign of mitochondrial morphological abnormalities was detected, such as 
swellings, a feature of mitochondrial dysfunction in Cox10-deficient skeletal muscle cells, 
hepatocytes and Schwann cells  (Diaz et al., 2005, 2008; Fünfschilling et al., 2012). This 
indicates that a physiological adaptation has taken place, possibly as a result of normal 
astroglial differentiation. Unfortunately, the relative percentage of Bergmann glial cells to the 
total cell number of the cerebellum is too small for the application of 3H-NMR spectroscopy 
as a tool to quantify the cerebellar lactate concentration. 
Axonal swellings, APP accumulation and neuroinflammation comprise a sensitive response 
to neurodegenerative processes. The absence of any tested neuroinflammatory marker 
suggests that mutant Bergmann glia (and their neighbors) are not distressed by the 
conditional lack of mitochondrial respiration. Bergmann glia, which are in intimate contact to 
synapses play an important role in the maintenance of synapses in vitro (Ullian et al., 2001). 
Moreover, it has been shown that Bergmann glia are necessary to retain physiology and 
plasticity between parallel fiber (pf) and Purkinje cell (pc) synapses (Saab et al., 2012). 
Morphological alterations of astrocytic processes engulfing their corresponding synapse 
would be indicators for astrocyte-derived energy disturbances (Saab et al., 2012). However, 
mutant cerebellar PF-PC synapse densities or the area of astrocytic processes enwrapping 
PF-PC synapses were comparable to control mice. 
This suggests that astrocytes can live by aerobic glycolysis alone, as already exhibited by 
the survival of cultured astrocytes upon rotenone treatment. More importantly, the lack of any 
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pathological alteration in the living brain of conditional Cox10 mutants confirmed their 
independency of ATP generation by mitochondrial respiration. In striking contrast, cultured 
neurons responded very sensitive to rotenone-induced complex I inhibition and led to 
massive apoptosis. Importantly, genetic targeting of Cox10 in a subset of neurons using 
CamKinaseIIα-Cre driver line (Minichiello et al., 2002) resulted in severely affected 
conditional mutants. CamKinaseIIα expression is restricted to cortical projection neurons of 
the forebrain, starting at P5–P10 and showed an activity peak phase around P60 in mice. 
These neuronal mouse mutants were obtained in normal Mendelian ratio, but showed 
already at age P21 signs of neurodegeneration, which were progressive with age resulting in 
complete paralysis of fore- and hindlimbs and the premature death by the age of 4 months. 
Histological analysis at this final timepoint revealed vigorous axonopathy determined by APP 
accumulations that were accompanied by severe neuronal cell death. Bearing in mind that 
Cox10 depletion is not followed by an immediate loss of mitochondrial function, predicted to 
take around 1 month (Beattie et al., 1967; Menzies and Gold, 1971) and the 
comprehensively late postnatal CamKinaseIIα-mediated Cre-expression might explain the 
relative late onset of prominent features of neuropathy by 2 months in neuronal Cox10 
mutant mice. However, the severity of neurodegeneration is remarkable since only a small 
subpopulation of neurons is targeted by Cre-recombination. This highly emphasizes the 
absolute dependency of neurons on mitochondrial ATP production (Fukui et al., 2007, own 
observation). Both conditional mutants develop different phenotypes, ranging from not 
(astrocytes) or severely (neurons) affected. This is in perfect agreement with previous 
transcriptome analyses displaying variations of the metabolic enzyme profiles of neurons and 
astrocytes, and even an astrocytic preference for glycolytic pathways (Lovatt et al., 2007; 
Cahoy et al., 2008). Moreover, nitric oxide-stressed neurons in culture are unable to respond 
with enhanced glycolysis due to missing glycolytic activators in their enzymatic repertoire 
(Almeida et al., 2001). Interestingly, genetic and pharmacological approaches both leading to 
the upregulation of glycolytic activators in cultured neurons and thus to an increased rate of 
glycolysis, concomitantly caused massive neuronal apoptosis (Herrero-Mendez et al., 2009). 
The observed neuronal cell death is explained by the diversion of glucose towards glycolysis 
and away from Pentose-Phosphate-Pathway (PPP) resulting in oxidative stress-induced 
apoptosis. The authors further concluded that neuronal consumption of glucose by the PPP 
to maintain their antioxidant status may take priority over the use of glucose to fulfill their 
energetic requirements (Herrero-Mendez et al., 2009). Thus this finding is in good 
accordance to the ANLS concept proposing that neuronal compartments are metabolically 
supported by shuttled lactate which derived from astrocytes. 
The rapid exchange of metabolites across the plasma membrane of cells requires expression 
of appropriate transporters. By the close contact to blood vessels and the expression of 
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glucose transporters (GLUT) astrocytes are best positioned and equipped to excessively 
take up glucose from the blood stream. In fact, it has been shown that the blood flow velocity 
can even be adapted by astrocytes due to neuronal activity (Gordon et al., 2007; Attwell et 
al., 2010). Moreover, MCTs are expressed on glia and neurons, which serve as routes for 
monocarboxylates like lactate and pyruvate, and remained stably expressed in adulthood 
(Vannucci and Simpson, 2003). Importantly, the shRNA-mediated loss of MCT1 and MCT4 
from astrocytes, or MCT2 from neurons perturbed long-term memory formation, whereas 
short-term memory appeared independent of lactate shuttling (Suzuki et al., 2011). These 
data denote the importance of lactate transport between cells for the establishment of higher 
brain functions, but remain to a high extent indirect with respect to the in vivo source of brain 
lactate. Since the transport direction of MCTs is dependent on lactate and hydrogen 
concentration gradients, these investigations do not serve as a clear in vivo proof for the 
ANLS hypothesis. However, it has to be mentioned that MCT1 was detected to be as well 
expressed by oligodendrocytes (Lee et al., 2012). Thus, the metabolic consequence of 
blocking MCT1 of oligodendrocytes was not considered in this study. Indeed, Suzuki and 
colleagues demonstrated that the inhibition of glycogen breakdown, which is exclusively 
found to be stored in astrocytes, reduced long-term memory establishment (Suzuki et al., 
2011). However, the interconnection between astrocytes and oligodendrocytes has been 
shown to be important for maintaining brain physiology. This was reflected by the premature 
death of mice by 3 months, caused by the disruption of astrocyte-oligodendrocyte by the 
selective loss of their gap junctions (Tress et al., 2012). The specific ablation of astrocyte–
oligodendrocyte connection results in hypomyelination of white matter tracts and revealed 
indications of osmotic problems within the oligodendroglial compartment at ultrastructural 
level (Tress et al., 2012). Moreover, mutations in gap junctions are known to contribute to the 
development of the Charcot-Marie-Tooth disease, an inheritated peripheral neuropathy and 
as well the Pelizaeus-Merzbacher disease, which is a severe leukodystrophy (Uhlenberg et 
al., 2004; Kleopa and Scherer, 2006). Although the function of astrocyte-oligodendrocyte gap 
junctions is not well understood, they are able to shuttle energy metabolites such as glucose 
(Rouach et al., 2008) and possibly could also transport lactate. This emphasizes the 
importance of proper coupling of neurons, astrocytes and oligodendrocytes and implied that 
the rapid exchange of metabolites within different cell types is essential for their function and 
survival.  
Our findings provide in vivo evidence that the survival of respiration-deficient Bergmann glia 
is ensured by ATP generation by aerobic glycolysis alone, which contributes to the general 
understanding of brain metabolism. While of interest as an artificial experimental situation, 
the data also imply that these astrocytes must be a continuous source and not a sink of 
lactate, and this not for short time but for a year and more. In the cerebellum, this applies to 
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more than 90 % of all Bergmann glial cells, in the absence of any sign of pathology or 
cerebellar dysfunction. These in vivo data are no in vivo proof, but in perfect agreement with 
the original ANLS hypothesis.    
However, this work provides new insights and raised further questions to the understanding 
of brain metabolism. Further investigations are needed to clarify metabolic capabilities of 
oligodendrocytes and the trophic interconnection of oligodendrocytes and astrocytes to 
neurons and among each other. This is important to fully reconstruct the contribution of glial 
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5.3 DETAILED SUMMARY 
Glucose is assumed to be the major energy metabolite of the adult brain. With the discovery 
of an uncoupling between cerebral oxygen utilization, blood flow and glucose consumption 
during brain activation, the participation of lactate as an important energy substrate to fuel 
the brain has been widely accepted in recent years. Astrocytes that are in intimate contact to 
synapses are widely discussed to support local energy requirements at glutamatergic 
synapses by shuttling glucose-derived lactate. However, the cellular origin and fate of lactate 
and its contribution to CNS energy metabolism are important and still open issues and led to 
diverse hypotheses mainly based on conflicting in vitro data.  
To address the open question whether astrocytes in vivo are capable of providing lactate to 
neighboring cells to satisfy neuronal energy demands, conditional mouse mutants were 
generated. Therefore, the mitochondrial cytochrome c oxidase (COX) was indirectly 
disrupted by targeting the Cox10 allele. COX10 is an essential assembly factor for COX and 
its ablation causes the gradual ablation of mitochondrial function. Hence, mutant astrocytes 
can survive by aerobic glycolysis or simply die. Cell type-specific Cox10 inactivation in adult 
astrocytes was achieved by using the tamoxifen-inducible GLASTcreERT2 mouse line, which 
drives Cre-recombination in the majority of Bergmann glia, a specific astrocyte subpopulation 
in the cerebellum. This was confirmed by Cre-mediated reporter expression. However, 
conditional mouse mutants were fully viable and long-lived. Respiration-deficient astroglial 
cells showed no sign of cell death or any morphological alterration. Interestingly, using the 
same genetic modification conditional mouse mutants with Cox10-ablated projection neurons 
were apoptotic emphasizing their strict dependency on ATP generation by oxidative 
phosphorylation. In the astroglial mutants, not even unspecific indications of inflammatory 
processes and abnormal proliferation were detectable. Furthermore, synapses between 
parallel fibers and Purkinje cells were present in normal number and were normally covered 
by Bergmann glia processes when compared to control mice.  
This work provides in vivo evidence that the physical survival of respiration-deficient 
Bergmann glia is ensured by ATP supply by aerobic glycolysis alone and strongly indicates 
that astrocytes must be a continuous source and not a sink of lactate and this applies to 
more than 90% of all Bergmann glial cells in the cerebellum. These in vivo data are no final 
proof yet, but further strengthen the original ANLS hypothesis and contribute to the general 
understanding of energy metabolism of the brain.    
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6 PART III:  
PKM2- A MODULATOR OF THE BALANCE BETWEEN GLYCOLYSIS 
AND OXIDATIVE PHOSPHORYLATION 
6.1 RESULTS 
The pyruvate kinase, a key enzyme of the glycolysis, exists in several isoforms catalyzing the 
conversion of phosphoenolpyruvate (PEP) to pyruvate. The most active isozyme is PKM1, 
which is ubiquitous expressed, whereas the other forms show cellular and developmental 
specificity. PKM2, whose activity is described to be adjustable, displays strong expression 
during embryonic phases when cells are highly mitotic and is replaced by PKM1 expression 
in postnatal states. However, it has been shown that PKM2 is still present in highly 
proliferating tissues like lung or fat tissue. Moreover, an abundant PKM2 expression was 
detected in cancer cells, which are the most prominent glycolytically living cells, and has 
caught much attention by cancer research. There is emerging evidence that PKM2 is 
necessary for tumor growth and proliferation (Mazurek et al., 2005; Christofk et al., 2008; 
Spoden et al., 2009; Sun et al., 2011). 
We hypothesize that oligodendrocytes are not only responsible for myelination, but might as 
well provide metabolites, most likely glycolytic end products, to their associated axons to 
locally support neuronal energy requirements. The underlying mechanism how 
oligodendrocytes can adapt to a rather glycolytic metabolism remains to be elusive. 
Therefore we focused our PKM2 due to its role in adapting cancer metabolism.   
6.1.1 PKM2 IS EXPRESSED IN DIFFERENT CELL TYPES IN VITRO 
To get a first impression whether PKM2 is expressed by brain cells in vitro, immunolabelling 
of PKM2 was performed on isolated glial and neuronal cells obtained from rats. In neurons, 
PKM2 was detectable in the cytoplasm and axons. By strong colocalization with NeuN, a 
neuron-specific transcription factor, a nuclear PKM2 expression could not be excluded 
(Fig.III - 1a.). A prominent PKM2 expression was found in astrocytes. The signal was 
homogenously distributed in astrocytic cytoplasm and cell processes, whereas the nuclear 
DAPI-positive area was only sparsely covered with PKM2-positive staining, indicating that 
this weak PKM2 signal might rather derive from the above located layer of cytoplasm than to 
a true nuclear expression (Fig.III - 1b.). Oligodendrocytic PKM2 expression was investigated 
at different developmental states. For the more immature state, oligodendrocytes were just 
grown for 12 h in the differentiation medium SATO to achieve the polydendrocytes status. To 
obtain differentiated oligodendrocytes that already developed myelin sheaths, cultures were 
left for 6 days in SATO medium. Microscopic analysis of immunolabeled cells indicated a  
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Fig. III - 1 PKM2 is expressed by main CNS cell types in vitro 
Microscopic inspection of cultured (a.) neurons identified by NeuN expression, (b.) astrocytes positive 
for GFAP and (c.) immature oligodendrocytes visualized by O4 signal revealed co-immunolabelling of 
PKM2 (red). Confocal microscopic analysis of (d.) immature oligodendrocytes confirmed partly the 
microscopically observed nuclear PKM2 expression and (e.) differentiated oligodendrocytes identified 
by MBP expression exhibited PKM2 signals mainly distributed in the cytoplasm and processes. Scale 
bars are for a., b., 50 µm; c., d., 5 µm; and e., 10 µm. oligod., oligodendrocyte; diff., differentiation. 
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shift in the expression pattern between immature and more differentiated oligodendrocytes. 
In polydendrocytes, immuno-positive for O4 (sulfatide, an oligodendroglial surface marker), 
PKM2 expression seemed to be restricted to the nucleus (Fig.III - 1c.). To get a better insight 
into true localization of PKM2 expression, confocal analysis was performed. For more 
immature oligodendrocytes, a partial nuclear accumulation of PKM2 could be confirmed, 
while a cytoplasmic distribution was as well observable (Fig.III - 1d.). However, differentiated 
oligodendrocytes still revealed a cytoplasmic and myelin-associated localization, and only 
weak PKM2 expression in the nucleus (Fig.III - 1e.). Several studies describe a correlation 
between the cellular expression domain of PKM2 and its activity state. It has been reported 
that nuclearly expressed PKM2 had dissociated to dimers resulting in less affinity to its 
substrate PEP and thus a reduced activity. In comparison, PKM2 expression found to be 
localized in the cytoplasm is a strong indication for a tetrameric, full-active kinase 
(Dombrauckas et al., 2005; Gui et al., 2013; Yang et al., 2011). Hence, an alteration of the 
PKM2 expression pattern is a hint that oligodendrocytes change their metabolic program with 
regard to their differentiation state. This could mean that polydendrocytes which are at the 
beginning of myelination might slow down their glycolytic rate to accumulate glycolytic 
intermediates that are needed to build up macromolecules by other debranching pathways. 
In turn, when oligodendrocytes have already synthesized myelin sheaths, PKM2 associates 
to active tetramers promoting glycolysis and thus energy production. 
 
6.1.2 PKM2 IS EXPRESSED IN THE LIVING BRAIN 
To evaluate whether PKM2 is as well expressed in the living brain, immunolabelling against 
PKM2 on sagittal sections of wildtype mice (3 months) was performed. Throughout the brain, 
PKM2-positive cells could be observed. In all grey matter regions including hippocampus, 
striatum and hindbrain PKM2-labeled cells of similar size and morphology characteristics 
were found. All of them displayed a prominent PKM2 signal in the cytoplasm and processes. 
The highest density of PKM2 expressing cells was distributed over the cortex (Fig.III - 2a.,b.). 
Microscopic analysis of wildtype optic nerve samples (1 month), where oligodendrocytes 
make up to 60% of all residing cells, revealed that many cells expressed PKM2 in the 
cytoplasm (Fig.III - 2c.). Theses cells were often located in a row, which is a typical feature of 
oligodendrocytes. Due to missing co-labelling these cells can not be reliably classified as a 
specific cell population in the brain. However, that PKM2 is at all expressed in the adult brain 
is remarkable. So far, PKM2 expression was mainly described being exclusively restricted to 
embryonic, highly proliferating, mature cells and tumors. 
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Fig. III - 2 PKM2 is expressed in the adult mouse brain in vivo 
(a.) Microscopic analysis of sagittal brain sections of 3 months old wildtype mice showed PKM2- 
positive cells throughout the brain. The cortical region is exemplarily depicted, where the highest 
density of PKM2-expressing cells of all grey matter areas was observed. (b.) High power magnification 
of (a.) showing single PKM2-labeled cells. PKM2 expression was detectable in cytoplasmic regions 
and processes. (c.) Microscopic inspection of longitudinal optic nerve sections of 1 month old wildtype 
optic nerves revealed PKM2-expressing cells, lined up in a row, which is a characteristic of 
oligodendrocytes. Scale bar 50 µm was applied for all images. 
 
6.1.3 PKM1/ PKM2 TRANSCRIPT EXPRESSION PATTERN OVER AGE 
PKM2 is expressed in adult cells of the rodent brain. To extend this analysis with regard to 
PKM2 time course expression, transcript levels of PKM2 in different tissues at various 
developmental states were investigated by quantitative RT-PCR. Therefore, optic nerves as 
oligodendrocyte-enriched and cortices as a neuron-dominated region were examined. The 
focus was set on the analysis of P8 tissue (when myelination is at its starting point), P15 (a 
peak phase of myelination), P24 (when almost all axons are covered with myelin) and 
3 months old tissue (when myelination is finished). PKM1, which is described to be the 
ubiquitous form of the pyruvate kinase, and total amounts of PKM transcripts were as well 
studied. Therefore, specific primer pairs were designed which were located to span 
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alternatively spliced exons. To quantify specifically PKM1 transcripts primers were positioned 
in exon 9 and 11 (exon 10 is excized) and for PKM2 in exon 8 and 10 (exon 9 is excluded). 
To detect both isozymes (total PKM) forward and reverse primers were located in exon 11, 
which is never spliced (Fig.III - 3a.). As  
The analysis of total PKM transcripts revealed that its expression in optic nerves was stable 
at all timepoints tested and showed only a little increase over age (Fig.III - 3b.). Considering 
only PKM1 mRNA expression, optic nerves revealed a significant reduction between P8 and 
P15, which is a developmental state characterized by high myelinogenesis. In older ages a 
strong and significant rise of PKM1 transcripts could be detected (Fig.III - 3c.). In turn, PKM2 
transcript expression in optic nerves was slightly elevated from P8 to P15, dropped 
significantly in P24 optic nerve samples and was found to be significantly raised again by the 
age of 3 months (Fig.III - 3d.). 
In comparison, cortical samples showed a clear elevation of total PKM transcripts during 
development, which was even significant between P8 and P15 as well as P15 and P24 
(Fig.III – 3e.). PKM1 mRNA levels were also continuously enhanced in cortical homogenates 
over age, but the significance was not as strong as in optic nerves (Fig.III - 3f.). Comparable 
to optic nerves similar PKM2 mRNA expression patterns could be detected in cortices with 
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Fig. III - 3 PKM, PKM1 and PKM2 mRNA expression in cortex and optic nerve of at 
different ages 
(a.) Scheme representing the localization of primer pairs for specific detection of relative mRNA 
expression levels of PKM (blue/red), PKM1 (red/red) and PKM2 (green/green). (b.) In optic nerves 
PKM mRNA expression remained mainly constant, only a slight trend to an increase of PKM 
transcripts could be observed over age (P8, 1 ± 0.034; P15, 1.15 ± 0.033; P24, 1.36 ± 0.014; ad, 1.46 
± 0.046). (c.) PKM1 mRNA expression in optic nerves dropped from P8 to P15 (P8, 1 ± 0.096; P15, 
0.47 ± 0.027), whereas a significant raise could be observed in older states (P24, 1.13 ± 0.168; ad, 
4.22 ± 0.548). (d.) PKM2 transcript levels were constant from P8 to P15 (P8, 1 ± 0.107; P15, 1.08 ± 
0.039), decreased by P24 and exhibited a rise in adult states of optic nerves (P24, 0.68 ± 0.03; 
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ad, 1.2 ± 0.078). (e.) PKM mRNA expression in cortical regions revealed a significant increase over 
age (P8, 1 ± 0.026; P15, 1.66 ± 0.055; P24, 2.53 ± 0.077; ad, 2.8 ± 0.103), (f.) which was also true for 
the analysis of PKM1 mRNA expression in cortices showing similar expression patterns 
(P8, 1 ± 0.064; P15, 1.51 ± 0.102; P24, 2.06 ± 0.04; ad, 3.11 ± 0.335). (g.) PKM2 transcript levels in 
cortical regions increased from P8 to P15 (P8, 1 ± 0.088; P15, 1.7 ± 0.099), dropped by P24 and rose 
again by adulthood (P24, 0.73 ± 0.047; ad, 1.53 ± 0.11). Transcript levels of PKM, PKM1 and PKM2 
are relative data that were normalized to averaged Rpl13a and Rpl0 mRNA expression. Asterisks 
denote significance level (* p < 0.05; ** p < 0.01; *** p < 0.001) and referred to the flanking time points 
each. Depicted are averaged means ± s.e.m of grouped tissues from individual wildtypes (n=3–10). 
 
 
6.1.4 PKM/ PKM1/ PKM2 PROTEIN EXPRESSION IN THE BRAIN 
To get better insights into PKM2 protein expression quantities, western blot analysis was 
performed. Therefore, different brain regions displaying varying cell type compositions were 
investigated. Optic nerve and corpus callosum homogenates served as oligodendrocyte-
enriched tissues and cortices were used as neuron-dominated region. Moreover, the 
expression level between developmental states (P15) when myelination reaches its peak 
phase and adult animals (3 months) were compared. Since PKM2 is not the only isozyme in 
brain and PKM2 activity can be negatively modulated by phosphorylation at tyrosine residue 
105, the expression of PKM1 and p-PKM2 was as well explored (Hitosugi et al., 2009).  
The analysis of PKM1 demonstrated abundant expression in all examined tissues at both 
time points when compared to GAPDH signal used as loading control and for normalization. 
A trend of stronger PKM1 expression in adult samples of both corpus callosa and optic 
nerves when compared to their corresponding P15 time point and in comparison to adult 
cortical homogenates was clearly visible, but without significance. In neuron-enriched 
cortices no alterations of PKM1 expression could be observed between P15 and adult stages 
(Fig.III - 4a.). These results were in good accordance with the data obtained from the PKM1 
mRNA expression study.  
In contrast, optic nerve and corpus callosum homogenates of P15 and adult animals showed 
a high abundance of PKM2 signal when compared to GAPDH signal and cortical PKM2 
expression levels. Quantification of western blots uncovered a 4-fold (for P15) and a 5-fold 
(for adult) stronger PKM2 signal in optic nerves compared to the corresponding cortical time 
point. Similarly, strong PKM2 expression, but to a lesser extent, was found for corpus 
callosum homogenates, where a 3-fold (for P15) and 4-fold (for adult) more abundant PKM2 
signal was detected in contrast to respective cortical time points. A significant 
higher expression level was obtained in P15 optic nerves compared to P15 corpora callosa.  
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Fig. III - 4 Protein expression of PKM1, PKM2 and p-PKM2 in mouse white matter tracts 
and cortical samples at P15 and adult states 
(a.) PKM1 western blot analysis revealed a slight enrichment of PKM1 expression in adult optic nerves 
and adult corpora callosa homogenates in comparison to adult cortices. Quantification of PKM1 
expression levels displayed: P15, 1.36 ± 0.34; adult, 2.13 ± 0.38 for optic nerves; P15, 1.21 ± 0.13; 
adult 1.19 ± 0.03 for cortices; P15, 1 ± 0.19; adult, 1.45 ± 0.3 for corpora callosa. (b.) Strong PKM2 
protein abundance was obvious in optic nerves and also in corpus callosum homogenates. Cortical 
samples exhibited weak PKM2 expression. Quantification numbers were P15, 4.82 ± 0.12; adult, 4.20 
± 0.20 for optic nerves; P15, 1 ± 0.10; adult 1.08 ± 0.1 for cortices; P15, 3.1 ± 0.16; adult, 3.8 ± 0.22 
for corpus callosa. (c.) Strong p-PKM2 expression was detected in all adult tissues compared to the 
corresponding P15 region. In comparison to P15 optic nerve samples the p-PKM2 level was more 
abundant in P15 cortices and weaker in P15 corpora callosa. Quantification revealed: P15, 0.08 ± 
0.03; adult, 0.67 ± 0.18 for optic nerves; P15, 0.18 ± 0.05; adult 0.59 ± 0.14 for cortices; P15, 0.02 ± 
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0.03; adult, 1 ± 0.37 for corpus callosa. Asterisks depict significance level (* p < 0.05; ** p < 0.01; *** p 
< 0.001). Asterisk colour referred to the compared tissue and comparison was performed between 
time points of the same tissue or between tissues at the same age. GAPDH was used as loading 
control and for normalization. CNP indicated content of myelin. Numbers are ± s.e.m. opt.n., optic 
nerve; ctx, cortex; cc, corpus callosum; P15, postnatal day 15; ad., adult.    
 
When comparing both time points of each tissue, no difference in PKM2 abundance could be 
revealed (Fig.III - 4b.), which is, at least for cortical regions, in agreement with the PKM2 
transcript analysis. However, the strong PKM2 expression found in white matter tracts 
(dominated by oligodendrocytes) might be related to oligodendrocytes and suggests that 
oligodendrocytes might exhibit the enzymatic prerequisite to balance between energy 
production and synthetic pathways.  
To detect the status of PKM2 activity that is regulated by posttranscriptional modulation, the 
phosphorylation of PKM2 at tyrosine residue 105 (p-Y105-PKM2) was investigated. In all adult 
tissues tested a significant stronger p-Y105-PKM2 expression in comparison to the 
corresponding P15 time point could be quantified, with similar abundance in both white 
matter regions and in cortical homogenates. Compared to P15 optic nerve samples the p-
PKM2 protein level was more abundant in P15 cortices and weaker in P15 corpora callosa 
(Fig.III - 4c.). Of note, in contrast to GAPDH, the p-PKM2 signal was in general not as strong 
as obtained for PKM1 and PKM2 (Fig.III - 4a.,b.).  
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6.2 DISCUSSION 
There is emerging evidence that oligodendrocytes are not only responsible for myelination, 
but might as well provide metabolites, most likely glycolytic end products, to their associated 
axons to locally support neuronal ATP demands in the adult brain (Nave, 2010; Amaral et al., 
2013; Morrison et al., 2013; Lee et al., 2012; Fünfschilling et al., 2012b). Recently, a link 
between a glycolytic metabolism of mature oligodendrocytes and the maintenance of axonal 
function and integrity was identified, which emphasizes the importance to investigate the 
oligodendroglial energy metabolism (Fünfschilling et al., 2012b). Generation of ATP mainly 
by aerobic glycolysis requires mechanisms controlling the shift away from mitochondrial 
oxidative phosphorylation. Since Otto Warburgs´ discovery that cancer cells cover their own 
ATP demands by enhanced glycolysis in the presence of O2, a central dogma of cell biology 
was disproved and opened a new research direction exploring underlying mechanisms 
(Warburg, 1956). Initial work considered mitochondrial defects as the reason for the onset of 
tumors and the concomitant increase of glycolysis as a necessary adaptation to the lack of 
ATP generation by oxidative phosphorylation. Recently, it was shown that mitochondrial 
damage is rare in cancer tissue (Fantin et al., 2006; Frezza and Gottlieb, 2009). Moreover, 
enhanced glycolytic rates cover basic needs of rapidly proliferating tumor cells to facilitate 
construction of new cells by ensuring energy production and the synthesis of 
macromolecules at the same time. Similarly, aerobic glycolysis is a characteristic of many 
highly dividing normal tissues (Vander Heiden et al., 2009).  
Microarray studies of different human and rodent cancers revealed an upregulation of 
glycolytic genes, including a significant elevation of pyruvate kinase transcript that catalyzes 
the rate-limiting final step of glycolysis (Altenberg and Greulich, 2004; Majumder et al., 
2004). In mammals, four isozymes of pyruvate kinase (PK) exist: L and R isozymes are 
found in liver and red blood cells, respectively (Domingo et al., 1992; Rodriguez-Horche et 
al., 1987). The M1 form is expressed in most adult tissues, whereas the expression of its 
splice transcript M2 is spatio-temporally restricted to cells during embryonic development, 
highly proliferating cells in adulthood, like in lung or fat tissue and especially in cancer cells 
(Hacker et al., 1998; Reinacher and Eigenbrodt, 1981). Normally, PKM2 appear in an active, 
tetrameric state, which is the usual form of all PK forms, but exclusively in cancer cells PKM2 
is present in an inactive, dimeric state (Yamada and Noguchi, 1999; Zwerschke et al., 1999, 
2003) leading to the accumulation of glycolysis intermediates due to a decreased glycolytic 
rate. Thus, PKM2 can be considered as key enzyme balancing the direction of glucose 
metabolism dependent on cell requirements for macromolecule biosynthesis or ATP 
generation. Several studies with cancer cell lines strongly indicate that the switch from PKM1 
to PKM2 expression in tumors is an essential mechanism adapting anabolic and catabolic 
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metabolism according to the needs of tumor growth and proliferation (Christofk et al., 2008; 
Mazurek et al., 2005; Spoden et al., 2009; Sun et al., 2011). It has been shown that 
downregulation of PKM2 diminished the ability of human tumor cell lines to proliferate and, 
moreover, the replacement of PKM2 by PKM1 reduced the ability forming tumors in nude 
mouse xenografts (Christofk et al., 2008). 
To proof whether PKM2 might function as a possible modulator, regulating the glycolytic flux 
in oligodendrocytes, analyses concerning PKM2 expression in wildtype mouse brains were 
performed. Interestingly, immunostainings with PKM2 in adult brain sections revealed that 
many cells throughout the CNS were clearly positive for PKM2. This was intriguing and in 
contrast to the widespread belief that expression of the PKM2 isoform is restricted to rapidly 
dividing cells in adulthood (Cairns et al., 2011; Christofk et al., 2008; Gui et al., 2013; Vander 
Heiden et al., 2010). In fact, only sporadic PKM2-positive cells were found in the 
subventricular zone and dentate gyrus, which represent the regions of adult neurogenesis in 
the CNS. However, PKM2 expression was already detected in two independent studies 
(Bluemlein et al., 2011; Jahn et al., 2009). By mass spectrometry Blümlein and colleagues 
showed that PKM2 is expressed in several terminally differentiated tissues, including kidney, 
lung and liver, whereas the brain remained unstudied by this analysis (Blümlein et al., 2011). 
More important, proteome analysis of purified myelin samples identified the presence of 
PKM2 and further exhibited that about 5% of all myelin proteins are referred to glycolysis or 
gluconeogenesis (Jahn et al., 2009).  
This is in line with our observation that PKM2 is expressed in cells of CNS white matter tracts 
of adult mice that possess morphology characteristics of oligodendrocytes. So far, cell type-
specific PKM2 expression patterns in the brain could not be surely validated. In vitro, PKM2 
was expressed by neurons, astrocytes and oligodendrocytes, which did not reflect its 
expression in the living CNS, where only a subset of cells showing similar shape and size 
was labelled by PKM2. However, immunocytochemistry indicated another important aspect 
of PKM2 expression. When comparing cultured polydendrocytes with more differentiated 
oligodendrocytes, that already developed myelin sheaths, an alteration of PKM2 localization 
was indicated. It seems that in younger developmental stages PKM2 was at least partially 
expressed in the nucleus of polydendrocytes, whereas more mature oligodendrocytes 
displayed a widespread PKM2 signal distributed over the cytoplasma, including myelin 
compartments. Importantly, localization of PKM2 expression is correlated to its activity state. 
Whereas cytoplasma-specific PKM2 expression is associated to an active quaternary 
structure, a nuclear localization is linked to inactive PKM2 dimers (Dombrauckas et al., 2005; 
Lv et al., 2013; Yang et al., 2011; Yang, Zheng, et al., 2012). These findings suggest that 
oligodendrocytes change their metabolic program according to specific requirements that 
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depend on the developmental state. This further indicates that polydendrocytes at the 
beginning of myelinogenesis might slow down their glycolytic rate leading to the 
accumulation of glycolytic intermediates which are necessary for the synthesis of major 
building blocks of myelin, including fatty acids, cholesterole and phospholipids (Aeberhard 
and Menkes, 1968; Cuzner and Davison, 1968; Orth and Bellosta, 2012; Saher et al., 2005). 
For instance, glycerate-3-phosphate is used in a debranching pathway of the glycolysis to 
produce phospholipids (Newsholme et al., 2003; Mazurek et al., 2005). Moreover, the 
Pentose-Phosphate-Pathway, another debranching pathway of glycolysis, is indirectly 
coupled to fatty acid synthesis, due to its delivery of NADPH that is crucial for the production 
of fatty acids and cholesterol (Baquer et al., 1977, 1988; Mazurek, Boschek, et al., 1997; 
Wood, 1986). It has to be mentioned that acetyl-CoA is the basic substrate for fatty acid 
synthesis, which is converted from pyruvate in mitochondria. Thus, mechanisms are required 
to equilibrate between sufficient NADPH generation and the entry of pyruvate into 
mitochondria to maintain proper fatty acid production for myelin generation. In contrast, when 
oligodendrocytes have already synthesized their myelin sheaths, PKM2 might associate to 
active tetramers promoting glycolysis and thus energy production. According to this, it is 
conceivable that PKM2 might act as a glycolytic key enzyme balancing between lipid 
syntheses that are needed for myelination during development and energy production in 
adulthood.  
PKM1 and PKM2 transcripts are alternative splicing products from one gene. PKM1 mRNA 
levels in optic nerves, a region enriched by oligodendrocytes (Burne et al., 1996; Walhovd et 
al., 2014) were the lowest at the onset of myelination (P15) and rose with high significance 
with the peak and further by the termination of myelinogenesis. A continuous raise of PKM1 
mRNA expression was as well observed in cortical tissue, but not as strong as in optic 
nerves. Although cortices are dominated by neurons, there is indeed a considerable residing 
oligodendrocyte population mediating myelination (Herculano-Houzel and Lent, 2005; Ling 
and Leblond, 1973). In agreement, PKM2 transcript expression was found to be elevated at 
P15 in both optic nerves and cortices. That PKM1 expression was comparatively low at P15 
and PKM2 mRNA levels elevated at P15 in optic nerve samples suggest a role of PKM2 
during the phase of high myelination. However, this analysis gives only a comparison of 
expression levels during important developmental and adult states of PKM isozymes 
respectively, but an exact ratio of PKM1 and PKM2 can not be calculated. Since PKM2 can 
appear as inactive dimers or active tetramers no information about PKM2 activity could be 
gained by this study. This was overcome by western blot analysis. As expected, PKM1 was 
found to be more or less equally strongly expressed in white matter tracts including optic 
nerve and corpus callosum and cortices at P15 and adult tissues. A pronounced enrichment 
of PKM2 protein concentrations was found in optic nerves and in corpus callosum samples in 
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comparison to cortices. These findings imply that PKM2 expression can be attributed to 
oligodendrocytes, because the main difference in cell type composition of white matter tracts 
and cortical samples is the percentage of oligodendrocytes, which make up to 60% in optic 
nerve and a clearly minor proportion in cortical fractions (Burne et al., 1996; Herculano-
Houzel and Lent, 2005; Mori et al., 2006b; Walhovd et al., 2014; Ling and Leblond, 1973). 
However, the high expression level of PKM2 in white matter regions of the CNS further 
indicates that PKM2 seems to have a necessary function regulating the glycolytic flux in 
these parts of the brain. Investigation whether PKM2 is phosphorylated at the tyrosine 
residue 105 (p-Y105-PKM2) revealed that in comparison to P15 time points p-PKM2 
expression was significantly stronger in tissue-matched adult fractions. Phosphorylation at 
this residue has been shown to disrupt the binding site for its substrate fructose-6-phosphate 
leading to a decreased growth of cancer cells (Hitosugi et al., 2009). Similarly, 
phosphorylation at serine 37 of PKM2 was detected to result in the dissociation of active 
tetramers to dimers (Yang, Zheng, et al., 2012). Furthermore, other studies indicate that 
acetylation, oxidation and sumoylation are as well involved in PKM2 dimer formation in 
different cancer cell lines (Anastasiou et al., 2011; Lv et al., 2011; Spoden et al., 2009). The 
apparent complexity of posttranscriptional modifications of PKM2 that all caused the 
reduction of PKM2 activity hampers the interpretation of the western blot analysis of p-Y105-
PKM2. If indeed this modification results in a decreased glycolytic rate, it is conceivable that 
adult tissues might be stronger exposed to oxidative stress and thus to the production of 
reactive oxygen species. Slowing down glycolysis favors the PPP, by which NADPH is 
regenerated necessary for the glutathione-based detoxification of cells (Hirrlinger et al., 
2002). However, it has to be mentioned that the true percentage of phosphorylated PKM2 
can not be calculated, but when compared to GAPDH signals, only a little ratio of PKM2 
seems to be phosphorylated. On the other hand, immunohistological investigations revealed 
a clear cytoplasmic expression of PKM2 in adult brains. Since PKM2 inactivity is directly 
associated to a nuclearly localized expression (Lv et al., 2013; Yang et al., 2011; Yang, 
Zheng, et al., 2012) these results do not support the suggestion that p-Y105-PKM2 is inactive. 
However, that the embryonic isozyme PKM2 is expressed in a subpopulation of cells in the 
adult CNS, that do not belong to highly proliferating zones is remarkable. Since there is 
emerging evidence of an increased glycolysis metabolism in mature oligodendrocytes that is 
coupled to the maintenance of axonal integrity and regarding the relevance of PKM2 
balancing the glycolytic flux denotes the importance to further investigate the role of PKM2 in 
brain metabolism in the healthy CNS. 
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6.3 DETAILED SUMMARY 
Oligodendrocytes contribute to the maintenance of axonal integrity by shuttling energy-rich 
glycolytic end-products to neuronal compartments which requires an enhanced glycolytic rate 
of mature oligodendrocytes that may underlie a ‘developmental’ switch. This necessitates 
mechanisms controlling the shift away from mitochondrial respiration towards aerobic 
glycolysis. In order to determine the metabolic properties of oligodendrocytes, the focus was 
set on tumor-related key enzymes that are widely debated to be responsible for the glycolytic 
metabolism in cancer cells. 
Therefore, the expression profile of the pyruvate kinase isozyme PKM2 was investigated 
since the switch from ubiquitous PKM1 to PKM2 expression in tumors is discussed to be an 
essential mechanism adapting cellular metabolism assuring cancer growth and proliferation. 
Contrary to the general belief, histological analyses of adult wildtypish mouse brain-sections 
revealed a robust PKM2 expression in cells with oligodendrocyte-like morphology. In line with 
this, when compared to cortical regions white matter tract lysates showed a strong PKM2 
expression, whereas PKM1 was mainly stably expressed in these tissues. This argues for a 
crucial role of PKM2 in regulating the glycolytic flux in oligodendrocytes of CNS white matter 
tracts.  
Since PKM2 activity is regulated by various posttranslational modifications, the affinity to its 
substrate phosphoenolpyruvate is difficult to determine. Indeed, the expression of a 
presumably inactive PKM2 that is phosphorylated at tyrosine residue 105 was detected in the 
adult brain, including cortices and white structures. This implied at least one regulatory 
mechanism controlling PKM2 activity in adulthood. To which extent PKM2 is modulated by 
specific phosphorylation and whether other modifications contribute to a regulatory network 
remains to be elusive. However, in vitro, practically all main CNS cell-types express PKM2 in 
this artificial environment. Interestingly, there are indications that during development PKM2 
expression partially shifts in cultured oligodendrocytes from nuclear (polydendrocytes) to 
cytoplasmatic (myelin-forming oligodendrocytes) localization. Since PKM2 translocation is 
described to correlate with its inactivity, this finding further emphasizes the complexity of 
control mechanisms mediating the velocity of glycolysis. Further studies are needed to 
unravel the spectrum of metabolic capabilities of oligodendrocytes to gain more insight about 
the metabolic interdependency of CNS cell-types and the actual participation of PKM2.  
 
  MATERIAL AND METHODS 
 
   73
7 MATERIAL AND METHODS 
7.1 MATERIALS 
7.1.1 CHEMICALS AND KITS 
All chemicals were purchased from Sigma-Aldrich GmbH (Munich, Germany), Merck KGaA 
(Darmstadt, Germany) and SERVA (Heidelberg, Germany) unless stated otherwise. General 
laboratory materials were from BD Falcon (Heidelberg, Germany), Eppendorf (Hamburg, 
Germany) Bio-rad (München, Germany) Gilson (Limburg-Offheim, Germany) and Brand 
(Radebeul, Germany). 
Kits 
RNA purification ‘RNeasy mini prep’         Qiagen (Portland, USA)  
DC Protein Assay (Lowry)           Bio-Rad (Munich, Germany)  
LSAB2 kit             Dako (Hamburg, Germany)  
Vector Elite ABC Kit            Vector Labs (Loerrach, Germany)  
DAB Zytomed Kit            Zytomed Systems GmbH (Berlin, Germany) 
DeadEnd™ Colorimetric TUNEL System        Promega Corporation (Madison, USA) 
AlexaFluor-647 Click-iT EdU Cell Proliferation Assay Kit   
Invitrogen, Life Technologies GmbH (Darmstadt, Germany) 
 
7.1.2 MOLECULAR BIOLOGY 
Extraction Buffer  
0.05 M Tris/HCl, pH 8.8  
0.1 M NaCl2  
3 mM EDTA 
0.5% [v/v] SDS 
Proteinase K (10 mg/ml)  
Added to Extraction Buffer buffer before use for tail digest 
Final concentration 0.5 mg/ ml  
10 mM dNTP (50x stock)  
2.5 mM each nucleotide (dATP, dCTP, dGTP, dTTP) (Boehringer-Ingelheim, Germany)  
200 μM final concentration in a PCR reaction (50 μM each nucleotide)  
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50x Trisacetate EDTA (TAE) buffer  
2.0 M Tris/Acetate, pH 8.0  
50 mM EDTA  
17.5% [v/v] Glacial acetic acid 
DNA marker  
GeneRuler 100 bp DNA ladder   Thermo Scientific (St. Leon-Rot, Germany)  
GeneRuler 1 kp DNA ladder    Thermo Scientific (St. Leon-Rot, Germany)  
Enzymes 
Proteinase K      Boehringer GmbH (Mannheim, Germany) 
GOTaq DNA polymerase     Promega (Mannheim, Germany)  
RedTaq DNA polymerase     Sigma-Aldrich (St. Louis, USA) 
Superscript III-reverse transcriptase   Invitrogen (Karlsruhe, Germany)  
DNase       Roche Diagnostics GmbH (Penzberg, Germany) 
Papain       Worthington Biochemical Corp (Lakewood, USA) 
Trypsin      Invitrogen (Darmstadt, Germany) 
 
7.1.3 PROTEIN BIOCHEMISTRY BUFFERS 
10x Phosphate buffered saline (PBS)  
1.7 M NaCl  
34 mM KCl  
40 mM Na2HPO4 x 2H2O  
18 mM K2HPO4  
pH 7.2 with 1N NaOH.  
10x Tris-buffered saline (TBS)  
500 mM Tris/HCl, pH 7.5  
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Protein lysis buffer 
1x TBS  
0.1% [v/v] SDS 
0.1% [v/v] Triton X-100  
Complete Mini protease inhibitor (Roche Diagnostics GmbH, Mannheim, Germany) was 
freshly added to the protein lysis buffer (1 tablet/10ml) before use.  
SDS separating gel  
12% or 10% [v/v] Acrylamid/ Bisacrylamid 29:1  
0.4 M Tris/HCl pH 8.8  
0.1% [v/v] SDS  
0.03% [v/v] APS  
0.08% [v/v] TEMED 
SDS stacking gel  
4% [v/v] Acrylamid/ Bisacrylamid 29:1  
125 mM Tris/HCl pH 6.8  
0.1% [v/v] SDS  
0.05% [v/v] APS  
0.1% [v/v] TEMED  
4x SDS sample buffer  
40% [v/v] Glycerol  
240 mM Tris/HCl pH 6.8  
8% [v/v] SDS  
0.04% [w/v] Bromophenol blue  
10x SDS running buffer (Laemmli buffer)  
250 mM Tris base  
1.92 M Glycine  
1% [v/v] SDS  
Transfer buffer  
96 mM Tris base  
78 mM Glycine  
10% [v/v] Methanol  
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20x Tris buffered saline (TBS)  
1 M Tris/HCl, pH 7.4  
3 M NaCl  
1x TBS with Tween-20 (TBST)  
50 mM Tris/HCl, pH 7.5  
150 mM NaCl  
0.05% [v/v] Tween-20  
Immunoblot blocking buffer  
5% [w/v] non-fat dry milk powder in 1x TBST  
or 5% [w/v] BSA powder in 1x TBST  
Protein marker  
PageRuler Plus Prestained Protein Ladder 10-250K  Fermentas (St. Leon-Rot, 
Germany) 
Additional materials  
- Enhanced Chemiluminescence (ECL) Immunoblot detection kit Western Lightning™  
Plus ECL, Enhanced luminol reagent plus (Perkin Elmer Life Sciences, Inc., Rodgau, 
Germany).  
- ECL-Hyperfilms (Amersham Biosciences, Uppsala, Sweden)  
- PVDF membrane Hybond P pore size 0.45 μm (Amersham Biosciences, Uppsala, Sweden)  
 
7.1.4 SOLUTIONS FOR FIXATION  
Avertin  
2% [w/v] 2,2,2 Tribromethanol 99%  
2% [v/v] Amylalkohol  
Mixed at 40°C for 30 min while stirring and subsequently filtered  
Stored at -20°C  
16% [w/v] Paraformaldehye (PFA) stock solution  
16% [w/v] Paraformaldehyde cooked at 65°C for 20 min while stirring  
5 N NaOH droplets until solution was cleared and then filtered  
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0.2M Phosphate buffer (fixation buffer)  
0.36% [w/v] Sodiumdihydrogenphosphate (NaH2PO4)  
3.1% [w/v] di-Sodiumhydrogenphosphate (Na2HPO4)  
1% [w/v] Sodium chloride  
4% [v/v] Paraformaldehye (PFA) for immunohistochemistry  
4% [v/v] PFA  
0.1 M Phosphate buffer  
Karlsson-Schultz (K+S) fixative for electron microscopy  
4% [w/v] PFA  
2.5% [v/v] Glutaraldehyde  
0.1 M Phosphate buffer  
 
7.1.5 IMMUNOHISTOCHEMISTRY AND STAINING SOLUTIONS  
Phosphate buffer (0.2 M, pH 7.4)  
0.04 M Sodiumdihydrogenphosphate (NaH2PO4)  
0.16 M di-Sodiumhydrogenphosphate (Na2HPO4)  
Always prepared freshly  
Citrate buffer (0.01 M, pH 6.0)  
1.8 mM Citric acid (C6H8O7 * H2O)  
8.2 mM Sodium citrate (C6H5O7Na3 * 2H2O)  
Always prepared freshly  
BSA/PBS  
0.04M Sodiumdihydrogenphosphate (NaH2PO4)  
0.16M di-Sodiumhydrogenphosphate (Na2HPO4)  
1.8% [w/v] Sodium chloride  
1.0% [w/v] Bovines serum albumin (BSA)  
Tris buffer (pH 7.6)  
50 mM Tris/HCl, pH 7.6  
0.9% [w/v] Sodium chloride (NaCl)  
Always prepared freshly.  
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Mayer’s haematoxylin solution  
0.1% [w/v] Haematoxylin  
0.02% [w/v] Sodium iodate  
5% [w/v] Potassium aluminium sulphate (K2Al2(SO4)4 * 24H2O)  
Added under constant shaking, solution turned violet blue  
5% [w/v] Chloralhydrate  
0.1% [w/v] Citric acid added  
Added and filtered before use  
Eosin solution  
0.1% [v/v] Eosin  
12 drops of glacial acetic acid in 250ml  
Scott’s solution  
0.2% [w/v] Potassiumhydrogencarbonate  
2% [w/v] Magnesium sulphate 
HCl-alcohol  
0.09% [v/v] HCl  
70% [v/v] Ethanol  
Gallyas silver impregnation  
Incubation solution  
0.1% [w/v] Ammonium nitrate  
0.1% [w/v] Silver nitrate  
12‰ [w/v] Sodium hydroxide (pH 7.5)  
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Physical developer  
Solution A 5% [w/v] Sodium carbonate (dehydrated) in H2O  
Solution B 0.2% [w/v] Ammonium nitrate  
0.2% [w/v] Silver nitrate  
1% [w/v] Wolframosilicic acid (silicotungstic acid)  
Solution C 0.2% [w/v] Ammonium nitrate  
0.2% [w/v] Silver nitrate  
1% [w/v] Wolframosilicic acid (silicotungstic acid)  
0.26% [w/v] Paraformaldehyde  
To reconstitute physical developer: 70ml of solution B added to 100ml of solution A with 
constant and gentle shaking and then slowly added to 1000ml solution C.  
Fixing solution  
2% [w/v] Sodium thiosulphate  
Permeabilization and blocking buffer for vibratome sections  
5% [v/v] Horse serum  
0.3% [v/v] Triton X-100  
Dissolved in 1x PBS 
Permeabilization and blocking buffer for coverslips 
10% [v/v] Horse serum  
0.2% [v/v] Tween-20  
Dissolved in 1x PBS 
Mounting media  
Eukitt Kindler (Freiburg, Germany)  
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7.1.6 ELECTRON MICROSCOPY  
Epon  
Mixed 30 min before embedding in the following way:  
171.3 g Glycidether 100  
115 g DDSA (Dodecenyl succinic anhydride)  
89 g MNA (Methyl nadic anhydride)  
Mixed using magnet stirrer for 10 min and then  
6.5 ml DMP-30  
Added and mixed using magnet stirrer for 20 min  
Methylene blue - Azure II staining solution  
Methylene blue  
1% [w/v] Na-tetraborat (Borax)  
1% [w/v] Methylenblau  
Azure II  
1% [w/v] Azure II  
Methylene blue and Azure II were freshly mixed 1:1 before use. 
 
7.1.7 CELL CULTURE MEDIA AND SOLUTIONS 
OPC medium 
DMEM (4.5 g glucose/l, Lonza, BioWhittaker)   500 ml    
Glutamax-I (100x stock solution, Gibco)    5 ml 
Penicillin/Streptomycin (Lonza)    5 ml 
Fetal calf serum      50 ml 
Neurobasal medium 
Neurobasal (- Glutamine, Gibco)    100 ml 
Glutamax-I (100x stock solution, Gibco)    1 ml 
Penicillin/Streptomycin (Lonza)    1 ml 
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HBSS 
HBSS (Lonza, BioWhittaker)     99 ml 
HEPES (500 mM, sterile filtered)    1 ml 
DMEM low glucose 
DMEM (1 g glucose/l, Lonza, BioWhittaker)   200 ml 
Glutamax-I (100x stock solution, Gibco)    2 ml 
Penicillin/Streptomycin (Lonza)    2 ml 
B27 supplement (50x stock solution, Gibco)  4 ml 
Fetal calf serum      25 ml 
Sato medium 
DMEM (SIGMA D-6546) 
Streptomycin/ Penicillin (Lonza)    5000 U/ml 
L-Glutamine (SIGMA G-6392)    4 mM 
Putrescine (SIGMA P-5780)     16 µg/ ml 
L-Thyroxine (SIGMA T1775)     400 ng/ ml 
Tri-iodothyroxine (SIGMA T-6397)     400 ng/ ml 
Progesterone (SIGMA P-8783)    6.2 ng/ ml 
Sodium Selenite (SIGMA S-5261)    5 ng/ ml 
Bovine Serum Albumin Fraction V (SIGMA A-4919) 100 µg/ ml 
Insulin (SIGMA I-0516)     5 µg/ ml 
Holo-Transferrin human (SIGMA T-0665)   50 µg/ ml 
The medium ist stable for 4 weeks at 4 °C. 
Digestion mix 
MEM (Invitrogen, 11095-080) 
DNAseI        0.1 mg/ ml 
Papaine       1.58 mg/ ml 
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antibody dilution and purpose  species company 
APP 1:750 (IHC) mouse Chemicon 
BrdU 1:200 (IHC) mouse Chemicon 
CD3 1:150 (IHC) rat Serotec 
CNP 1:500 (WB) mouse SIGMA 
Cox4-1 1:1000 (IHC) 
1:2000 (WB) 
rabbit Mitoscience 
GAPDH 1:200 (IHC) 
1:1000 (WB) 
mouse ENZO BioMol 
GFAP 1:200 (ICC) 
1:200 (IHC) 
mouse Novocastra 
GFP 1:1000 (IHC) goat Rockland 
Mac3 1:400 (IHC) mouse Chemicon 
MBP 1:200 (ICC) mouse Novocastra 
NeuN 1:100 (ICC) mouse Chemicon 
O4 1:50 (ICC) mouse Gift of J. Trotter, 
Mainz 
Olig2 1:200 (IHC) rabbit Gift of J. Alberta, 
Harvard 
PKM1 1:1000 (WB) rabbit Proteintech 
PKM2 1:200 (IHC) 
1:100 (ICC) 
rabbit SAB 
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1:1000 (WB) 
p-PKM2 1:1000 (WB) rabbit Cell Signaling 
S100ß 1:200 (IHC) rabbit Abcam 
Tuj-1 1:200 (ICC) rabbit Covance 





antibody dilution species company 
Alexa488-anti-mouse 1:2000 donkey Molecular Probes 
Alexa488-anti-rabbit 1:2000 donkey Molecular Probes 
Alexa555-anti-rabbit 1:2000 donkey Molecular Probes 
 
To colabel the nucleus DAPI was co-incubated with the secondary antibody at final a 
concentration of 0.025 µg/ ml. 
 
7.1.9 OLIGONUCLEOTIDES  
Oligonucleotides were synthesized by the service facility of the Max-Planck-Institute for 
Experimental Medicine. 
7.1.9.1 Genotyping primer for used mouse lines  
floxed Cox10 mouse line (Diaz et al., 2005b) 
5´- TGAGTAGAATGGCTTCCGGAAGGG -3´ 
5´- CACTGACGCAGCGCCAGCATCTT -3´ 
5´- AGCAGCAAAGAGGGCTCACTTCTTGC -3´ 
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CNP1-cre driver mouse line (Lappe-Siefke et al., 2003) 
5´- GCCTTCAAACTGTCCATCTC -3´ 
5´- CCCAGCCCTTTTATTACCAC -3´ 
5´- CATAGCCTGAAGAACGAGA -3´ 
PLP1-CreERT2 driver mouse line (Stahl et al., 1990) 
5´- TGGACAGCTGGGACAAAGTAAGC -3´ 
5´- CGTTGCATCGACCGGTAATGCAGGC -3´ 
CamKinaseIIα-Cre driver mouse line (Minichiello et al., 1999) 
5´- GGGAGGTAGGAAGAGCGATG -3´ 
5´- CCATGAGTGAACGAACCTGG -3´ 
GLAST-CreERT2 driver mouse line (Mori et al., 2006b) 
5´- GAGGCACTTGGCTAGGCTCTGAGGA -3´ 
5´- GAGGAGATCCTGACCGATCAGTTGG -3´ 
5´- GGTGTACGGTCAGTAAATTGGACAT -3´ 
R26R-EYFP mouse line (Srinivas et al., 2001a) 
5´- AAAGTCGCTCTGAGTTGTTAT -3´ 
5´- GCGAAGAGTTTGTCCTCAACC -3´ 
5´- GGAGCGGGAGAAATGGATATG -3´ 
 
7.1.9.2 Quantitative real-time PCR primer 
on genomic DNA:  
Cox10:    forward 5´- CGGGGATCAATTCGAGCTCGCC -3´ 
reverse 5´- CACTGACGCAGCGCCAGCATCTT -3´ 
Neuregulin 1 type III:   forward 5´- GTGTGCGGAGAAGGAGAAAACT -3´ 
reverse 5´- AGGCACAGAGAGGAATTCATTTCTTA -3´ 
on genomic DNA for quantitative PCR: 
Cox10:   forward 5´- CGGGGATCAATTCGAGCTCGCC -5´ 
    reverse 5´- CACTGACGCAGCGCCAGCATCTT -3´ 
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on mRNA for quantitative PCR: 
PKM1:    forward 5´- GTTCTCACGGAGTCTGGCA -3´ 
reverse 5´- TTCGAGTCACGGCAATGATAG -3´ 
PKM2:    forward 5´- TACCCTCTGGAGGCTGTTC -3´ 
reverse 5´- TCTGCCTCTCGGGCAATCT -3´ 
PKM total:    forward 5´- CTGGGCTGAGGACGTTGAT -3´ 
reverse 5´- TGACCACATCTCCCTTCTTGA -3´  
Rpl13a:   forward 5´- ATCCCTCCACCCTATGACAA -3´ 
reverse 5´- GCCCCAGGTAAGCAAACTT -3´ 
Rplp0:    forward 5´- GATGCCCAGGGAAGACAG -3´ 
reverse 5´- CACAATGAAGCATTTTGGGTAG -3´ 
 
7.2 METHODS  
7.2.1 ANIMALS  
All animals used in experiments of this thesis were bred and kept in the mouse facility of the 
Max Planck Institute of Experimental Medicine. All experiments were performed in 
accordance with the guidelines for German animal welfare. Mice were sacrificed by cervical 
dislocation or by perfusion using anaesthetics. Animals were maintained on a C57/Bl6 
genetic background. All tamoxifen-sensitive mutant and control mice were treated with 
tamoxifen or the vehicle only. Tamoxifen was dissolved in corn oil to obtain a 10 mg/ml 
solution. Mice were i.p. injected with a tamoxifen dosage of 100 mg/ kg body weight for 5 
consecutive days or 2 weeks (except for the weekends) at P30. 
 
7.2.2 MOLECULAR BIOLOGICAL METHODS 
7.2.2.1 Genotyping of mice 
0.5 cm long tail tips were taken from P21 young mice. They were digested overnight (o/n) in 
400 μl Extraction buffer with 20 μl Proteinase K at 55°C under steady agitation. To extract 
the DNA 75 µl KAc and 400 µl chloroform were applied and mixed by inversion. To separate 
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the DNA containing aqueous phase from the chloroform, the sample was centrifuged at 
700 x g for 10 min. 200 µl from the supernatant was removed, mixed with 400 µl EtOH for 
DNA precipitation, followed by a centrifugation step (at 700 x g for 10 min) to pelletise the 
DNA. The supernatant was carefully and completely removed and after the pellet had been 
air dried, the DNA was dissolved in 10 mM Tris buffer. 
Polymerase chain reaction was used to amplify specific DNA segments (Mullis et al., 1986; 
Saiki et al., 1988). 1 μl of DNA samples were used per 20 μl PCR reaction. Primers were 
selected manually using the DNASTAR Lasergene 9 core suite. 
For separation of PCR products gels containing 1.5% [w/v] agarose in 1x TAE buffer were 
used. For DNA visualization 1 μg/ml ethidiumbromide was added to the gel prior to 
polymerization. 20 μl of PCR samples were loaded and separated at 150V for 45 min in 
1x TAE buffer. GeneRuler 100 bp DNA ladder or GeneRuler 1 kp DNA ladder (both Thermo 
Scientific, St. Leon-Rot, Germany) was used as a marker. For documentation pictures were 
acquired with the Intas UV system. 
7.2.2.2 PCR on genomic DNA 
30 μg of total cerebellar and brain purified genomic DNA was used in a PCR reaction to 
detect the recombined Cox10 allele with 0.1 µM of following primers 
TGAGTAGAATGGCTTCCGGAAGGG and AGCAGCAAAGAGGGCTCACTTCTTGC 
generating a template of 465 bp.  
7.2.2.3 Quantitative PCRs on genomic DNA 
Sciatic nerves (epineurium was removed), optic nerves and brains were collected from P21 
animals and DNA was isolated as usual. Quantitative PCR was performed using 10 ng of 
sciatic nerve DNA in a 12.5 µl assay using PowerSYBR Green PCR Master Mix (Applied 
Biosystems) on an Applied Biosystems 7500 Fast real time PCR system in triplicates. A 
standard curve was generated using DNA from Cox10flox/flox, Cox10flox/wt, and Cox10wt/wt 
animals. The values were standardized to an independent genomic marker to correct for 
small differences in the amount of DNA. Primers CGGGGATCAATTCGAGCTCGCC and 
CACTGACGCAGCGCCAGCATCTT amplify a 167 bp band specific for the Cox10flox allele. 
For genomic input control we used an intron-exon stretch of Neuregulin 1 type III were used. 
The percentage of recombination was calculated assuming that every Cre-expressing cell 
recombines both Cox10flox alleles. The values were shown as histograms using Adobe 
Illustrator CS3 and p-values were calculated using the Student’s t-test of Microsoft Excel 
2003. The levels of significance were set as * p < 0.05; ** p < 0.01; *** p < 0.001. Analysis 
was performed by Dr. Ursula Fünfschilling. 
  MATERIAL AND METHODS 
 
   87
7.2.2.4 RNA isolation (‘RNeasy mini prep’)  
RNA isolation from frozen (-80°C) half brain as well as separated cortex, optic nerve and 
cerebellum was performed using “Qiagen’s RNeasy Mini Prep” kit. The kit is based on a 
selective binding of RNAs bigger than 200 bases to a silica-gel based membrane under high-
salt conditions, which excludes binding of 5S, 5.8S and tRNAs. RNA isolation and purification 
was carried out following the manufacturer’s instructions. Briefly, apart from optic nerves of 
adult rats that were homogenized in Trizol (Invitrogen, Karlsruhe, Germany) with the 
Precellys for 3 x 10 sec at 5500 rpm followed by addition of half volume of chloroform, 
inversion for mixture and an incubation step of 3 min. All other tissue were homogenized in 
RLT buffer (containing 1% (v/v) ß-Mercaptoethanol). Here, for half brains and cerebella the 
KINEMATICA AG POLYTRON PT 3000 (1 min  at 14.000 rpm) and for the cortices and optic 
nerves of developing states the Precellys (2 x 10 sec at 5500 rpm) were used. The 
subsequent steps were for all tissues equally performed. After 15 min certification at 
16000 x g (Heraeus Biofuge Pico table centrifuge, 13000 rpm) the upper aqueous phase was 
transferred to a new 2 ml Eppendorf tube. One volume of ethanol was added to the samples, 
mixed and applied to RNeasy columns. After 1 min centrifugation at 16000 x g the columns 
were washed one time with the RW1 buffer and two times with the RPE buffer. The RNA was 
eluted from the column by adding 20-40μl of RNase-free ddH2O. 
7.2.2.5 RNA measurement with Agilent  
The quality and the amount of RNA were measured using the Agilent RNA 6000 Nano KIT 
and the Agilent 2100 Bioanalyzer following the company’s instructions. Only RNA samples 
with a RNA integrity number above 8.5 were further used. The RNA concentration for all 
samples was adjusted to 100 ng/ μl.  
7.2.2.6 cDNA synthesis 
cDNA synthesis is based on the characteristic feature of eukaryotic messenger RNAs to 
harbor defined polyadenylated tail on the 3′ end. First-strand cDNA was mainly synthesized 
for quantitative RT-PCR. Total RNA is mixed with a random nonamer and oligo-dT primers. 
The amplification reaction is carried out by Superscript III reverse transcriptase (Kotewicz et 
al., 1985; Gerard et al., 1986) at 55ºC providing high specificity and yields of cDNA (from 
100bp to >12kb). For the cDNA synthesis, 6 pmol of random primers, 0.03 pmol of oligo dT 
nucleotides were incubated with 400 ng - 1 μg total RNA for 10 min at 70°C and then cooled 
on ice for 2 min. 2 μl of 5X First-Strand Buffer, 1 μl of 0.1 M DTT, 1 μl of 10 mM dNTP and 
1μl of SuperScript™ III RT (200 units/ μl) were added to the tubes. The reaction mixture was 
incubated in the thermocycler with the following settings: 25°C for 10 min, then 50°C for 45 
min, 55°C for 45 min. The cDNA was then used as a template for amplification in PCR.  
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7.2.2.7 Quantitative real time PCR for mRNA expression 
The quantification of amplified gene fragments relied on the usage of the fluorescent dye 
SYBR Green, which intercalates specifically in double stranded DNA. All reactions were 
carried out in quadruples. Data evaluation was performed with the 7500 Fast System SDS 
software Version 1.3 (Applied Biosystems) and Excel 2003. As endogenous gene controls 
Rpl13a and Rplp0 were used for normalization. Values were further calculated to the 
P8 time-point of every brain region. The values were shown as histograms using Adobe 
Illustrator CS3 and p-values were calculated using the Student’s t-test of Microsoft Excel 
2003. The levels of significance were set as * p < 0.05; ** p < 0.01; *** p < 0.001.  
 
7.2.3 PROTEIN BIOCHEMICAL ANALYSIS  
7.2.3.1 Sample preparation  
Collected tissue was quickly frozen on dry ice and stored at -80°C. Optic nerves, corpora 
callosa, cerebella and cortices were homogenized in Lysis buffer using the Tissue Lyser 
(Peqlab, Erlangen, Germany) at 50 Hz (2 min for optic nerves, for all other tissues 5 min) 
according to manufactor´s instructions. Half brains were homogenized with the KINEMATICA 
AG POLYTRON PT 3000 for 1 min at 14.000 rpm as well in Lysis buffer. Lysates were 
centrifuged for 15 min at 13000 rpm at 4°C. Supernatants were transferred into new tubes 
and stored at -80°C. Protein concentration was measured and samples were used for SDS 
Page.  
7.2.3.2 Protein concentration measurement by the Lowry method  
The Protein concentration was measured using the Bio-Rad DC Protein Assay kit according 
to the manufacturer’s 'microplate assay' protocol. The working principle of the kit is similar to 
the well-documented Lowry assay (Lowry et al., 1951; Peterson, 1979). The optical density 
was measured at 650 nm in the microplate reader ThermoMax (Molecular Devices, Biberach, 
Germany). 10 µg protein of each sample were used for SDS-Page. 
7.2.3.3 Separating Proteins using SDS Page  
10% [w/v] acrylamid gels were prepared using the Bio-rad system. For this, SDS separating 
gel mix was casted between a 1.5 mm thick spacer plate and thin coverplates. It was overlaid 
with isopropanol and polymerized for at least 60 min. The stacking gel mix was added on top 
after removing the isopropanol. A Teflon comb (10 or 15 wells) was used to generate pockets 
for the protein samples. After polymerization gels were used immediately or were stored wet 
at 4°C, but not longer than a week. Proteins were separated using the protocol established 
by Laemmli (Laemmli, 1970). To denature the proteins, lysates were mixed with 1x SDS 
sample buffer and 5% [v/v] mercaptoethanol, and heated for 5 min at 95°C. Bio-rad 
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chambers were used to assemble the gels and filled with 1x Laemmli running buffer. Protein 
samples were carefully pipetted und were separated by constant current using the Bio-rad 
power supply (30 mA per gel). After about one and a half hour, gels were removed, 
incubated for 15 min in transfer buffer and proteins were transferred to a PVDF membrane 
(immunoblot).  
7.2.3.4 Immunoblot  
For immunodetection, proteins were transferred to a PVDF membrane as described by 
Towbin and colleagues (Towbin et al., 1979). Therefore, the wet chamber from Biorad Mini 
Trans-Blot Ceil was used. The PVDF membrane was activated using 100% [v/v] methanol for 
1 min and kept then in transfer buffer. The nitrocellulose membrane, Whatman paper and 
blotting sponges, that had been pre-soaked in ice cold transfer buffer, were assembled in a 
Biorad adapter cassette according to manufactor´s instructions. Proteins were transferred at 
a constant voltage of 200 V and at maximum current of 350 mA for 1 h at 4 °C. 
7.2.3.5 Immunodetection of blotted proteins  
After the protein transfer, the PVDF membrane was blocked at room temperature (RT) for 
1 hour in blocking buffer (usually 5% [w/v] non-fat dry milk in TBST, apart from phospho-
antibodies that were blocked in 5% [w/v] BSA in TBST). Primary antibody was diluted in the 
same blocking buffer and incubated on the membrane o/n at 4°C. Afterwards, the membrane 
was washed three times in TBST and incubated with the HRP coupled secondary antibody, 
which was diluted in the blocking buffer, at RT for one hour. After additional washing with 
TBST (3x), the Enhanced Chemiluminescence Detection (ECL) solution was added 
according to the manufacturer’s recommendations (Western Lightning™, Western Blot 
Chemiluminescence Reagent Plus, PerkinElmer Life Sciences, Inc., Rodgau, Germany). As 
protein loading control all membranes were incubated with GAPDH as a standard afterwards. 
The densitometric analysis of immunoblots was performed using gele analysis of ImageJ. 
The integrated density or mean grey values for the band of interest was calculated and 
normalized to the integrated density or mean grey values of GAPDH. The normalized values 
were shown as histograms using Adobe Illustrator CS3 and p-values were calculated using 
the Student’s t-test of Microsoft Excel 2003. The levels of significance were set as * p < 0.05; 
** p < 0.01; *** p < 0.001.  
 
7.2.4 PERFUSION AND FIXATION OF MOUSE TISSUE  
Mice were deeply anesthetized by intraperitoneal injection of avertin (0.2 ml per 10 g of body 
weight). The abdomen was opened and the diaphragm was removed to expose the heart. A 
butterfly cannula (27G, Venofix) connected to a peristaltic pump was inserted into the left 
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ventricle, while the right atrium was cut, generating a small opening. The blood was flashed 
out with HBSS (Invitrogen, Karlsruhe, Germany) until the vessels were cleared. Afterwards 
ice-cold fixative was used to fix the tissue. Depending on further processing different fixatives 
were used. All used mice were regenotyped using a tail biopsy. 
 
7.2.5 HISTOLOGY 
7.2.5.1 Tissue processing using paraffin wax 
Mice were perfused with 4% [v/v] PFA and post-fixed in the same fixative o/n at 4°C. For thin 
sectioning, brains were embedded in wax (Paraplast, Leica, Wetzlar, Germany) using an 
automated system (HMP 110, MICROM) with the following program: 50% EtOH for 1 hour, 
twice in 70% EtOH for 2 hours each, twice in 96% EtOH for 2 hour each and twice in 100% 
EtOH for 2 hour each, at RT. 100% EtOH was replaced by isopropanol for 1 hour and then 
incubated twice in Xylene for 2 hours each. Finally brains were impregnated two times with 
paraplast at 60ºC for 2 hours each. Afterwards, the tissue was placed in metal forms and 
casted in blocks with 60°C warm wax. Blocks were removed from the molds and can now be 
stored stably and for years on a dry place at RT.  
For further use, the tissue was cut in 5 μm thick paraffin wax sections using a microtome (HM 
400, MICROM) and dried at 37°C o/n. Sections were deparaffinized by the following steps: 
60°C 10 min, Xylol 2 x 10 min, Xylol/ Isopropanol (1:1) 10 min, 100% [v/v] EtOH 5 min, 90% 
[v/v] EtOH 5 min, 70% [v/v] EtOH 5 min, 50% [v/v] EtOH 5 min and ddH2O 5 min. 
7.2.5.2 Gallyas silver impregnation  
Deparaffinized 5 μm brain sections were used to visualize myelin. The technique developed 
by Gallyas based on binding of colloidal silver particles to myelinated fibers (Gallyas, 1979). 
First, in order to avoid labelling of other tissue than myelin, the sections were incubated with 
a 2:1 mixture of pyridine and acetic anhydride for 30 min at RT. Then, tissue was washed 
with ddH20 three times 10 min each, incubated in pre-warmed incubation solution for 10 min 
and washed with 0.5% [v/v] acetic acid three times for 5 min each. Afterwards, sections were 
incubated in the developer solution for 5–10 min. The extent of silver ion deposition in the 
developing step was controlled under the microscope and the reaction was stopped by 
washing in 1.0% [v/v] acetic acid. After additional washing with ddH2O, silver staining was 
stabilized by incubation with 2% [v/v] sodium thiosulfate solution for 5 min. Tissue was 
dehydrated by an alcohol gradient (50% [v/v], 70% [v/v], 90% [v/v], and 100% [v/v] for 5 min 
each), incubated with Xylol/Isopropanol (1:1, 5 min) followed by two times Xylol (5 min) and 
finally mounted using Eukitt.  
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7.2.5.3 Detection of apoptotic cells using TUNEL staining 
To check for apoptosis, we applied DeadEnd™Colorimetric TUNEL System (Promega) to 
paraffin-embedded sections (Naruse and Keino, 1995) according to manufactor´s 
instructions. This method relies on the ability of TdT to label blunt ends of double-stranded 
DNA breaks and thus the detection of extensive DNA degradation during the late stages of 
apoptosis. Briefly, after deparaffination and rehydration the sections were washed at first in 
0.85% NaCl for 5 min and then for 5 min in 0.1 M PBS, followed by fixation with 4% PFA for 
15 min, washing in 1x PBS (twice 5min), permeabilization with 20 μg/ ml Proteinase K in 
1x PBS for 10 min and subsequent washing in 1x PBS for 5 min. Then the slides were 
refixed in 4% PFA for 5 min, washed in PBS (twice 5 min) and equilibrated in Equilibration 
buffer at RT for 10 min. TdT reaction solution was applied and slides were incubated for 
60 min at 37ºC in a humidified chamber. The TdT reaction was stopped by immersion in 
2x SSC solution for 15 min, followed by washing in PBS (3x 5min). After blocking in 0.3% 
hydrogen peroxide for 5 min the slides were washed in PBS (3x 5min) again. Sections were 
incubated with Streptavidin-HRP (diluted 1:500 in PBS) for 30 min and then washed 3 times 
in PBS. DAB solution was prepared freshly and applied to the sections for approximately 10 
min until there was a light brown background. The slides were rinsed with ddH2O before they 
were counterstained with Haematoxylin to label nuclei. Therefore they were incubated in 
0.1% [w/v] Haematoxylin for 5 min. Blue coloration appears due to the interaction with the 
basic nuclear compartment. Sections were rinsed with ddH2O, incubated with HCl-Alcohol for 
5–10 sec and with Scott’s solution for 5 min. This was followed by two rinse with ddH2O. 
Tissue was dehydrated by an alcohol gradient (50% [w/v], 70% [w/v], 90% [w/v], and 100% 
[w/v] for 5 min each), incubated with Xylol/ Isopropanol (1:1, 5 min) followed by two times 
Xylol (5 min) and mounted using Eukitt. 
7.2.5.4 Immunohistochemistry of paraffin embedded tissue  
5 μm thin sections were deparaffinized and dehydrated and then incubated in citrate buffer 
for 5 min, followed by a cooking step of 10 min in boiling citrate buffer to permeabilize the 
tissue (650 watts in microwave oven). After cooling for at least 20 min at RT, sections were 
rinsed with Tris buffer containing 2% [w/v] milk powder for 5 min. Glass slides were placed 
into Shandon coverplates (Thermo Scientific, Cheshire, UK) for equal distribution of solutions 
and rinsed again with Tris buffer containing 2% milk powder. Horse radish peroxidase (HRP) 
coupled secondary antibodies were used. Therefore, it was necessary to suppress the 
endogenous peroxidase activity by applying 3% [v/v] hydrogen peroxide for 5 min. After 
additional washing with Tris buffer containing 2% [w/v] milk powder, slides were incubated in 
the blocking solution (20% [v/v] goat serum in BSA/PBS) for 30 min at RT. Primary 
antibodies were diluted in BSA/PBS and incubated o/n at 4°C. Subsequently, slides were 
washed with Tris buffer containing 2% [w/v] milk powder. For primary antibodies mono 
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mouse or polyclonal rabbit the LSAB2 kit (Dako, Hamburg, Germany) and for primary 
antibodies monoclonal rat the Vector Elite ABC Kit (Vector Labs, Loerrach, Germany) was 
used according to manufactor´s instructions. Then, the coverplates were removed and 
sections were rinsed with Tris buffer without milk-powder. The HRP substrate 
3,3' -Diaminobenzidine (DAB) was applied by using the DAB Zytomed Kit (Zytomed Systems 
GmbH, Berlin, Germany) and incubated for 10 min. After additional washing with ddH2O, 
sections were incubated in 0.1% [w/v] Haematoxylin for 5 min to label nuclei. Sections were 
rinsed with ddH2O, incubated with HCl-Alcohol for 5–10 sec and with Scott’s solution for 
5 min. This was followed by two rinses with ddH2O. Tissue was dehydrated by an alcohol 
gradient (50% [w/v], 70% [w/v], 90% [w/v], and 100% [w/v] for 5 min each), incubated with 
Xylol/Isopropanol (1:1, 5 min) followed by two times Xylol (5 min) and mounted using Eukitt.  
7.2.5.5 Imaging and quantification of DAB developed stainings  
Tissue was imaged using the Zeiss Axio Z1 and processed with the Zen 2011 software 
(Zeiss, Oberkochern, Germany). The quantification of positive signal was done with ImageJ. 
For GFAP the positive area was measured. Therefore, an ImageJ plugin written by Sven 
Wichert was used. Briefly, the color threshold was transformed to a black and white picture, 
whereby brown DAB staining as positive black signal appeared. Then the area of the positive 
black signal was measured and related to the size of the analyzed area. For CD3, Mac3 and 
APP the Cell Counter plugin of ImageJ was used in order to determine the number of 
positive cells. The values were shown as histograms using Adobe Illustrator CS3 and 
p-values were calculated using the Student’s t-test of Microsoft Excel 2003.  
7.2.5.6 Fluorescent immunodetection on paraffin sections 
5 μm thin sections were deparaffinized and dehydrated and then incubated in citrate buffer 
for 5 min, followed by a cooking step of 10 min in boiling citrate buffer to permeabilize the 
tissue (650 watts in microwave oven). After cooling for at least 20 min at RT, the sections 
were rinsed 3 x 5 min in Tris buffer containing 2% milk powder. To minimize the unspecific 
binding of the antibody and to reduce the background staining the blocking of free sites on 
sections were carried out by incubating them with goat serum diluted in PBS/BSA (1:5) for 
20 min at RT, followed by the incubation with the primary antibody diluted in its appropriate 
dilution in PBS/BSA o/n at 4°C. Sections were washed 3 x 5 min in Tris buffer containing 2% 
milk powder. To visualize the site of binding of primary antibodies, sections were incubated 
with the fluorescently labeled antibodies diluted in PBS/BSA, for about 1 hour at RT. 
Counterstaining was carried out with DAPI (0.5 μg/ ml final conc.) and was applied together 
with the secondary antibody. Finally sections were washed 3 x 5 min in Tris buffer without 
milk powder and were mounted in water based mounting medium such as Aquapoly mount. 
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The Cell Counter plugin of ImageJ was used in order to determine the number of labelled 
cells and values were shown as histograms using Adobe Illustrator CS3. 
7.2.5.7 Detection of proliferating cells (BrdU staining) 
For detection of proliferating cells in vivo BrdU (5-bromo-2'-deoxyuridine) was provided to 
mice. This is a nucleoside analog that is incorporated into newly synthesized cells during 
replication and can be detected by specific antibodies. BrdU (Sigma, Germany) was 
dissolved in 0.9% NaCl and sterile filtered. 16 week old mice received daily intraperitoneal 
(i.p.) injections of 100 mg/kg body weight (5 days per week) for 4 weeks and were 
subsequently perfused with 4% (v/v) PFA. Immediately after immunohistochemistry to 
colabel dividing cells (see protocol for 'Fluorescent immunodetection on paraffin sections'), 
BrdU was visualized using an antibody specifically directed against BrdU. Sections were kept 
in dark from now on. First, sections were incubated in 0.2 M Glycine for 30 min, followed by 
2 x 5 min washing steps in 1x PBS and the incubation in 2 M HCl at 37°C for 30 min to break 
open the DNA structure. After rinsing them 2x 5 min in 100 mM Di-Natiumtetraborat (pH 8,5), 
the sections were washed 3x 5 min in 1x PBS and blocked with 1x PBS containing 10% goat 
serum for 30 min at RT. Then the tissue was incubated with anti-BrdU (Bioscience) diluted in 
2% goat serum in 1x PBS o/n at 4°C followed by 30 min at RT. Sections were washed 
3x 5 min in 1x PBS and the secondary antibody was applied in its recommend dilution in 
1x PBS containing 2% goat serum and DAPI (0.5 μg/ ml final conc.) for 1 h at RT. After 
additional wasing in 1x PBS (3x 5 min), the sections were mounted in Aquapoly mount. The 
Cell Counter plugin of ImageJ was used in order to determine the number of positive cells. 
The values were shown as histograms using Adobe Illustrator CS3 and p-values were 
calculated using the Student’s t-test of Microsoft Excel 2003.  
7.2.5.8 Detection of proliferating cells (EdU staining) 
For detection of dividing cells in vivo, EdU (5-ethynyl-2'-deoxyuridine, Invitrogen) was 
provided to P80 mice in the drinking water at the concentration of 0.2 mg/ml, which was 
shown to be nontoxic (Young et al., 2013). The water was exchanged every 2 days and mice 
were exposed to EdU for 14 days in total. EdU is a nucleoside analog for thymidine that 
incorporates into the DNA of proliferating cells. This method based on click chemistry that 
relies on covalently coupling an azide with an alkyne. Due to the small size of click detection 
reagent, no harsh treatment of tissue is required. EdU was visualized using the AlexaFluor-
555 Click-iT EdU Cell Proliferation Assay Kit (Molecular Probes, Invitrogen) according to 
manufactor´s instructions immediately after immunohistochemistry (see protocol for 
'Fluorescent immunodetection on paraffin sections'). Paraffin sections were incubated at RT 
for 60 min in 1x PBS containing 0.5% (v/v) Triton X-100 and 3% horse serum, followed by 2 
blocking steps in 3% horse serum diluted in 1x PBS for 10 min at RT each. Then the sections 
  MATERIAL AND METHODS 
 
   94
were transferred to the EdU developing cocktail, incubated in the dark at RT for 45 min, and 
blocked again 3 times in 3% horse serum in 1x PBS for 10 min each. Cell nuclei were 
visualized by poststaining with DAPI (0.5 μg/ ml final conc.) and sections were mounted in 
water based mounting medium (Aquapoly mount). The Cell Counter plugin of ImageJ was 
used in order to determine the number of labelled cells. The values were shown as 
histograms using Adobe Illustrator CS3 and p-values were calculated using the Student’s 
t test of Microsoft Excel 2003.  
7.2.5.9 Immunohistochemistry of vibratome sections 
Mice were perfused with 4% [v/v] PFA, the brain was cut sagittally between the two 
hemispheres with a razor blade and post-fixed o/n at 4°C. Sagittal sections (25- 30 μm) were 
sliced using the Leica VT1000S vibratome (Bensheim, Germany), collected in 1x PBS and 
stored at 4°C till proceeding with fluorescent immunodetection. Therefore sections were 
incubated in 0.2 % (v/v) Triton X-100 and 10% horse serum in a 24 wells plate. The primary 
antibody was prepared according to its appropriate dilution in the same solution and was 
incubated o/n at 4°C. After washing 3x 5 min in 1x PBS the fluorescently labeled antibody 
was applied in its recommend dilution together wit DAPI (0.5 μg/ ml final conc.) in 2% horse 
serum in 1x PBS for 1 h at RT, followed by 3 washing steps in 1x PBS for 5 min each. 
Finally, the sections were mounted in Aquapoly mount. The Cell Counter plugin of ImageJ 
was used in order to determine the number of positive cells. The values were shown 
as histograms using Adobe Illustrator CS3 and p-values were calculated using the Student’s 
t-test of Microsoft Excel 2003.  
7.2.5.10 Immunohistochemistry of cryosections  
Mice were perfused using 4% [v/v] PFA. After fixation, brains and optic nerves were 
transferred to 10% [w/v] sucrose in 0.1 M phosphate buffer. After 12 hours at 4°C, tissue was 
first transferred to 20% [w/v] sucrose and then to 30% [w/v] sucrose in 0.1 M phosphate 
buffer, each o/n at 4°C. Following this cryo-protective step, brains and optic nerves were 
frozen on dry ice and stored at -80°C. A cryostat (Leica, Wetzlar, Germany) was used to 
generate 20 μM thick longitudinal or coronar sections of stabilized tissue, which were 
collected on glass slides, dried at RT and stored at -20°C. For immunofluorescent stainings, 
tissue was permeabilized and blocked with 0.5% (v/v) Triton X-100 and 10% horse serum in 
1x PBS for 1 hour. The primary antibodies were diluted in the same buffer and incubated at 
4°C for 40 hours. Afterwards, slides were washed three times for 10 min with 1x PBS and 
incubated for two hours with the secondary antibodies and DAPI (0.5μg/ ml final conc.) 
diluted in 0.5% (v/v) Triton X-100 and 10% horse serum in 1x PBS at RT. Tissue was 
washed 3x 5 min in 1x PBS and mounted using Aquapoly mount. 
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7.2.5.11 SDH/ COX histochemistry 
Mice were perfused with 4% PFA and collected brains were cryoprotected with a descending 
gradient of sucrose of 10%, 20% and 30% sucrose diluted in 1 x PBS each overnight. 8-mm 
thick sections were cut using a cryostat and air-dried for 30 min. Sections were exposed to 
COX medium containing 500 mM cytochrome c, 5 mM diaminobenzidine tetrahydrochloride 
and 20 mg/ ml catalase at 37 °C for 40 min. Sections were washed three times with 1x PBS 
and a subsequent incubation with SDH medium containing 130 mM sodium succinate, 
200 mM phenazine methosulphate, 1 mM sodium azide, 1.5 mM nitroblue tetrazolium in 
0.1M phosphate buffer (pH 7.0) for 30 min at 37 °C. After dual SDH/ COX histochemistry 
normal immunohistochemistry was performed to identify Cox10-deficient oligodendrocytes. 
Performance and image acquisition were done by Dr. Don Mahad and Graham Campbell. 
 
7.2.6 ELECTRON MICROSCOPY  
7.2.6.1 Tissue preparation  
Mice were perfused with Karlsson-Schultz fixative (Schultz and Karlsson, 1965), optic 
nerves, sciatic nerves and cerebella were removed and kept in the same solution for at least 
12 h at 4°C. Post-fixed cerebella were cut sagittally into 300 µm thick sections using a 
vibratome (Leica, VT1000S) and the lobe 3 were punched out before Epon embedding. 
7.2.6.2 Epon embedding  
Tissues were embedded in Epon using an automated system (EMTP, Leica, Wetzlar, 
Germany). Steps included osmification, dehydration and Epon impregnation. Briefly, samples 
were incubated in phosphate buffer 3x for 10 min at 4ºC, followed by 2% [w/v] OsO4 for 
4 hours at 4ºC, 3x ddH2O 3 for 10 min at 4ºC. Then the samples were treated with an 
ascending alcohol gradient at 4°C, which included 30% [v/v] EtOH for 20 min, 50% [v/v] 
EtOH for 20 min, 70% [v/v] EtOH for 20 min, 90% [v/v] EtOH for 20 min and 100% [v/v] EtOH 
4x for 10 min. Subsequently, samples were Epon embedded at RT and were incubated with 
Propylenoxid 3x for 10 min, Propylenoxid/Epon 2:1 for 2 hours, Propylenoxid/Epon 1:1 for 2 
hours, Propylenoxid/Epon 1:2 for 4 hours and finally Epon for 4 hours. Tissue was then 
placed into the Epon filled molds and left o/n at 60ºC for Epon polymerization.  
7.2.6.3 Sectioning of Epon embedded samples  
Semithin (300 nm) and ultracut sections (50 nm) were cut with a diamond knife (Diatome 
Ultra 45º) using an Ultramicrotome (Leica, Vienna, Austria) and were collected on a double 
sized slot grid (2mm-1mm, AGAR scientific, Essex, UK) coated with formvar polyvinyl and 
contrasted.  
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7.2.6.4 Staining and analysis of semithin sections 
300 nm thin sciatic nerve sections were labeled using the Methylene blue- Azure II stain 
(Richardson et al., 1960). Sections were dried for 1 min on a 60°C hot plate and then 
extensively rinsed with ddH2O. After drying, tissue was mounted using Eukitt and imaged 
with the Zeiss Axio Z1 (Zeiss, Oberkochern, Germany). Schwann cell nuclei were counted 
using ImageJ and the entire cross sectional area of sciatic nerves was scored. Analysis was 
performed by Dr. Ursula Fünfschilling. 
7.2.6.5 Contrasting of ultra-thin sections  
Grids were placed upside-down on drops of the following solutions at RT: 30 min uranyl 
acetate, 3x 1 min ddH2O, 6 min lead citrate according to Reynolds et al. (1963) and 4x 1 min 
ddH2O. Grids were carefully dried with a stripe of filter paper. 
7.2.6.6 Analysis of EM pictures  
Ultrathin sections were analyzed with the Zeiss EM900 (Zeiss, Oberkochen, Germany) and 
digital pictures were obtained using the wide-angle dual speed 2K-CCD-Camera (TRS, 
Moorenweis, Germany). Counting of myelinated axons of the sciatic nerve on electron 
microscopic pictures, all axons in three random fields (5500 µm2 total) per nerve were traced 
using ImageJ. Parallel fiber-Purkinje cell synapses were counted using ImageJ and divided 
by the respective image area. The resulting synapse density was averaged per genotype. 
The area of Bergmann glial processes was analyzed with the point-hit method (Rabouille et 
al., 1999) using ImageJ and a grid area of 2.49 μm2. Bergmann glial processes were 
identified by their irregular shape and characteristic bundles of intermediate filaments in a 
comparatively clear cytoplasm (Rubio and Soto, 2001). The values were shown as 
histograms using Adobe Illustrator CS3 and p-values were calculated using the Student’s 
t test of Microsoft Excel 2003. The levels of significance were set as * p < 0.05; ** p < 0.01; 
*** p < 0.001. The calculation of the myelinating axon number of sciatic nerves was 
performed by Dr. Ursula Fünfschilling. 
 
7.2.7 CELL BIOLOGY METHODS  
7.2.7.1 Preparation of coverslips 
Prior to coating glass coverslips needs to be roughen. This was done by incubating them in 
65% HNO3 for 1- 2 h under rotating agitation, followed by several washing steps (5x in 
dd H2O, 3x in 70% EtOH) and o/n drying at 60°C. Before use coverslips were sterilized by 
UV light exposure for 10 min. 
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7.2.7.2 Coating with poly-L-lysin 
To enable adherence of primary cells by their negatively charged polysaccharid structures to 
plastic (flasks) and glass surfaces (coverslips), coating with poly-L-lysin (PLL), which is 
positively charged, was necessary. 0.1 mg/ ml PLL were diluted in ddH2O for flasks and in 
boric acid buffer (pH 8.5) for coverslips and incubated for at least 60 min at 37°C, then 
washed twice with sterile water and air-dried. 
7.2.7.3 Preparation of primary rat oligodendrocytes 
Protocol was adapted from Eyermann et al., 2012. Briefly, a litter of P2 rats were 
decapitated. After opening the scull, sagittal brain halves without cerebellum and bulbi were 
placed in a petridish containing MEM medium. Under a binocular the midbrain, hippocampus 
and meninges were carefully removed and the cerebra were collected in a 15 ml falcon tube 
filled with 1 ml MEM at RT. The digestion mix was freshly prepared in 5ml plastic bijoux tube. 
In order to activate the papaine the digestion solution was preincubated at 37°C, 7.5 % CO2 
for 5 min. All further steps were performed under a cell culture hood. The mix was applied to 
the cerebra by pressing through a filter for sterilization. Then the tissue was homogenized by 
pipetting up and down several times and put in a cell culture incubator (40–60 min depending 
on number of cerebra) at 37°C and 7.5 % CO2 for digestion. The digestion was stopped by 
adding 10 ml OPC medium and subsequent inverting. The cell solution was centrifuged at 
1200 rpm for 15–20 min. The supernatant was removed using a glass pipette and fresh OPC 
medium was added. Each flask was filled with 10 ml already prewarmed and equilibrated 
OPC medium and 2 ml of the cell suspension was added (2 cerebra per flask). Mixed glial 
cultures were cultivated at 37°C and 7.5 % CO2 for 10–14 days. Every 2–3 days half of the 
medium was exchanged. Usually within one week an astrocyte layer was formed with 
oligodendrocyte precursor cells (OPCs) growing on top of it. Prior to OPC harvest, microglial 
cells were removed by harsh manual shaking. Afterwards, the OPC medium was replaced by 
fresh OPC medium and OPCs were enriched in the supernatant by manual shaking 
(approximately 30 times). The remaining astrocytes were taken for primary astrocytes 
cultures. The OPCs were pelleted by centrifugation (at 1200 rpm for 20 min) and counted 
using a Neubauer chamber. Usually, 10000–20000 cells were plated on coverslips in a 
24-well format previously coated with PLL (0.1 mg/ ml) in Sato medium for differentiation and 
further cultivated at 37°C and 7.5 % CO2. Every 2 days a half Sato media change was 
performed. Within five to six days of culturing in vitro most oligodendrocytes had 
differentiated into a myelin basic protein (MBP)-positive state. 
7.2.7.4 Preparation of primary rat astrocytes  
For astrocyte cultures the astrocyte layer from the preparation of primary oligodendrocytes 
were used. First, to get rid of remaining OPCs and microglia the flaks were shaken o/n at 
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400 rpm and 37°C using the innova 4000 shaker (New Brunswick Scientific). The flasks were 
washed with OPC media to remove all detached OPCs. In order to loose astrocytes 
1x Trypsin containing EDTA was applied and incubated under gentle agitation for 3–5 min at 
RT. The supernatant was collected and the trypsination was stopped by adding OPC 
medium containing 10% serum. After centrifugation at 1200 rpm for 15 min, the cell number 
was calculated using the Neubauer chamber and cells were plated on coverslips  in a density 
of usually 10000–20000 per well in a 24-well format previously coated with PLL (0.1 mg/ ml). 
Astrocytic cultures were maintained in DMEM containing 10% [v/v] heat-inactivated fetal 
bovine serum, 1% [v/v] glutamine and 1% [v/v] penicillin/ streptomycin at 37°C and 5% CO2. 
7.2.7.5 Preparation of primary rat cortical neurons 
Method based on routine practices for culturing neurons (Meberg and Miller, 2003). Briefly, 
embryos on embryonal day (E) 17 were dissected, decapitated and stored in HBSS+. 
Meninges and hippocampi from 2–3 brains were carefully removed and cortices were 
isolated under a binocular. The tissue was transferred into 15 ml falcons containing HBSS+. 
After washing 2x with HBSS, the cortices were digested with 2.5 % Trypsin in HBSS for 
20 min at 37°C under gentle agitation. Then the medium (as much as possible) was removed 
and the trypsination was stopped by adding DMEM medium containing 10 % FCS, followed 
by an incubation step with DNAse (2 % in DMEM) for 5 min at RT and 3 washing steps with 
DMEM medium. Afterwards the supernatant was removed and 2 ml fresh DMEM was 
applied. Then the tissue was titruated by performing a liquid stream using a firepolished 
pasteur pipette und the supernatant (cell solution) was let flow through a cell strainer into a 
50 ml falcon tube. The cell strainer was washed with additional 2 ml DMEM. The cell number 
was determined using a Neubauer chamber. Usually, 10000–20000 cells were plated on 
coverslips per well in a 24-well format previously coated with PLL (0.1 mg/ ml) in DMEM 
medium. Cells were cultivated at 37°C and 5% CO2. The next day the entire media was 
exchanged to Neurobasal medium and from there on every 3–4 days a half medium change 
was performed. To obtain pure neuronal cultures AraC was added (to a final concentration of 
5 µM) at DIV4 and DIV8 to kill postmitotic glial cells. Usually, neuronal cultures were used for 
experiments at 10 DIV.  
7.2.7.6 Rotenone treatment 
Rotenone treatments were induced at astrocyte DIV 25 and neuron DIV 10. The duration of 
all experiments was 24 h. Fresh rotenone powder (Sigma) was diluted in dimethyl suloxide 
(DMSO) to a 10 mM dilution. The final rotenone concentrations used in each experiment are 
indicated in the figures. 
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7.2.7.7 Trypan blue exclusion 
Cells were cultured as stated above and treated in the presence or absence of rotenone. 
Subsequently, they were harvested by light trypsinization and suspended in a defined 
medium volume. Cells were incubated in 0.2% [v/v] trypan blue solution and the number of 
trypan blue negative cells was counted using a hemocytometer to determine viable cells per 
coverslip (Ø 13 mm, 132.7 µm2). 
7.2.7.8 Immunocytochemistry 
Cells were washed with 1x PBS (pH 7.4) and fixed with 4% [v/v] paraformaldehyde at 37°C. 
Cells were washed 3 times in 1x PBS and permeabilized with 0.2% [v/v] Triton X-100, 
10% [v/v] horse serum in 1x PBS for 1 h at RT. Primary antibodies were incubated o/n at 4°C 
in the same solution. Secondary antibodies were incubated in 2 % horse serum or PBS/ BSA 
for 1 h at RT. For nuclei labelling DAPI (0.025 μg/ ml final concentration) was added to the 
secondary antibody. Sections were mounted using Aqua-Polymount (Eppelheim). 
 
7.2.8 ELECTROPHYSIOLOGY 
7.2.8.1 Nerve conduction velocity measurements 
Mice were anesthetized with Xylacin and Ketamin intraperitoneally. Two recording electrodes 
were inserted into the intrinsic foot muscle. Distal stimulation electrodes were inserted at the 
ankle and the proximal stimulation electrodes were inserted at the sciatic notch. Compound 
muscle action potentials (CMAPs) were recorded with a Jaeger-Toennies Neuroscreen 
(Würzburg, Germany) instrument. Nerve conduction velocities were calculated from the 
distance between proximal and distal stimulation electrodes and the latency difference 
between the CMAPs after successive proximal and distal stimulation. CMAP amplitudes 
were calculated peak to peak. Analysis was performed by Dr. Bastian Brinkmann. 
 
7.2.9 MAGNETIC RESONANCE SPECTROSCOPY 
MRI/MRS was performed on CNP1Cre/+ * Cox10flox/flox mice and CNP1Cre/+ * Cox10flox/+ mice as 
controls at the age of 4 to 5 (n = 6/6) and 6 to 7 months (n = 7/7). Mice were initially 
anesthetized with 5% isoflurane, subsequently intubated and kept under anesthesia with 
1.75% isoflurane in ambient air. In 4 mice additional spectra were obtained without 
anesthesia. In these mice, pancuronium (15 mg/kg) was administrated 15 min before 
switching off the isoflurane supply to avoid movement artifacts. 
In vivo localized proton MRS (STEAM, TR/TE/TM = 6000/10/10 ms) in different regions of 
the brain (cortex: 3.9 x 0.7 x 3.2 mm3, NA = 160; corpus callosum: 2.5 x 1.0 x 2.0 mm3, 
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NA = 160; striatum: 1.2 x 1.4 x 2.0 mm3, NA = 160; cerebrum: 4 x 3 x 4 mm3, NA = 32) was 
performed at 9.4 T (Bruker Biospin GmbH, Germany). For a proper positioning of the 
volumes of interest T2-weighted images (2D FSE, TR/TE = 4200/43 ms, 8 echoes, resolution 
100 x 100 µm2, slice thickness 300 µm) were obtained in axial and horizontal orientation. 
Metabolite quantification involved spectral evaluation by LCModel (Provincher, 1993) and 
calibration with brain water concentration. Metabolites with Cramer-Rao lower bonds above 
20% were excluded from further analyses unless noted otherwise. Analysis was performed 
by Prof. Susann Boretius and Prof. Jens Frahm. 
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